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Abstract
Since its initial documentation in 1981, the acquired immunodeficiency syndrome (AIDS) epidemic has
impacted more than 70 million people. As the causative agent of AIDS, human immunodeficiency virus
(HIV) is a retrovirus that integrates a copy of its viral genome (termed provirus) into the genome of target
cells known as CD4+ T cells. With antiretroviral therapy (ART), persons living with HIV (PLWH) can
suppress viral replication and prevent progression to AIDS. However, ART is usually a lifelong requirement
as interruption can lead to viral rebound via transcription at the integrated viral genome. During early HIV
infection, some infected cells can enter a quiescent state that results in a state of infection known as
latency. Persistent infection and reversible latency are characteristics of the HIV reservoir. As a result,
there is no universally accessible cure for HIV. A functional cure of HIV – which is to suppress viral
replication without ART – is a primary goal of HIV cure research. Such a strategy requires an in-depth
understanding of the HIV reservoir but many CD4+ T cells, each with different function and phenotype,
contribute to the collective HIV reservoir that is located throughout different tissue environments. To
address this challenge, this study deciphers the reservoir through the lens of tissue versus blood
compartmentalization at a subset resolution to address the impact of residency and circulation as well as
with a novel single-cell approach to enable a comprehensive analysis of the HIV reservoir during ART.
While the characteristics of integration were generally the same across compartments, there was a lack
of overlap between tissues and blood to suggest the existence of sub-reservoirs where there may be
unique reservoirs based on residency status. Furthermore, the single-cell profiling revealed extensive
heterogeneity between and within individuals with some infected cells displaying a poised signature for
reactivation. These results provided a clearer picture of the HIV reservoir to come closer to the goal of a
functional cure that can effectively target latency across the location and phenotypic diversity of the HIV
reservoir.
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ABSTRACT

DECIPHERING THE HETEROGENEITY OF HIV RESERVOIR IMMUNOLOGY:
A SINGLE-CELL PERSPECTIVE
Vincent H. Wu
Michael R. Betts

Since its initial documentation in 1981, the acquired immunodeficiency syndrome (AIDS)
epidemic has impacted more than 70 million people. As the causative agent of AIDS, human
immunodeficiency virus (HIV) is a retrovirus that integrates a copy of its viral genome (termed
provirus) into the genome of target cells known as CD4+ T cells. With antiretroviral therapy
(ART), persons living with HIV (PLWH) can suppress viral replication and prevent progression to
AIDS. However, ART is usually a lifelong requirement as interruption can lead to viral rebound via
transcription at the integrated viral genome. During early HIV infection, some infected cells can
enter a quiescent state that results in a state of infection known as latency. Persistent infection
and reversible latency are characteristics of the HIV reservoir. As a result, there is no universally
accessible cure for HIV. A functional cure of HIV – which is to suppress viral replication without
ART – is a primary goal of HIV cure research. Such a strategy requires an in-depth understanding
of the HIV reservoir but many CD4+ T cells, each with different function and phenotype,
contribute to the collective HIV reservoir that is located throughout different tissue environments.
To address this challenge, this study deciphers the reservoir through the lens of tissue versus
blood compartmentalization at a subset resolution to address the impact of residency and
circulation as well as with a novel single-cell approach to enable a comprehensive analysis of the
HIV reservoir during ART. While the characteristics of integration were generally the same across
compartments, there was a lack of overlap between tissues and blood to suggest the existence of
sub-reservoirs where there may be unique reservoirs based on residency status. Furthermore,
vi

the single-cell profiling revealed extensive heterogeneity between and within individuals with
some infected cells displaying a poised signature for reactivation. These results provided a
clearer picture of the HIV reservoir to come closer to the goal of a functional cure that can
effectively target latency across the location and phenotypic diversity of the HIV reservoir.
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CHAPTER 1
INTRODUCTION

1.1 Human immunodeficiency virus: its discovery and connection as the causative agent
for Acquired Immune Deficiency Syndrome (AIDS)
The first documentation of the symptoms associated with human immunodeficiency virus (HIV)
infection – and what would be the start of the HIV epidemic – was the 1981 report of rare lung
infections (Pneumocystis carinii pneumonia; PCP) in five gay men that were previously healthy
(Centers for Disease Control (CDC), 1981a). This article from the United States Center for
Disease Control (CDC) reported dysfunctional immune systems and additional opportunistic
infections in these individuals. Around the same time, the CDC also received reports of a high
prevalence of a rare cancer known as Kaposi’s Sarcoma in gay men living in New York and
California along with additional reports on opportunistic infections amongst gay men in the US
(CDC Task Force on Kaposi’s Sarcoma and Opportunistic Infections, 1982; Centers for Disease
Control (CDC), 1981b). Between June 1, 1981 and September 15, 1982, there were a reported
593 cases of severe immune deficiency in the US, with 41% of these cases resulting in death
indicating a relatively sudden occurrence of symptoms as well as high mortality rates (Centers for
Disease Control (CDC), 1982a).

Over the course of several months, this phenomenon was more formally described as Acquired
Immune Deficiency Syndrome (AIDS) in which disease presentation is associated with a
dysfunctional immune system and with no prior indications of increased susceptibility (Centers for
Disease Control (CDC), 1982a). More cases of opportunistic infections associated with
immunodeficiency, caused by the loss in CD4+ T cells, in previously healthy individuals had been
reported across the United States (Centers for Disease Control (CDC), 1982b, 1982c). These
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include documentation of immunosuppression, PCP, Kaposi’s sarcoma, swollen lymph nodes,
weight loss, and/or fever. Of note, one of these reports include an AIDS diagnosis of a 20-monthold infant that had received blood-derived transfusions from a person subsequently diagnosed
with and died from AIDS (Centers for Disease Control (CDC), 1982d). This observation along with
the high prevalence of AIDS diagnoses amongst homosexual or bisexual men through sexual
encounters and amongst intravenous drug users (CDC Task Force on Kaposi’s Sarcoma and
Opportunistic Infections, 1982) suggested that the causative agent of AIDS was likely spread
through blood and/or other bodily fluids. This was further supported by the first report of AIDS in
women from male sexual partners that were subsequently diagnosed with AIDS (Centers for
Disease Control (CDC), 1983).

The search for the cause of AIDS continued into 1983 when French scientists, spearheaded by
Drs. Françoise Barré-Sinoussi and Luc Montagnier, isolated a retrovirus from a lymph node
biopsy of an individual in the early stages of AIDS (Barré-Sinoussi et al., 1983). This retrovirus
was termed lymphadenopathy associated virus (LAV) and was corroborated by American
scientists, led by Dr. Robert Gallo, in isolating a retrovirus that was identical to LAV and was
termed human T-lymphotropic virus-III (HTLV-III) (Gallo et al., 1984). A third study in San
Francisco, by Drs. Jay Levy, Lyndon Oshiro, and others, isolated virus from multiple people
diagnosed with AIDS with the name AIDS-related retroviruses (ARV) (Levy et al., 1984). All
individuals from this study with a diagnosis of AIDS had antibodies that reacted against ARV. The
findings from these groups consisted of the same virus despite the different names (LAV, HTLVIII, and ARV). Together, these studies identified this viral infection as the causative agent of AIDS
and resulted in the official name of human immunodeficiency virus (HIV) (Coffin et al., 1986).
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Since this initial documentation, HIV has had a profound impact on global heath with an
estimated 79.3 million people that have lived with HIV and an estimated 36.3 million that have
died from complications relating to HIV infection according to the Joint United Nations
Programme on HIV and AIDS (UNAIDS). This global epidemic persists to this day with more than
37 million people living with HIV and over one million new people living with HIV in 2020
(UNAIDS). The monumental impact of the HIV epidemic has transformed many aspects of
medicine and society and highlights the urgent need for a functional cure for existing HIV infection
and increased prevention-based protection from acquiring HIV.

1.2 Origins and classification of HIV
Upon the discovery of AIDS and HIV, international efforts were under way to understand HIV and
how it emerged as a human pathogen by identifying its source and ancestral lineage through
genetic tracing. In this effort, a similar virus was isolated from an individual with AIDS in west
Africa but was antigenically different than the HIV strain identified in 1983 (Clavel et al., 1986).
The discovery of different HIV strains led to a clearer nomenclature in which the strain associated
with the 1983 discovery was termed human immunodeficiency virus type 1 (HIV-1) and the strain
isolated in 1986 from west Africa was termed human immunodeficiency virus type 2 (HIV-2)
(Guyader et al., 1987). Multiple studies had analyzed different viruses from animal hosts and
noted similarities to viruses obtained from primates that were collectively called simian
immunodeficiency virus (SIV) (Hirsch et al., 1989; Huet et al., 1990). A phylogenetic analysis in
1999 led by Dr. Beatrice Hahn established the emergence of the pandemic HIV-1 from a single
cross-species transmission event from SIV in chimpanzees (SIVcpzPtt, specifically from Pan
troglodytes troglodytes) to humans (Gao et al., 1999). Through earlier work with HIV-2 and this
phylogenetic analysis, simian viruses from chimpanzees and sooty mangabeys were found to be
the primate origins of HIV-1 and HIV-2, respectively.
3

HIV-1 is grouped into four separate lineages that each represent an independent cross-species
transmission event from simians to humans (Robertson et al., 2000). HIV-1 group M (main) and
group N (not M or N) viruses are all derived from the SIVcpzPtt chimpanzee reservoir while the
primate origin of group O (outlier) is unknown (Keele et al., 2006). HIV-1 group P is derived from
a transmission event from the SIVgor (gorilla) reservoir (Plantier et al., 2009; Vallari et al., 2011).
HIV-1 group M was the first strain to be discovered and as its name implies, is the strain
associated with the global HIV-1 pandemic. Groups N and O have a lower prevalence (<1% of
HIV infections) and group P has only been identified in a small number of individuals primarily
from Cameroon (Plantier et al., 2009). HIV-1 group M is classified into additional further subtypes
(denoted as A-D, F-H, J, and K) which were identified in different regions around the world and
have been associated with genetic bottlenecks that have led to distinct genomic signatures
(Sharp and Hahn, 2011). HIV-1 group M, subtype B is the dominant subtype in European and
American cases of HIV-1 infection (Taylor et al., 2008). Furthermore, these different subtypes,
while all can cause AIDS, have varied degrees of pathogenicity and the exposure of different
subtypes into the same human population have created circulating recombinant forms (CRF)
(Sharp and Hahn, 2011; Taylor et al., 2008). The recombination and diversity of HIV-1 strains
highlight not only the global impact of HIV-1, but also the high genomic diversity of HIV-1 which
complicates HIV treatment and cure.

In this study, HIV-1 and HIV are used interchangeably as all studied samples come from
individuals living with HIV-1, group M. While HIV-2 is not studied here, this virus type is still an
important viral infection. HIV-2 is associated with a lower level of pathogenicity and lower
likelihood of progression into AIDS (Popper et al., 1999; Rowland-Jones and Whittle, 2007).
However, it is naturally more resistant to several classes of antiretrovirals used to treat HIV-1
4

(Brower et al., 2008; Desbois et al., 2008; Witvrouw et al., 1999) and has historically confounded
treatment of individuals who were either misdiagnosed with HIV-1 or have a dual infection of HIV1 and HIV-2 (Gottlieb et al., 2003, 2020; Rodés et al., 2005). No antiretrovirals are approved by
the Food and Drug Administration (FDA) for the treatment of HIV-2 (Gottlieb et al., 2020). As
such, research into HIV-1 and HIV-2 are both highly needed and the less pathogenic nature of
HIV-2, despite very similar characteristics with HIV-1, can help inform our understanding and
corresponding differences in phenotypes in terms of the host-viral interactions.

1.3 HIV-1 classification and replication cycle
HIV-1 classification and genome
HIV is formally classified as a member of the family Retroviridae and genus Lentivirus
(International Committee on Taxonomy of Viruses., 1991). Retroviruses are characterized by a
linear and dimeric positive-strand single-stranded RNA (ssRNA(+)) genome as well as several
proteins including a reverse transcriptase to convert the ssRNA genome into double-stranded
DNA (dsDNA) and an integrase that inserts the viral dsDNA into the target cellular genome
(Coffin et al., 1997). Members within the Lentivirus genus share the same retrovirus
characteristics and are further classified as lentiviruses due to their ability to cause chronic
disease with relatively long incubation periods before the emergence of the disease state (AIDS
in the case of HIV infection) (Coffin et al., 1997). These unique retroviral and lentiviral aspects
play a significant role in the pathogenesis of HIV and its complex interactions with the human
immune system.

The HIV-1 genome consists of slightly under 10 kilobase pairs of single-stranded RNA
nucleotides in a positive-stranded sense. The 5’ end of the RNA genome contains an
untranslated region consisting of subregions known as R and U5 sequences while the 3’ end of
5

the genome contains U3 and R sequences. Upon conversion to the dsDNA form during reverse
transcription, these identical regions are termed long terminal repeats (LTR), with each end
containing the U3, R, and U5 sequences. After the U5 region at the 5’ untranslated region, there
is a primer binding sequence (PBS) region that is critical for reverse transcription (see below).
There are nine open reading frames encoding 15 viral proteins (Frankel and Young, 2003). The
gag gene encodes the Gag polyprotein which includes the matrix (MA), capsid (CA), spacer
peptide 1 (SP1), nucleocapsid (NC), spacer peptide 2 (SP2), and P6 proteins. The pol gene
encodes a Pol polyprotein consisting of reverse transcriptase (RT), RNase H, integrase (IN), and
protease (PR). The env gene encodes the envelope (Env) subunits: gp120 and gp41. Two open
reading frames, tat and rev, encode the regulatory proteins Tat and Rev, respectively. Finally, the
open reading frames nef, vpr, vif, and vpu each encode accessory proteins, which are important
for antagonizing the immune system and promoting infection.

HIV-1 replication cycle
The pathogenesis and the consequent lack of a functional cure for HIV-1 is firmly rooted in its
viral replication cycle, which can be generally defined by seven major steps from initial entry to
the budding and maturation of the HIV virion.

Entry. The first step is the binding of the HIV-1 envelope protein (Env) to the target cellular
receptor CD4 (Maddon et al., 1986; McDougal et al., 1986), which is found on CD4+ T cells as an
important component in immune synapse formation (Terhorst et al., 1980). As the expression of
CD4 is largely restricted to CD4+ T cells (Terhorst et al., 1980), these cells are the preferred
target of HIV infection which can be confirmed with the early observations of CD4+ T cells
depletion (historically referred to as T-helper cells) in individuals diagnosed with AIDS. Upon CD4
engagement, HIV-1 Env undergoes a conformational change to allow interaction with another
6

cellular co-receptor known as CCR5 (Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996;
Doranz et al., 1996; Dragic et al., 1996) that is found on certain CD4+ T cells, especially those
that are in an activated state (Ostrowski et al., 1998). HIV-1 can acquire different tropisms
through mutations to use different co-receptors. A common tropism switch is to the CXCR4
receptor, which can occur later in HIV infection and is associated with a more rapid disease
progression (Connor et al., 1997; Ostrowski et al., 1998; Schuitemaker et al., 1992). This
increase in progression is in part due to the already accelerated immunodeficiency caused by the
depletion of activated and memory CD4+ T-cells (i.e. those expressing CCR5) and the shift to
CXCR4 increases the infectability of naïve CD4+ T-cells which have a high expression of CXCR4
(Bleul et al., 1997). Env consists of a trimer of heterodimers that each consist of a heavily
glycosylated gp120 glycoprotein and a gp41 transmembrane glycoprotein (Kwong et al., 1998; Lu
et al., 1995; Rizzuto et al., 1998; Wilen et al., 2012). The binding of HIV-1 Env to CD4 and the coreceptor exposes the HIV-1 fusion peptide found in the gp41 subunit for insertion into the target
cell’s membrane (Chan et al., 1997; Wilen et al., 2012). This fusion forms a six-helix bundle of
gp41 subunits to bring virion and host membranes together for fusion (Chan et al., 1997). Upon
fusion, virion contents can diffuse into the target cell’s cytoplasm.

Reverse transcription. After entry into the target cell, the viral genome is still encapsulated by the
viral capsid. Within this protein shell compartment, HIV-1 reverse transcriptase (RT), which is
composed of two subunits (a catalytic p66 and a structural p51) (Jacobo-Molina et al., 1993;
Kohlstaedt et al., 1992; Lightfoote et al., 1986; di Marzo Veronese et al., 1986), catalyzes the
formation of double stranded DNA from the initial genomic ssRNA (Hu and Hughes, 2012). The
first step in reverse transcription is the extension of the minus (-) strand from the primer binding
site (PBS) which uses host-derived tRNA3Lys as the primer. The resultant DNA/RNA hybrid is
disrupted by the cleaving of the (+) RNA strand by RNase H, which is a component of the p66
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subunit. The (-) DNA strand (along with the tRNA3Lys) dissociates and rebinds at the 3’ end of the
genomic ssRNA. This allows for the extension of the (-) DNA sequence to complement the
genomic ssRNA. During this extension, RNase H cleaves the (+) RNA strand at multiple points
except at the polypurine tract (PPT) region. This enables for (+) DNA extension which will
generate a (+) DNA PBS region that is complementary to the tRNA3Lys. RNase H hydrolyzes the
PPT and the connection between DNA and tRNA3Lys. The newly synthesized PBS region of the
(+) DNA strand can then anneal with the PBS region of the 3’ end of the (-) strand DNA.
Extension occurs on both strands leading to the final product of linear dsDNA with LTR regions at
both ends (Hu and Hughes, 2012).

The movement of the viral capsid core from the post-entry stage to the nucleus involves host
machinery and microtubule-dependent transportation (Arhel et al., 2006; Sabo et al., 2013). The
temporal and spatial coordination of reverse transcription, nuclear import, and assembly of the
pre-integration complex is actively being researched and has led to a challenge against the
original notion of uncoating occurring in the cytoplasm. Recent studies have since shown that the
viral capsid core enters the nucleus via the nuclear pore complex and is uncoated after the
completion of reverse transcription (Burdick et al., 2020; Cosnefroy et al., 2016; Selyutina et al.,
2020; Zila et al., 2021).

Integration. The viral dsDNA, capsid, integrase, and various cellular proteins are assembled in a
complex known as the pre-integration complex (PIC) which assists in targeting the dsDNA to the
host genome (Bowerman et al., 1989; Ellison et al., 1990; Farnet and Haseltine, 1990). The
integration stage of the replication cycle is largely catalyzed by the viral integrase in a two-step
manner followed by a host-mediated step (Brown et al., 1989; Craigie and Bushman, 2012;
Fujiwara and Mizuuchi, 1988; Yoder and Bushman, 2000). The first step is a 3’ processing where
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the viral integrase removes two deoxynucleotides from both 3’ ends of the viral dsDNA The
second step is a DNA-strand transfer where the processed 3’ ends react with target DNA,
specifically at the 5’ phosphates of two nucleotides that are five base pairs apart on separate
strands. Integration culminates with DNA repair in which the 5’ overhang from the viral dsDNA
(after the 3’ processing) is removed, gaps filled in, and the 5’ viral end is ligated with the host
genome. This cleavage, extension (which subsequently leads to a five base pair duplication of the
host genome), and ligation are performed by host DNA repair machinery (Yoder and Bushman,
2000).

The viral dsDNA has at least two alternative fates, whereas only the integration of viral dsDNA
into the host genome leads to productive infection (Farnet and Haseltine, 1991). These two
episomal forms are both circular dsDNA referred to as 1-LTR and 2-LTR circles. Their formation
does not require viral proteins (Farnet and Haseltine, 1991) but do require host proteins such as
important members of the host process of nonhomologous DNA end-joining (NHEJ) repair
process (Jeanson et al., 2002; Kilzer et al., 2003; Li et al., 2001). As their name implies, 1-LTR
circles contain one copy of the LTR and are formed via recombination between opposite end
LTRs or from DNA products that not have completed reverse transcription (Farnet and Haseltine,
1991; Kilzer et al., 2003; Miller et al., 1995) while 2-LTR circles are formed by the ligation of LTR
ends of an unintegrated form of linear viral dsDNA (i.e. post successful reverse transcription) and
thus contains two copies of the LTR (Farnet and Haseltine, 1991).

The PIC targets active transcription units and the outward surface of nucleosomes due to the
tethering function of different host proteins that interact with integrase and capsid – the most
notable being the host cellular LEDGF/p75 that interacts with integrase (Cherepanov et al., 2003;
Ciuffi et al., 2005; Han et al., 2004; Maertens et al., 2003; Wang et al., 2007). Other host cellular
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proteins that have been implicated include CPSF6 (Lee et al., 2010; Sowd et al., 2016) and INI1
(Kalpana et al., 1994). Knockdown of LEDGF/p75 resulted in a loss of targeting to transcription
units, leading to a more random distribution of integration sites across the cellular genome (Ciuffi
et al., 2005). Numerous studies have shown integration sites to be enriched in epigenetic marks
(modifications of histone tails that impact the compaction of DNA with nucleosomes) associated
with active transcription (such as H3K4me1 and H3K27ac) (Berry et al., 2006; Einkauf et al.,
2022; Wang et al., 2007). This targeting of active transcription units is likely not due to the
increased accessibility of DNA as targeting of other retroviruses demonstrate different
preferences. Chimeric viruses with integrase regions from another retrovirus, murine leukemia
virus (MLV), resulted in retargeting of HIV viral DNA to transcription start sites (Lewinski et al.,
2006). Furthermore, studies that swap out LEDGF/p75’s chromatin-binding domain with other
cellular proteins’ chromatin-binding domain (such as HP1) result in insertion of viral DNA into
regions more specific to swapped cellular protein (in the case of HP1, integration was targeted to
sites enriches in H3K9me2 and H3K9me3 which are associated with heterochromatin and not
associated with active transcription) (Silvers et al., 2010). These studies and others definitively
show the role of LEDGF/p75 in targeting HIV-1 integration to active transcription units. This
integration, while preferential for active transcription units, is not strongly associated with any
specific DNA motif signatures (Cohn et al., 2015). Studies from persons living with HIV indicate a
wide diversity of integration sites in different areas of the human genome. The impact of these
sites in terms of the latent nature of HIV infection will be discussed in later sections.

Replication. The integrated viral DNA is referred to as the provirus and can now be transcribed by
host machinery into various messenger RNA (mRNA) species over the course of two different
stages. In the early stage, the first species to be produced are short (~1.8 kb) (Kim et al., 1989)
and are initiated by recruitment of transcriptional machinery by the transcription factor NF-κB
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binding to the 5’ LTR (Alcamí et al., 1995; Pomerantz et al., 1990). These initial transcripts are
completely spliced to encode the viral proteins Tat, Rev, and Nef (Kim et al., 1989; Klotman et al.,
1991). Tat is responsible for promoting transcription elongation from transcripts starting at the
LTR by binding to the transactivation-responsive region (TAR) of the nascent RNA transcript
(Muesing et al., 1987; Sodroski et al., 1985a, 1985b). Tat-mediated interaction with host P-TEFb
releases the negative elongation factor (NELF) (Zhang et al., 2007) and leads to
hyperphosphorylation of RNA polymerase II (RNAP II) (Isel and Karn, 1999). This modification of
RNAP II along with other elongation factors enables efficient elongation, thus allowing for latestage HIV gene expression to occur with longer mRNA species (He et al., 2010; Sobhian et al.,
2010). One set of these species includes incompletely spliced versions (~4 kb) which encode
Env, Vpu, Vif, and Vpr (Kim et al., 1989). Additional full-length unspliced transcripts are produced
which function both as the genomic viral RNA needed for new virions (as HIV genome is positive
sense ssRNA) and the mRNA template for the Gag and Pol polypeptides (Kim et al., 1989). Rev
is essential for preserving unspliced variants and transporting to the cytoplasm for translation and
packaging by binding to the Rev-responsive element (RRE) region of the mRNA (Malim et al.,
1989; Sodroski et al., 1986).

Assembly: Translation of the various mRNA species into viral protein and processing by cellular
machinery leads to the accumulation of viral products at the cell membrane in preparation for
assembly and budding. The Env protein is produced, processed, and exported into the plasma
membrane (Blot et al., 2003). The Gag and Gag-Pro-Pol polypeptides are important for recruiting
the other viral products and certain host proteins (including the tRNA (Kleiman et al., 2010) used
during reverse transcription) to the cell plasma membrane for virion formation and budding
(Chukkapalli et al., 2010; Sundquist and Kräusslich, 2012). These polypeptides contain domains
that allow for protein-protein and protein-RNA interactions for recruitment of viral genomic RNA
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and viral proteins to the budding area (Chukkapalli et al., 2010; Jouvenet et al., 2009; Ono et al.,
2004). At the budding area, the Gag polypeptide polymerizes to assemble an immature lattice for
budding (Briggs et al., 2006; Fuller et al., 1997; Nermut et al., 1998; Wright et al., 2007).

Budding and maturation: The p6 protein of the Gag polypeptide contains domains that recruits the
host “endosomal sorting complexes required for transport” (ESCRT) machinery (Martin-Serrano
et al., 2003; Strack et al., 2003). This interaction with ESCRT along with other host-viral protein
interactions results in the budding of the immature lattice and viral products into an extracellular
immature virion that contains the host cellular membrane with the embedded HIV Env (Jouvenet
et al., 2011; Morita et al., 2011). Upon (or during) budding, the viral protease (found in the GagPro-Pol polypeptide) cleaves the Gag-Pro-Pol and Gag polypeptides to produce the final viral
proteins (Kohl et al., 1988; Prabu-Jeyabalan et al., 2000, 2002). The series of cleavage events
results in an ordered maturation process (Pettit et al., 1994) that includes the activation of Env to
allow for fusion to a target cell (Wyma et al., 2004), condensation of viral RNA and assembly with
nucleocapsid (Kafaie et al., 2008; Ohishi et al., 2011), and formation of the final mature capsid
core (de Marco et al., 2010). Upon maturation, the virion can now complete the viral replication
cycle and enter another target cell.

1.4 HIV-1 general pathogenesis and timescale
As seen from the early documentation of HIV infection and AIDS, the initiation of HIV-1 infection
occurs through exposure of the virus to mucosal or blood interfaces. In the case of mucosal
transmission via sexual contact, most productive infections occur from either a single or a lowdiversity population CCR5-trophic virion, known as the founder virus, because of a transmission
bottleneck on the typical high diversity from the source of the infection (Abrahams et al., 2009;
Haaland et al., 2009; Iyer et al., 2017; Keele et al., 2008; Wolfs et al., 1992; Zhang et al., 1999).
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Virions can be captured by dendritic cells and transported to mucosal regions such as the lamina
propria where CCR5+ CD4+ T cells are present and can then be productively infected (Cavarelli
et al., 2013; Lapenta et al., 1999; Meng et al., 2000; Pope and Haase, 2003). Virions could also
diffuse or transcytose towards the lamina propria (Blaskewicz et al., 2011). This initial infection
can lead to the local production of many newly synthesized virions for an initial propagation of
HIV-1 and creation of a proinflammatory response that brings in CD4+ T cells to the area (Abel et
al., 2005). Infected cells and virions can then begin to appear and accumulate in the draining
lymph nodes (Abel et al., 2005), which are structures in the lymphatic system where lymphocytes
reside and circulate to sample antigens brought from the periphery and tissues by antigen
presenting cells (APCs). The draining lymph node is interlinked with other lymph nodes via the
lymphatic system and cells that egress from lymph nodes will eventually recirculate back into the
blood via the thoracic duct or the right subclavian vein (Gowans, 1959). The preferential infection
of CD4+ T cells and especially HIV-specific CD4+ T cells (Douek et al., 2002) leads to a systemic
spread of infection throughout the body (Abel et al., 2005; Deleage et al., 2016). In the case of
bloodborne routes of transmission (i.e. shared needle use and unscreened blood/blood-derived
transfusions), the infection can spread quickly throughout the body. As such, bloodborne
exposure is the highest risk for infection followed by exposure to mucosal surfaces (Hladik and
McElrath, 2008).

HIV-1 infection follows a three-phase timeline, which can vary in time amongst individuals living
with HIV but is generally comparable in untreated infections (Coffin and Swanstrom, 2013; Fiebig
et al., 2003; Shaw and Hunter, 2012). The initial infection results in systemic spread of infected
cells throughout multiple tissue sites. This results in high levels of viremia as measured by viral
RNA copies per milliliter of blood (cps/mL). Peak viral load can differ amongst individuals and be
greater than 107 cps/mL (Little et al., 1999) and occurs around 2 weeks after initial detection of
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viral RNA in blood (Robb et al., 2016). In some individuals, this acute stage can be characterized
by symptoms that include fever and lymphadenopathy. The adaptive immune response in this
acute stage begins to fight back against the virus which can initially contribute to the high viremia
as CD4+ T cells become activated which leads to CCR5 expression and are then subsequently
infected (Ostrowski et al., 1998). Productive infection of CD4+ T cells leads to the observed
depletion of CD4+ T cells due to the cytopathic effects associated with viral production and virion
budding (Lenardo et al., 2002) and the death of bystander CD4+ T cells as a result of activation
(Finkel et al., 1995). The immune response with CD8+ T cells (Borrow et al., 1994; Walker et al.,
1987) can recognize viral antigens on infected cells that are presented by the major
histocompatibility complex class I (MHC-I) complex via the T cell receptor (TCR; which is also
defined as CD3) on the CD8+ T cell (Grakoui et al., 1999). Engagement of this immune synapse
between MHC-I and the TCR along with other activation signals leads to activation and priming of
these cells to eliminate infected cells through a cytotoxic process involving granzyme B and
perforin (Kuerten et al., 2008). Additionally, the humoral immune response can also produce
antibodies that target HIV Env and impede infection (Levy et al., 1984).

The drop in viremia due to HIV-specific cytotoxic CD8+ T cells (Borrow et al., 1994; Walker et al.,
1987) leads to the next phase known as chronic infection. This phase varies between individuals
and can range between 1 to 20 years where viremia drops to a stable level which is referred to as
the setpoint viral load (Coffin and Swanstrom, 2013). The level of CD4+ T cells may return closer
to normal levels at first but will continue to slowly decline over this phase as the virus continues to
infect and propagate (Coffin and Swanstrom, 2013). During this stage, the person living with HIV
is asymptomatic but is still viremic. Upon a loss of CD4+ T cells to below 200 cells per microliter
of blood, the immune system is severely compromised and is referred to as the AIDS phase
(Coffin and Swanstrom, 2013). At this stage, opportunistic infections begin to emerge either from
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existent or newly acquired infections – both of which are usually controlled by a healthy immune
system. These infections along with the continued compromise of the immune system also leads
to increased viremia and results in eventual death.

Given the asymptomatic nature of the chronic stage and sometimes in the acute stage, there was
an urgent need for accurate diagnosis of HIV infection. The gold standard for measuring HIV
infection is a reverse transcription quantitative polymerase chain reaction (RT-qPCR) to measure
genomic viral RNA from blood. Other techniques include measuring the presence of different viral
proteins or host antibodies that are specific to viral antigens. A staging system based on these
different detections was created in 2003 for characterizing and diagnosing HIV infection and is
referred to as the Fiebig stages (Fiebig et al., 2003). During acute infection, Fiebig I is marked by
the detection of HIV-1 RNA in blood and Fiebig II starts with the detection of p24 (viral capsid).
Fiebig III is marked by the detection of virus-specific antibodies via enzyme-linked
immunosorbant assays (ELISA). For Fiebig stages IV-VI which corresponds to the early chronic
infection phase, these three stages are determined by different staining patterns for virus-specific
antibodies via Western blot analysis. Fiebig IV is represented by present but indeterminate bands
against p24, gp41, and/or gp120/160. Fiebig V has clear diagnostic banding against two of the
three viral antigens from Fiebig IV but without p31 (Pol) reactivity. Finally, Fiebig VI has clear
bands against p31. These Fiebig stages are commonly used to describe different infection stages
in connection with the more acute, chronic, and AIDS phases.

1.5 HIV-1 pathogenesis and importance of tissues
As seen with the mucosal route of transmission and the systemic spread of HIV through the
lymphatics and bloodstream, HIV is highly interfaced with the tissue compartments and an
understanding of HIV pathogenesis and immunology therefore requires a contextual
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understanding of the tissue environment. This was highlighted very early during the AIDS
epidemic with reports of what was referred to as “HIV enteropathy” whereupon biopsy samples
from the jejunum and rectum from AIDS-diagnosed patients contained abnormalities during
histological study (Batman et al., 1989; Kotler et al., 1987). Jejunal biopsies indicated partial
villous atrophy with crypt hyperplasia and increased distribution of intraepithelial lymphocytes
(Batman et al., 1989). These reports of enteropathy highlighted the significant disruption of the
gut tissue during HIV, with indications of immune activation and compromised gut barrier integrity.

Whole body profiling of HIV RNA and HIV DNA has shown that there is a high level of HIV
replication and infected cells in the gut tissue (62.3% before any treatment) and is the
predominant site (98%) of infected cells after treatment (Estes et al., 2017). Mucosal CD4+ T
cells express high levels of CCR5 thus representing a significant source for HIV infection
(Lapenta et al., 1999). This consequently leads to a large depletion of CD4+ T cells from the gut
associated lymphoid tissue (GALT) (Bishop et al., 1987; Brenchley et al., 2004; Clayton et al.,
1997). Toxic effects of viral proteins can occur including Tat negatively regulating enterocyte
metabolism (Canani et al., 2006) and gp120 leading to tubulin depolymerization and ionic
imbalance in enterocytes (Maresca et al., 2003). The loss in gut integrity can result in microbial
translocation (Brenchley et al., 2006) and increased activation of the immune system which can
promote more rounds of infection (Brenchley et al., 2006; Stein et al., 1997). Increased levels of
microbial products from commensal bacterial are present in the blood of PLWH (Brenchley et al.,
2006). The chronic infection caused by continuous HIV infection and the reaction to microbial
translocation is a hallmark of HIV infection and accelerates the progression into AIDS through the
exhaustion of the immune system, especially with regards to CD8+ T-cells. As an example in the
context of the mucosal environment, mucosal invariant T cells (MAIT; mostly CD8+ T cells that
have a restricted T cell receptor rearrangement) are depleted during early and chronic HIV
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infection (Cosgrove et al., 2013; Leeansyah et al., 2013). Remaining MAIT cells are activated and
exhausted (Leeansyah et al., 2013). Upon initiation of antiretroviral therapy and the associated
immune restoration, MAIT cell frequencies are not restored thus highlighting one of the many
profound impacts of HIV infection on the mucosal tissue environment (Cosgrove et al., 2013;
Leeansyah et al., 2013).

Before and after treatment, non-GALT-associated lymphoid tissue is also a dominant site of HIVinfected cells (Deleage et al., 2016; Estes et al., 2017). Lymph nodes are structures in the
lymphatic system that are sites for a concentrated exposure of lymphocytes to antigens by
antigen presenting cells (von Andrian and Mempel, 2003). Afferent lymphatic vessels bring in
lymph containing antigens, lymphocytes, and APCs into the subscapular sinus and then into the
cortex space (von Andrian and Mempel, 2003). APCs in the intranodal lymph channels sample
the antigens and present them to B and T cells (von Andrian and Mempel, 2003). The outer
cortex contains B cells which are arranged in follicles and form germinal centers upon antigen
simulation where B cell maturation continues with the help of CD4+ T follicular helper (Tfh) cells
(von Andrian and Mempel, 2003; Breitfeld et al., 2000; Garside et al., 1998). The lymph then
proceeds to the paracortex containing the T cell zone where T cells interact with dendritic cells for
immune activation (von Andrian and Mempel, 2003; Mondino et al., 1996). The paracortex is also
enervated by high endothelial venules (HEVs) where naïve and central memory lymphocytes
from the circulatory system can enter the paracortex via an adhesion cascade that allows
transmigration into the lymph node (von Andrian and Mempel, 2003; Marchesi and Gowans,
1964). Activated T cells proliferate and differentiate before leaving the lymph node to mediate
their immune function (Mondino et al., 1996). Some CD4+ T cells upon antigenic stimulation will
express CXCR5 and downregulate CCR7 which allows for exit from the T cell zone and entrance
to the B cell follicle for interaction with B cells (von Andrian and Mempel, 2003; Breitfeld et al.,
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2000). These cells are referred to as Tfh cells as previously mentioned (Breitfeld et al., 2000;
Garside et al., 1998). The lymph proceeds to drain through the cortex and medullary sinuses to
the medulla where mostly B cells and some macrophages and memory T cells reside (von
Andrian and Mempel, 2003). The medulla then leads to the efferent lymphatic vessels which
connect to the rest of the lymphatic network (von Andrian and Mempel, 2003).

The movement of CD4+ T cells around the body is a highly regulated process as cells circulate
around the body through lymphatic and circulatory systems to monitor and execute immune
functions at different tissue sites. The movement of CD4+ T cells from the lymph node through
the efferent lymph and into peripheral blood is largely regulated by the sphingosine 1 phosphate
(S1P) gradient and one of its cognate receptors known as S1P receptor 1 (S1PR1 or S1P1)
(Graeler et al., 2002). S1PR1 can be expressed on lymphocytes which then promotes egress
toward the blood compartment as S1P is most concentrated in the blood, followed by lymph, and
then lowest in the lymphoid tissue (Graeler et al., 2002; Mandala et al., 2002). This gradient is
maintained by S1P lyase which is expressed in lymphoid tissues to degrade S1P (Serra and
Saba, 2010). Lymphocytes can, however, remain in the lymphoid tissue of which some of these
cells are referred to as resident memory T (Trm) cells (Beura et al., 2019; Masopust et al., 2001).
The inhibition of egress is largely due to the role of CD69, which is upregulated during T cell
activation and is a marker associated with residency (Bankovich et al., 2010; Shiow et al., 2006).
The interaction of CD69 and S1PR1 leads to the internalization of S1PR1, thus rendering the
lymphocyte less responsive to the S1P gradient which promotes residency within the tissue
(Mackay et al., 2015; Shiow et al., 2006).

As there is a high concentration of immune cells including CD4+ T cells in these interconnected
secondary lymphoid organs, the introduction of HIV to the lymphatic system results in the spread
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of HIV to virtually all lymph nodes. During acute infection, germinal centers are formed and show
a high level of HIV RNA indicating the presence of HIV virions and HIV replication (Pantaleo et
al., 1993). As mentioned above, these germinal centers harbor CD4+ Tfh cells that interface with
cells associated with high levels of virus which is in addition to the free virions and infected cells
traveling through the lymph (Banga et al., 2016; Pantaleo et al., 1993; Perreau et al., 2013). HIVspecific B cells can bind HIV virions (Moir et al., 2000) while follicular dendritic cells can trap
virions in its dendrites and cycling endosomes (Biberfeld et al., 1988; Heesters et al., 2015). This
intense exposure of Tfh cells to virus leads to a high level of infection of Tfh cells (Banga et al.,
2016; Pantaleo et al., 1993; Perreau et al., 2013). This can also drive expansion of HIV-specific
Tfh cells which can lead to altered B-cell response such as hypergammaglobulinemia (Lindqvist
et al., 2012) as Tfh cells are needed to promote class switching and affinity maturation of
antibody-producing B-cells (Breitfeld et al., 2000).

1.6 Agents against HIV-1: the impact of antiretroviral therapy
The rapid arrival of the AIDS epidemic and pressure from the HIV community for more rapid
development and approval of antiretroviral therapy (ART) against HIV to prevent AIDS-related
deaths prompted the first approval by the Food and Drug Administration (FDA) for zidovudine
(also known as azidothymidine; AZT) in 1987 (Young, 1988) which is a nucleoside reverse
transcriptase inhibitor (NRTI). The efforts in discovering new drugs ran concurrent with the efforts
in elucidating the HIV-1 replication cycle and the essential enzymes for HIV-1 infection and
replication (Arts and Hazuda, 2012). As such, each step of the viral replication cycle has a
corresponding class of inhibitors designed to block or interfere with the progression of that
replication cycle step, thus inhibiting viral replication.
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AZT is a nucleoside analog of thymidine, which is one of the main deoxynucleotides that
comprise DNA (Lin and Prusoff, 1978; Mitsuya et al., 1985). Thymidine has a 3’ hydroxyl group
that allows for DNA polymerization through a phosphodiester bond with the 5’ phosphate group of
a new deoxynucleotide. In contrast, the 3’ hydroxyl group of AZT is replaced with an alternative
modification that prevents addition of new DNA nucleotides by reverse transcriptase (Furman et
al., 1986). As such, AZT and other NRTIs prevent the completion of the viral dsDNA produced
during reverse transcription (Arts and Hazuda, 2012; Mitsuya et al., 1985). NRTIs, to date,
represent a key part of ART regimens for PLWH around the world (Saag et al., 2020). A second
subclass of reverse transcriptase inhibitors became available starting from 1996 with the approval
of nevirapine and was known as non-nucleoside reverse transcriptase inhibitors (NNRTIs)
(Bowersox, 1996; Havlir et al., 1995). NNRTIs inhibit reverse transcription by binding outside of
the active site of HIV-1 RT to induce a conformational change and reduce polymerase activity
(Schauer et al., 2014). These inhibitors are only available for HIV-1 group M viruses as HIV-2 and
other HIV-1 strains have intrinsic resistance in their wild-type form (Arts and Hazuda, 2012;
Witvrouw et al., 1999).

The approval of saquinavir in 1995 brought forth the second class of ART at the time, which is the
protease inhibitor class (James, 1995). Protease inhibitors impede the proteolytic cleavage of
Gag and Gag-Pol-Pro polypeptides during the maturation phase of the HIV-1 life cycle, thus
creating defective virions (Craig et al., 1991; Roberts et al., 1990). Another class of inhibitors
known as integrase inhibitors came with the approval of raltegravir in 2007 (Arts and Hazuda,
2012; Hazuda et al., 2000). These inhibitors inhibit the integration of viral dsDNA into the host
genome at the strand transfer step of viral integration by sequestering the magnesium metal ion
co-factors at the active site of integrase (Espeseth et al., 2000; Grobler et al., 2002; Tchertanov
and Mouscadet, 2007). These integrase strand transfer inhibitors represent a key component of
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combinatorial ART that is recommended for current use (Saag et al., 2020). A second subclass of
integrase inhibitors known as allosteric integrase inhibitors (ALLINIs) are also actively being
studied for their ability to negatively impact the interaction of integrase and LEDGF/p75 (Christ et
al., 2010).

The final class of ART consists of entry inhibitors which can be sub-classified by their mode of
action in either impeding the fusion step or antagonizing the interaction of CCR5 with HIV-1 Env.
Enfuvirtide was the first of the former subclass upon its approval in 2003 and inhibits the
formation of the six alpha-helical conformation of gp41 needed for fusion (Arts and Hazuda, 2012;
Kilby et al., 1998; Wild et al., 1993). The latter subclass was introduced with the approval of
maraviroc in 2007 as a small-molecule CCR5 antagonist (Dorr et al., 2005). These inhibitors
allosterically induce a conformation change in CCR5 that prevents binding with HIV-1 Env (Arts
and Hazuda, 2012; Kondru et al., 2008).

After the introduction of AZT, it soon became apparent that HIV could become resistant against
AZT and similar phenomenon would later be shown for other HIV inhibitors as well (Boucher et
al., 1992). The resistance is a result of viral evolution made quicker by the error prone nature of
the viral reverse transcriptase as it lacks the proofreading capability of other polymerases and the
high turnover rate of the virus (Bebenek et al., 1989; Coffin, 1995; Drake et al., 1998; Hahn et al.,
1986). As such, it is estimated (based on genome size and average error rates) that there are 110 mutations for every replication of the HIV genome (Abram et al., 2010; Mansky and Temin,
1995). This propensity for a high rate of mutations occurs without ART and mutants with drug
resistant are likely already to exist in the viral quasispecies prior to ART initiation (Coffin, 1995).
ART-induced pressure, however, leads to genetic selection of those mutants as these viruses
contain mutations allow for continued replication despite ART (Boucher et al., 1992). Depending
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on the inhibitor class and the specific inhibitor, the initial selection of mutations to escape the
inhibitor pressure often are mutations that come at a cost of viral fitness (i.e. reduced replicative
ability) (Harrigan et al., 1998). Additional rounds of subsequent mutations can lead to viruses that
acquire compensatory mutations that restore a varying degree of fitness for continued replication
in the host (Cong et al., 2007).

The emergence of mutations suggested that a single monotherapy would not be sufficient and
would lead to quick resistance to make AZT obsolete. The introduction of protease inhibitors with
saquinavir allowed for the creation of highly active antiretroviral therapy (HAART; also known as
combinatorial ART (cART)) (Arts and Hazuda, 2012). The success of HAART led to the first
annual decrease in AIDS-related deaths in 1997 (Crum et al., 2006) and to the continued
development of stronger and better HAART regimens. However, resistance continued to emerge
in the face of AZT and protease inhibitors (Boucher et al., 1992; Schapiro et al., 1999). This led to
the suggestion that the combination of at least three or more drugs was likely to provide
sustained inhibition of HIV-1 replication (Arts and Hazuda, 2012; Coffin, 1995; Frost and McLean,
1994). Many groups assessed different combinations of inhibitors and their relative impact on the
barrier to HIV-1 mutational resistance (Gulick et al., 1997; Kempf et al., 1997; Larder et al., 1995)
leading to the current clinical recommendation for regimens containing two NRTIs and one other
class of inhibitors, which typically are integrase inhibitors (Saag et al., 2020). For example, a
common regimen that follows this recommendation is tenofovir disoproxil fumarate (TDF) +
emtricitabine (FTC) + dolutegravir (DTG)) (Saag et al., 2020).

The advent of HAART has transformed the lives of PLWH in allowing for limiting HIV replication
and allowing for the partial restoration of the immune system. The usage of HAART, including its
usage for pre-exposure prophylaxis (PrEP), has effectively eliminated the transmission risk during
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sexual contact as studied via the HPTN 052, PARTNER, and Opposites Attract clinical studies
(Bavinton et al., 2018; Cohen et al., 2016; Rodger et al., 2019). In these studies, individuals who
are durably suppressed with undetectable viral load through complete adherence on their HAART
regimen, cannot effectively transmit the virus to a sexual partner. This fundamental improvement
in the lifestyles of PLWH is colloquially referred to as U=U (undetectable = untransmittable).

The successes of ART are dependent on the rigorous adherence to the ART regimen and
prevention of drug resistance mutants. Clinical efforts are active in finding new formulations or
delivery methods that reduce the number of required pills and/or frequency of medicine uptake
(Jaeger et al., 2021; Molina et al., 2021; Orkin et al., 2021). The issue of drug resistance is still
highly relevant despite the use of combinatorial therapy, especially in the context of transmission
of multi-drug resistant viruses to new individuals (Delaugerre et al., 2004). As such, research
efforts are active in finding preventative vaccines, alternative therapeutic options such as
immunotherapy, and additional inhibitors to improve the lives of PLWH.

1.7 HIV-1 reservoir: persistence and latency
While ART has transformed the lives of PLWH, ART does not serve as a functional cure (i.e. not
a complete cure) of HIV since durable suppression, for most individuals, requires constant
adherence to their ART regimen (Gardner et al., 2009; Vreeman et al., 2014). Upon cessation of
ART, the virus will inevitably rebound in most individuals leading to continued progression of HIV
infection and eventually into AIDS if left untreated (Davey et al., 1999; Wong et al., 1997a). This
rebound is due to the integration of HIV viral DNA into the target cell, which allows for a lifelong
infection of that cell as transcription of an intact provirus can produce new virions. The pool of
infected cells in an individual is collectively referred to as the HIV reservoir. This lifelong
persistence, multiple means to maintain infected cells, and the existence of multiple sub23

reservoirs in immune privileged sites are the major characteristics to the HIV latent reservoir –
and represent the challenges to a functional cure of HIV.

Latency can be defined for HIV as a state of infection at a per-cell basis where viral gene
expression is limited to the degree of non-productive infection (Siliciano and Greene, 2011).
Importantly, this latent status is reversible meaning that the provirus is fully capable of being
transcribed to lead to productive infection (Davey et al., 1999; Folks et al., 1986). This definition
of infection latency is not to be confused with the notion of clinical latency which is sometimes
used to describe the chronic phase of infection before the appearance of AIDS, as HIV is actively
still replicating during this (often) asymptomatic phase (Siliciano and Greene, 2011). The notion of
latency was identified early on with in vitro infections of cell lines where the cells that survived
infection had little to no viral gene expression (Folks et al., 1986). However, the reversible nature
was identified as different stimuli including T cell activation pathways, could lead to proviral
transcription (Folks et al., 1986). This suggested that transcription factors related to these stimuli
could play a role in modulating HIV gene expression. Analysis of the LTR region showed the
presence of host transcription factors including NF-κB and Sp1 that may promote a genomic
environment conducive to transcription at the proviral locus (Böhnlein et al., 1988; Harrich et al.,
1989; Nabel and Baltimore, 1987; Siekevitz et al., 1987).

Latency was confirmed in vivo by collecting resting (HLA-DR-) memory CD4+ T cells from ARTtreated PLWH (Chun et al., 1995). Upon cellular activation with phytohemagglutinin (PHA), viral
p24 antigen was detected in culture indicating that there were a small number of cells with
proviruses that could be reawakened to produce new virions (Chun et al., 1995). Further studies
solidified that the HIV reservoir was primarily in the memory CD4+ T cells from treated individuals
(Chomont et al., 2009; Chun et al., 1997a). This was confirmed to be true as well in PLWH
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treated with combinatorial ART after the approval of protease inhibitors which indicated that
combinatorial ART was not sufficient for a functional cure of HIV (Chun et al., 1997b; Finzi et al.,
1997; Wong et al., 1997b). These studies highlighted the need to better understand how latency
is established.

Interface with host epigenetics and repression of proviral transcription
The integration of the HIV viral DNA into the host genome interfaces with the host mechanism for
regulating chromatin compaction to modulate gene expression. This regulation, known as
epigenetics, is conserved in eukaryotic species. A major component of epigenetics deals with the
modular unit of chromatin compaction known as the nucleosome (Kornberg, 1974; Kornberg and
Thomas, 1974; Sandman et al., 1998). Each nucleosome is comprised of an octamer of proteins
known as histones (two copies each of H2A, H2B, H3, and H4) (Kornberg and Thomas, 1974).
DNA is wrapped around nucleosomes leading to a highly organized and compact chromatin state
(Kornberg, 1974). Histones contain many basic amino acids that create positive charges to
interact with the negatively charged phosphate groups in the DNA backbone (Arents et al., 1991;
Mirzabekov et al., 1978). This DNA-histone interaction can lead to the condensation of chromatin
around nucleosomes and higher-order chromatin structures (Kornberg, 1974).

Histones have N-terminal tails with basic amino acids that can interact with DNA (Arents and
Moudrianakis, 1995; Arents et al., 1991). Epigenetic writers and erasers are enzymes that can
post-translationally modify these amino acids to influence the degree of chromatin condensation
(Gillette and Hill, 2015). As one example of many possible modifications, histone
acetyltransferases (HATs) can transfer acetyl groups onto the ninth lysine of the H3 histone tail
(which is referred to as H3K9ac) (Bian et al., 2011; Vermeulen et al., 2010). This neutralizes the
positive charge of the lysine leading to a relative relaxing of DNA around the nucleosome to
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promote transcription (Gates et al., 2017; Simpson, 1978). Alternatively, deacetylation by erasers
such as histone deacetylases (HDACs) (Taunton et al., 1996) as well as trimethylation of that
same lysine by other writers known as histone methyltransferases (HMTs) (Rea et al., 2000;
Strahl et al., 1999) can result in H3K9me3 which will restore the positive charge to favor the
condensed form. This condensed form is referred to as heterochromatin while the
open/accessible form is referred to as euchromatin. These post-translational modifications,
collectively known as the histone code, can occur on different amino acids on the different tails
(Jenuwein and Allis, 2001). Studies have collectively identified certain modifications to be
indicative of different chromatin states and different genomic features (i.e. gene bodies,
promoters, etc.) (Jenuwein and Allis, 2001). Together, these epigenetic writers, erasers, and
readers modulate the chromatin compaction to impact gene expression – including at the
provirus.

Transcription factors are an important aspect of the regulation of host and HIV gene expression.
Different transcription factors are often induced by stimuli (whether extracellular or intracellular) to
bind to enhancer and promoter regions to regulate the recruitment of transcription machinery,
thus regulating gene expression (Core et al., 2014; Serfling et al., 1985). Most transcription
factors bind accessible DNA meaning that the compaction of DNA can influence transcription
factor activity (Adams and Workman, 1995; Robertson et al., 2008). A class of transcription
factors, known as pioneer factors, can bind DNA even in the condensed state (Cirillo et al., 2002;
Zaret and Carroll, 2011). As their name implies, these factors can lead to the recruitment of
additional transcription factors and epigenetic machinery that remodel the original repressed
chromatin environment towards a more accessible state. NF-κB and Sp1 – which have binding
sites in the HIV LTR sequence (Jones et al., 1986; Nabel and Baltimore, 1987; Perkins et al.,
1993; Steger and Workman, 1997) – are both considered to be pioneer factors in their ability to
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promote more accessible chromatin (Courey et al., 1989; Stormberg et al., 2021). Together,
these demonstrate a high level of coordination of the cellular program in regulating viral gene
expression.

Given this extensive interface, the proviral LTR region is unsurprisingly highly structured. Studies
by Drs. Carine van Lint and Eric Verdin have shown the specific positioning of certain
nucleosomes at the 5’ LTR (Verdin, 1991; Verdin et al., 1993). These nucleosomes, referred to as
nuc-0 and nuc-1, are formed even in euchromatin and impact the transcriptional activity of the
provirus (Verdin et al., 1993). The nucleosome-free region between nuc-0 and nuc-1 contains the
binding sites for several transcription factors (Verdin et al., 1993). Multiple HATs including
p300/CBP and GCN5 are recruited to the LTR through interactions with specific forms of NF-κB
and other proteins (Gerritsen et al., 1997; Lusic et al., 2003; Ogryzko et al., 1996). These HATs
lead to the remodeling of nuc-1, which is situated at the transcription start site (i.e. the R region of
the LTR), and subsequently promote the recruitment of RNA Pol II for transcription (Lusic et al.,
2003; Van Lint et al., 1996; Verdin et al., 1993). A separate in vitro study have also indicated
potential roles for a chromatin insulator known as CTCF and different families of transcription
factors (including Forkhead and Kruppel-like factors) at the provirus locus in establishing or
maintaining HIV latency (Jefferys et al., 2021).

The HIV-1 genome also contains an enhancer region located intragenically near the 3’ end of the
pol gene (Verdin, 1991; Verdin et al., 1990). This enhancer region, shown to be sensitive to
phorbol 12-myristate 13-acetate (which activates the protein kinase C pathway) (Verdin et al.,
1990), contains binding sites for multiple transcription factors including from the activator protein1 (AP-1) family, Sp1, and NF-κB (Van Lint et al., 1994). Later studies indicated that this enhancer
can increase the transcriptional activity of the HIV promoter in Tat-independent and Tat27

dependent manners (Colin et al., 2011; Goffin et al., 2005). However, binding of Oct-1 and/or Oct2 in this enhancer can negatively regulate the promoter activity (Goffin et al., 2005). The
combination of the promoter and enhancer of the HIV provirus highlights the complex regulation
of HIV proviral transcription.

Another component of host epigenetic regulation is DNA methylation where the fifth carbon of a
cytosine followed by a guanine dinucleotide (CpG) can be methylated by DNA methyltransferases
(Dnmts) (Holliday and Pugh, 1975; Moore et al., 2013; Yen et al., 1992). HDACs and HMTs have
potential cooperative activity in modifying histone tails and writing DNA methylation (Fuks et al.,
2003; Moore et al., 2013). Furthermore, readers that recognize methylated cytosine can also
impede the binding of transcription factors as well thus negatively regulating transcription (Moore
et al., 2013). In the context of the provirus, there are two CpG regions surrounding the
transcription start site that are methylated in cell lines harboring latent provirus and in a primary
cell model of HIV latency (Blazkova et al., 2009; Kauder et al., 2009). Demethylating agents can
lead to proviral transcription at least in vitro (Kauder et al., 2009). However, proviruses from ARTtreated PLWH were not detected to be highly methylated and had variable methylation patterns
both at the promoter and within the provirus (Blazkova et al., 2012). As such, DNA methylation is
not currently thought to play as big of a role in the establishment of latency as compared to
histone mediated modulation of the proviral epigenetics.

Additional routes for repressing proviral transcription
Transcriptional repression by way of transcriptional interference can also contribute to latency. To
explain the counterintuitive identification of latent proviruses in highly expressed genes in latency
cell line models and primary CD4+ T cells (Han et al., 2004; Lewinski et al., 2005), two models
have been proposed depending on the orientation of the provirus relative to the host gene
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(Siliciano and Greene, 2011). In the case of the same orientation, the first model, known as
promoter occlusion, can occur where readthrough by RNA polymerase II can occlude
transcription factors from binding on HIV-1 LTR (Greger et al., 1998; Lenasi et al., 2008) which
would impede transcription through the LTR given the importance of decondensing nuc-1. The
second model, known as the collision model, occurs when the provirus is integrated in an
opposite orientation relative to the host gene (Han et al., 2008). Extension from the proviral
promoter and the host gene promoter could lead to a collision of different RNA polymerase II
proteins (Han et al., 2008). Furthermore, double stranded viral RNA sequences could arise
leading to RNA interference, methylation, or antisense RNA that could negatively impact viral
replication (Siliciano and Greene, 2011).

Additional latency mechanisms also exist in terms of regulating the activity of RNA polymerase II.
As stated earlier, the recruitment of transcription factors at the promoter region subsequently
promotes the stable recruitment of RNA polymerase II at the promoter. The RelA subunit of NFκB contains lysines that are capable of being acetylated (Chen et al., 2001, 2002). Specifically,
acetylation of the lysine at position 310 has been shown to enhance transcriptional activity (Chen
et al., 2002). HDACs (specifically HDAC3 and SIRT1) can remove this acetylation (Chen et al.,
2001; Yeung et al., 2004). Importantly, HIV Tat has been shown to block the deacetylation ability
of SIRT1 at this specific lysine position (Kwon et al., 2008). Additional lysine positions of RelA are
also important in controlling the nuclear versus cytoplasmic positioning of NF-κB as its
cytoplasmic form has no transcription factor capability (Sun et al., 1993). HIV Tat is also important
in terms of leading to the hyperphosphorylation of RNA polymerase II which is necessary for
elongation through the provirus (Isel and Karn, 1999). As such, HIV Tat is critical in controlling the
change from transcription to actual productive replication and the fluctuations in Tat presence
may influence latency (Weinberger et al., 2005).
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These different mechanisms for latency indicate that latency is not characterized by a single
mechanism. Rather, there is a collection of different regulatory mechanisms which may be
different per cell given the landscape of different integration sites. The emergence of latency in
vivo from a broader perspective can be attributed to normal CD4+ T cell function during antigen
response. After immunological synapse, a resting CD4+ T cell will become activated which leads
to cell division and differentiation for an immune response. Most effector cells that are produced
from this initial cell will die (Ju et al., 1995) but some cells will survive as memory cells with a
more quiescent state (Gasper et al., 2014). These memory cells are retained as long-lived
surveyors to recognize and generate a rapid immune response if the same antigen is detected
again in the body (Gasper et al., 2014). In the context of HIV infection, activated CD4+ T cells are
preferentially infected, but most die off due to virus budding or from the immune response
(whether being acted upon as a target cell or because of a short half-life as an effector cell) (Ho
et al., 1995; Wei et al., 1995). However, some cells will revert their transcriptional program back
to a resting profile. As resting phenotypes have different transcription factor profiles than
activated cells, the lack of certain factors (i.e. NF-κB and others) needed for HIV transcription
renders some proviruses silent but capable of being awoken upon stimulation (Chun et al.,
1997b; Shan et al., 2017). Furthermore, resting memory CD4+ T cells contain a shorter form of
polypyrimidine tract binding protein (PTB) – which is an RNA export protein – compared to the
longer form found in activated CD4+ T cells (Lassen et al., 2006). This shorter form may play a
role in the observed difficulty in exporting Tat and Rev transcripts into the cytoplasm (Lassen et
al., 2006).
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Maintenance of the HIV reservoir
This pool of latently infected cells has been shown to have a long half-life on the order of years
(~44 months) for PLWH with an estimated >70 years needed for a full decay in an initial study of
the reservoir of resting CD4+ T cells (Crooks et al., 2015; Siliciano et al., 2003). This long half-life
is attributed not only to the relatively long lifespan of memory CD4+ T cells (Tough and Sprent,
1995) but also the ability of T cells to proliferate under both resting and activated conditions. This
notion of clonal expansion is observed early on in HIV infection where the same integration site
was detected in multiple cells (Coffin et al., 2019). Given the size of the human genome and the
random integration of HIV-1, it is unlikely that each of these cells was de novo infected at the
same location by different virions (Maldarelli et al., 2014). Instead, the more likely scenario is
clonal expansion where a single infected cell proliferates which would also copy the integrated
viral DNA such that each daughter cell also has the same provirus at the same genomic
coordinate. During chronic and eventual treatment under ART, the proportion of clonally
expanded infected cells increases in PLWH (Cohn et al., 2015; Maldarelli et al., 2014; Wagner et
al., 2014). Given the memory profile and nature of CD4+ T cells, these latently infected cells are
thought to be maintained by at least three different but not mutually exclusive processes: 1)
antigenic stimulation, 2) homeostatic proliferation, and 3) integration site-dependent proliferation.

Antigenic simulation is not a surprising phenomenon given that HIV preferentially infects HIVspecific CD4+ T cells (Douek et al., 2002) suggesting that antigen exposure and subsequent
exposure leads to more infection. HIV can also infect other cells with different specificities
including towards chronic viral antigens from Epstein Bar Virus (EBV) and cytomegalovirus
(CMV) (Douek et al., 2002). In one context, a PLWH who was under at least 12 years of ART
treatment had a diagnosis of metastatic squamous cell carcinoma (Simonetti et al., 2016). During
treatment and subsequent relapse of the cancer, an increase in HIV viral load was observed. This
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was traced to a clonal expansion of a cell found to be associated with anatomical sites containing
cancerous tissue, implying that this clonal expansion was the result of tumor-specific antigens
(Simonetti et al., 2016). In many PLWH with ART treatment, most measurements of viral load are
below the limit of detection (< 50 copies per milliliter of blood) (Nettles et al., 2005). However,
there are viral blips where viral load is detected above the limit of detection despite ART
adherence (Nettles et al., 2005). It is important to note that ART does not directly impede RNA
transcription, but instead focuses more on preventing newfound infections. As such, it is thought
that these viral blips are a result of antigenic simulation (Bailey et al., 2006; Mendoza et al., 2020;
Wagner et al., 2013; Wang et al., 2018). These observations lead to the “wax and wane” model of
clonal expansion by antigenic stimulation where the latent reservoir expands and contracts as the
immune system reacts with antigen and resolves its response (Liu et al., 2020a; Wang et al.,
2018).

Clonal expansions have been well documented for various antigen specificities. Expansions have
been detected in cells specific for chronic infections – including HIV, CMV, and EBV (Mendoza et
al., 2020). Similarly, clonally infected cells have been detected during seasonal/recurrent antigen
exposure as seen with a spike in plasma HIV RNA transcription after influenza vaccination (Jones
et al., 2012). Seasonal viral infections can also correlate with viral load rising above the limit of
detection in winter (van Sighem et al., 2008). These observations along with the studies
supporting the “wax and wane” model indicate that antigen stimulation likely plays a significant
role in maintaining and shaping the dynamics of the HIV latent reservoir.

Another mechanism for maintenance of the reservoir is homeostatic proliferation. During both
uninfected and infected settings, memory CD4+ T cells proliferate upon various signals including
from interleukin 7 (IL-7) and its cognate receptor known as IL-7 receptor alpha (CD127; IL7RA)
32

(Kondrack et al., 2003). CD127 is commonly expressed on Tcm and Ttm cells (Mahnke et al.,
2013) which comprise a large part of the latent HIV reservoir in PLWH (Chomont et al., 2009;
Dunham et al., 2008; Hsiao et al., 2020). Treatment of cells isolated from PLWH with IL-7 can
lead to expansion of infected cells without triggering HIV transcription (Katlama et al., 2016;
Vandergeeten et al., 2013). As such, IL-7 mediated homeostatic proliferation may play a large
role in maintaining the latent cells without triggering immune surveillance. Other homeostatic
cytokines including IL-2, IL-15, IL-6, and IL-10 can also play a role in proliferation and are
dependent on memory subset, presence of cognate receptors, immune state, and tissue
compartment (Bosque et al., 2011; Boyman et al., 2007).

The third process in which the reservoir is maintained is through integration site-dependent
proliferation. While HIV does integrate into highly transcribed genes which include genes related
to cellular growth, there are few documentations of HIV-1 integration causing a cancerous growth
of the infected cell (Mellors et al., 2021) unlike the higher prevalence of cancer caused by
oncogenic retroviruses such as human T lymphotropic virus (HTLV) (Liu et al., 2020a; Poiesz et
al., 1980). The documented cases of integration site-dependent proliferation have been seen with
the provirus oriented in the same sense as the host gene, especially one that regulates
proliferation or is known to be a tumor suppressor. In the case of integration within proliferation
related genes such BACH2, MKL2, and STAT5B which are commonly detected in clonal
expansions in PLWH, an integration upstream of the transcription start site can induce expression
of both viral and host genes as the viral promoter could drive and lead to a full coding transcript
(Ikeda et al., 2007; Maldarelli et al., 2014; Wagner et al., 2014). As such, these integrations would
promote the proliferation of these clones and would explain the high levels of clonal expansion
with integrations in these genes across a high number of PLWHs.
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Another example of integration site-dependent proliferation exists when the proviral integration
and subsequent incorrect splicing of the host-viral transcript leads to a truncated form of the host
gene. This has been observed in an integration event in VAV1 (a proto-oncogene) where the
incorrect splicing leads to a N-terminal truncation of VAV1 which happens to contain the
regulatory region (Liu et al., 2020b). The mutant VAV1 has a gain of function deletion leading to
increased proliferation (Katzav et al., 1991). A third example was observed recently with the
introduction of chimeric antigen receptor T (CAR-T) cells to treat chronic lymphocytic leukemia in
an individual (Fraietta et al., 2018). The genetic cassette containing the CAR-T is inserted into T
cells via a HIV-derived retroviral vector (Fraietta et al., 2018). In one cell from this individual, the
vector was integrated downstream of the TET2 gene which is a tumor suppressor gene and
involved in DNA methylation. Aberrant splicing resulted in a C-terminal deletion to create a loss of
function mutant that led to a large clonal expansion of this cell (Fraietta et al., 2018). Altogether,
these indicate the complexities of HIV-1 integration with the impact on host gene expression and
proliferation potential.

These three mechanisms – antigenic stimulation, homeostatic proliferation, and integration sitedependent proliferation – all can contribute to maintenance and dynamics of the HIV reservoir.
From the wide range of studies, no single mechanism can explain the dynamics of every
reservoir. Each PLWH has a different reservoir uniquely shaped by viral load, viral strains, and
host immune state/responses. A rarer form of latency has also been observed in elite controllers,
who are individuals that have a spontaneous control of HIV without ART (Jiang et al., 2020).
These elite controllers demonstrate correlates of immune protection including an increased
likelihood based on certain haplotypes and polyfunctional T cell responses (Walker, 2007). In a
recent report, infected cells from elite controllers were found to be enriched in heterochromatic
and centromeric satellite regions (Jiang et al., 2020) although this assessment was done via
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annotation references and not with a simultaneous measurement of chromatin accessibility from
the same infected cell. Furthermore, it is unclear if the enrichment of these sites is a hallmark of
initial infection in elite controllers or if the immune clearance has led to the selection of cells
containing these sites. Regardless, this highlights the complexity of latency as many factors
contribute to the latent identity and potential expansion of certain infected cells.

Amongst the 1 in 100-1000 CD4+ T cells from peripheral blood that contain integrated HIV DNA,
it is estimated that only 1 in 1000 of those infected cells (i.e. 1 in 106-107 total CD4+ T cells)
contains an intact provirus (Eriksson et al., 2013; Ho et al., 2013). An intact provirus is defined as
a proviral sequence that can produce a productive infection. The presence of insertions,
deletions, errors from reverse transcription, and hypermutations from host APOPEC3G
deamination can each generate a defective provirus (Ho et al., 2013; Yu et al., 2004). Most clonal
expansions contain defective provirus, which might explain the lack of productive infection during
their proliferation and their lack of clearance by the immune system (Ho et al., 2013). It is
important to note that defective proviruses can still have an intact LTR which can lead to
expression of viral antigens during random reactivation or during antigenic stimulation (Duette et
al., 2022; Einkauf et al., 2022; Imamichi et al., 2020). This phenomenon can contribute to the
persistent chronic infection that is a hallmark of HIV infection (Imamichi et al., 2020).
Furthermore, studies have shown that intact proviruses are further enriched in HLA-DR+ as well
as Tem cells of which many of them are actively producing viral RNA transcripts during ART
(Grau-Expósito et al., 2019; Hiener et al., 2017; Lee et al., 2019). Naïve (Tn) and stem cell
memory (Tscm) CD4+ T cells have also been shown to be a potential reservoir source that may
also be enriched in intact proviruses (Hiener et al., 2017; Morcilla et al., 2021).
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In addition to CD4+ T cells, other cell types may harbor virus as virions or integrated virus. As
mentioned earlier, follicular dendritic cells are not infected but rather trap virions on their dendrites
and can also internalize them in cycling endosomes during treated infection (Heesters et al.,
2015). Monocytes and macrophages can be infected in vitro and have been detected in
macrophages in vivo but their subsequent impact to latency in vivo is less clear (Shen et al.,
2009; Zalar et al., 2010). Circulating monocytes may be infected and their differentiation into
macrophages into tissues as well as tissue CD4+ T cells may lead to the spreading of the
infection into more immune privileged sites including the central nervous system (Cosenza et al.,
2002; Jenabian et al., 2016). Furthermore, CD34+ bone marrow cells were found to have latent
provirus in treated individuals (Carter et al., 2010). These different locations are difficult to study
in vivo from PLWH but highlight the full-body prevalence of HIV infection and the need for future
therapies to address these potential sources of reservoir rebound if treatment is interrupted.

1.8 Assessing the HIV reservoir: finding an infected cell in a haystack of cells
Describing the HIV reservoir is difficult for a multitude of technical and biological reasons but is
necessary for the development of targeted curative therapies. By measuring the different stages
of viral products, different conclusions can be drawn about the reservoir. Methods have generally
been more focused on the virologic and clinical aspects of the reservoir by acquiring one or a
combination of the following metrics: frequency of infected cells, intactness of the provirus, and
inducibility of the provirus. Assessing the reservoir in the context of cellular and tissue
immunology remains difficult but this understanding is critical for any future curative therapy.

Quantitative and qualitative assessments of the virologic aspects of the reservoir
Measuring HIV RNA via quantitative PCR (qPCR) is still the gold standard for determining viral
load (Abdel-Mohsen et al., 2020). However, this will not describe the frequency of infected cells
36

as latent infection can limit transcription in some cells. qPCR can also be used to measure cellassociated HIV DNA to get a better proportion of infected cells. This method will not discern
between intact versus defective proviruses as most infected cells during treatment are defective.
Near full-length proviral genomes can also be sequenced and determined for intactness with
next-generation sequencing, but with higher cost and time requirements (Abdel-Mohsen et al.,
2020).

Quantitative viral outgrowth assay (QVOA) was shown early on to highlight latent infection in
treated PLWH (Chun et al., 1997a; Finzi et al., 1997; Wong et al., 1997b). In this assay, many
resting CD4+ T cells (defined initially as HLA-DR-) are cultured with phytohemagglutinin (PHA)
along with irradiated cells from a HIV- donor to induce high levels of activation and subsequent
expansion with the goal of disturbing latency and inducing viral transcription. Viral p24 is
measured to determine viral replication. Another version of QVOA was developed and named
qualitative and quantitative viral outgrowth assay (Q2VOA) (Lorenzi et al., 2016). In this version,
cells are plated at limiting dilution before cells are activated and expanded as in regular QVOA.
Wells that are p24+ can be analyzed for proviral sequencing to determine whether the provirus is
intact or detective. Furthermore, the cells can also be profiled and used in downstream assays as
well. However, QVOA and Q2VOA require many cells to initiate the outgrowth assay and it has
been shown these methods greatly underestimate the number of latent cells as not all latent cells
are awoken under PHA-based stimulation (Abdel-Mohsen et al., 2020; Ho et al., 2013).

Additional assays were developed to measure the frequency of latently infected cells by
measuring multi-spliced RNA after stimulation. One of these assays, named Tat/rev Induced
Limiting Dilution Assay (TILDA), attempted to increase the sensitivity of detecting infected cells
while requiring both fewer cells and less time compared to QVOA (Procopio et al., 2015).
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However, these methods do not fully discern between defective and intact as some detective
viruses can still produce spliced transcripts (Pollack et al., 2017).

Two methods are currently used to discern the frequencies of cells harboring intact and defective
viruses. The first method, known as inducible proviral DNA assay (IPDA), uses a set of primers
that target the packaging signal (Ψ) and Rev response element (RRE) in env (Bruner et al.,
2019). These regions have high conservation and signals are required in both to deem a
detection as intact when acquired with a digital droplet qPCR instrument (Bruner et al., 2019).
Similarly, the quadruplex qPCR (Q4PCR) assay does a first round near full-length PCR reaction
to amplify the provirus (Gaebler et al., 2019). Amplicons are diluted to single-copy concentrations
for a plate-based qPCR where primers and probes target conserved regions in Ψ, gag, pol, and
env. Wells that are positive for at least 2 of the primer/probe sets are selected for NFL for
validation of intactness. Both methods, while relatively high throughput, are not able to capture all
possible sequences due to the large variability of HIV mutations and polymorphisms (Kinloch et
al., 2021).

Defining the specific phenotypes of HIV-infected cells
These above assays, while useful for characterizing the virologic and clinical aspects of infection,
are by themselves insufficient for defining the immunological characteristics of the CD4+ T cell
HIV reservoir. Defining the characteristics is difficult for a range of technical and biological factors
including 1) the heterogeneity of CD4+ T-cells, 2) the rarity of infected cells during treated
infection, and 3) the identification of infected cells.

CD4+ T cells are highly diverse in terms of functional and phenotypic and the pool of infected
cells are likewise diverse. Throughout HIV infection, infected cells can be found in a wide range of
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memory or activated phenotypes (Chomont et al., 2009; Hiener et al., 2017; Jones et al., 2020;
Morcilla et al., 2021) as well as in different tissue compartments that shape the cell’s functional
and phenotypic characteristics (Estes et al., 2017; Jones et al., 2020; Perreau et al., 2013).
Furthermore, some cells can stay resident within a tissue compartment (Cantero-Pérez et al.,
2019) which complicate the efforts in identifying signatures of the HIV reservoir as access to all
these cells and potential sub-reservoirs is difficult. CD4+ T cells are commonly described based
on whether they have encountered antigen (i.e. differentiation from the initial post-thymic naïve
state) and their current role in surveillance and/or active responses (i.e. memory or effector
states) (Mahnke et al., 2013). CD4+ T cells within these different descriptors are sub-classified
based on the presence of different surface markers, transcription factors, or cytokines that
indicate a more tailored response to certain types of pathogens (Geginat et al., 2014; Mahnke et
al., 2013). Additionally, memory cells are on a differentiation spectrum that appears to be
dependent on a series of factors including the strength of their initial TCR stimulation (Snook et
al., 2018). Memory T cells are classified based on their expression of different isoforms of CD45
and expression of CCR7, CD27, and CD28. Central memory T cells (Tcm) have increased
proliferative capacity and weaker effector activity upon recall while effector memory T cells (Tem)
have decreased proliferative capacity and a stronger effector response once recalled (Mahnke et
al., 2013; Sallusto et al., 2004).

As mentioned in the previous sections, multiple studies have assessed different characteristics of
the reservoir based on memory and functional subsets. These altogether have shown that a wide
range of subsets can be infected and persist during ART and across different PLWH (Chomont et
al., 2009). It was initially thought that the Tcm and transitional memory (Ttm) cells were the major
reservoirs during ART as indicated by their ability to undergo homeostatic proliferation via IL-7
signaling with relatively long half-lives (Buzon et al., 2014; Chomont et al., 2009; Jaafoura et al.,
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2014; Sáez-Cirión et al., 2013; Tough and Sprent, 1995). However, later studies have shown that
many of these cells in these subsets may contain defective proviruses and that the later
differentiated cells such as Tem cells contain a greater proportion of intact proviruses (Hiener et
al., 2017). Other studies have offered support of various functional subsets that were enriched in
infected cells including but not limited to T helper 17 (Th17) cells (Sun et al., 2015; Wacleche et
al., 2016) and Tfh cells (Banga et al., 2016; Perreau et al., 2013).

Many studies have attempted to uncover surface protein signatures of infected cells to identify the
pool of infected cells more specifically for a targeted therapy. However, there is no known
combination of markers to definitively mark an infected CD4+ T-cell from an uninfected CD4+ Tcell. Some of the markers that have been shown to partially enrich for cells containing HIV DNA
and/or HIV RNA include CXCR5 (Pantaleo et al., 1993; Perreau et al., 2013), CD2 (Iglesias-Ussel
et al., 2013), CD69 (Cantero-Pérez et al., 2019; Neidleman et al., 2020), CD161 (Li et al., 2019),
CCR6 (Gosselin et al., 2017), HLA-DR (Lee et al., 2019), as well as inhibitory receptors such as
PD-1, LAG-3, and TIGIT (Fromentin et al., 2016; Pardons et al., 2019). These and other studies
(Chomont et al., 2009; Ho et al., 2013; Mendoza et al., 2020) have combined to show that the
pool of infected CD4+ T-cells during sustained ART treatment is highly heterogeneous.

The heterogeneity of infected CD4+ T cells is further compounded by the difficulty in finding
infected cells during treated infection. On average, there is less than one infected cell per 1000
CD4+ T-cells in the peripheral blood of an ART-treated PLWH (Eriksson et al., 2013). Though
most of the infected cells are primarily restricted to the tissue compartment upon ART treatment
(Deleage et al., 2016; Estes et al., 2017), the frequency is still dilute (Eriksson et al., 2013;
McManus et al., 2019). Furthermore, some of these cells have low to no viral RNA production
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(Einkauf et al., 2022; McManus et al., 2019), thus decreasing detection and elimination by the
combined efforts of ART and the host immune system.

Any biological signature that is enriched or unique to the infected cells may be obscured by the
heterogeneity of CD4+ T cells when assessed in bulk assays. This heterogeneity mandates the
use of single-cell technologies to understand each infected cell separately to better understand
any underlying similarities. Recent technologies have enabled such resolution, by allowing the
input of a heterogeneous, bulk population to measure one or more “omics” at the single-cell level.
However, there have been limited single-cell studies of human HIV reservoir research, due to 1)
the high cost and the relatively low throughput (compared to bulk methods) of single-cell
technologies and 2) determining if a cell is infected.

Studies have navigated these limitations by either studying in vitro infection CD4+ T-cell models
(Bradley et al., 2018; Golumbeanu et al., 2018) or through ex vivo cellular activation (Cohn et al.,
2018; Liu et al., 2020b). The former studies suggest that cells that have transcriptionally latent
proviruses are less activated and greater proliferative potential. The latter studies activated (e.g.
with phorbol 12-myristate 13-acetate and ionomycin) samples from ART-treated PLWH to force
transcription of the provirus to produce viral RNA and viral protein for identification. Cells were
then sorted by vRNA+ staining by RNA probes via HIV-1 SortSeq (Liu et al., 2020b) or sorted for
surface HIV envelope protein expression (Cohn et al., 2018). These studies have found certain
activated gene signatures enriched in HIV+ cells, but at the expense of altered cellular phenotype
from the in vitro stimulation. A recently published study has tried to identify infected cells by the
presence of HIV RNA but are limited by not only the paucity of infected cells but also the rarity of
infected cells that produce HIV RNA (Collora et al., 2022).
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These studies using stimulation will bias the phenotype of infected cells as stimulation induces a
large transcriptomic shift (Cano-Gamez et al., 2020). Given that all HIV infected cells share a
common element, the presence of a provirus is the most reliable in determining whether a cell is
infected or not (but additional assays are needed to determine inducibility and intactness). One
recent study used limiting dilutions to plate single HIV-1 infected cells mixed with multiple
displacement amplification for simultaneous HIV-1 RNA, integration site, and proviral sequence
analysis (Einkauf et al., 2022). These metrics were then compared to bulk CD4+ epigenetic and
transcriptional annotations to infer the potential characteristics of intact/defective proviruses and
their transcriptional state. Although this comparison is not a direct assessment of the individual
cell’s epigenetics, a dynamic state of the reservoir was observed where transcriptionally active
proviruses were generally selected against during ART. However, there was persistence of large
clones of cells with transcriptionally active proviruses (Einkauf et al., 2022), thus indicating
complex reservoir dynamics. Another related study used single-cell Assay for Transposase
Accessible Chromatin (ATAC) by sequencing (scATACseq) to profile chimeric antigen receptor Tcells (CAR-T), which contain integration events analogous to an HIV provirus (Wang et al., 2020).
As hyperactive transposase (Tn5) preferentially breaks and adds DNA adapters to open
chromatin regions for sequencing (Buenrostro et al., 2013), there is a possibility that the CAR-T
cassette (or the provirus in the context of HIV) will be recovered. The authors found reads
aligning to the vector, indicating that the provirus can be profiled using transposase-based
methods (Wang et al., 2020). However, no single-cell study of the HIV reservoir using
transposase exists, likely due to the difficulty in both cost and technical feasibility. Overall, this
highlights the necessity and importance in developing and using methodologies that can address
T cell heterogeneity without altering the direct ex vivo phenotypes of infected cells.
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1.9 Current efforts in finding a cure for HIV-1
Two types of efforts currently exist for finding a cure for HIV-1 infection – sterilizing and functional
cures. Sterilizing cures result in the complete eradication of HIV-1 infected cells, while functional
cures suppress and silence HIV replication without the need for ART. Only three definitive cases
of a sterilizing cure have been shown: Timothy Ray Brown (Hütter et al., 2009), Adam Castillejo
(Gupta et al., 2019), and an individual from Düsseldorf (Jensen et al., 2019). In each of these
individuals, full body irradiation was performed to treat acute myeloid leukemia followed by
allogenic hematopoietic stem cell transplantation from donors with a homozygous mutation in
CCR5 known as CCR5Δ32/Δ32. Individuals with this mutation are neutrally resistant to infection
by R5-trophic viruses (Samson et al., 1996). The irradiation paired with transplantation of HIVresistant cells effectively cured these individuals of HIV as no viral RNA has been detected
without ART – thus representing a sterilizing cure. However, the requirement of full body
irradiation, genetic matching for donors with CCR5Δ32/Δ32, and the relative rarity of
CCR5Δ32/Δ32 in the global population (Samson et al., 1996) makes this sterilizing cure infeasible
for other PLWH. As such, efforts are still ongoing in finding new curative strategies.

Given the immense requirements for a sterilizing cure, many efforts are focused on the more
feasible strategy with functional cures. However, a functional cure remains elusive. There are
many approaches being explored (Hoxie and June, 2012) but one major approach is known as
the “shock and kill” strategy (Deeks, 2012). This approach uses an agent to “shock” latent
proviruses into transcription which allows for these cells to be recognized and eliminated in the
“kill” phase (whether by the cytopathic effects, autologous CD8+ T cell response, and/or in the
form of additional agents). Latency reversal agents (LRA) are used for the first part in inducing
transcription at the provirus. Given the previously mentioned proviral epigenetics and regulation
of transcription, initial studies with HDAC inhibitors induced HIV expression in vitro (Van Lint et
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al., 1996; Williams et al., 2006). In vivo studies of valproic acid, which is a weak HDAC inhibitor,
showed minor drops in the latent reservoir (Lehrman et al., 2005), but this decrease was not
durably maintained (Archin et al., 2010; Siliciano et al., 2007). Another HDAC inhibitor, vorinostat,
was tested in vivo with increases in HIV transcription but no significant changes in plasma HIV-1
RNA and reservoir size (Archin et al., 2012; Elliott et al., 2014). Immunomodulatory agents
against inhibitory receptors that dampen the immune response have been used in the context of
cancer treatment and have been studied as potential LRAs but have not shown any large and
consistent decreases in the latent reservoir (Ait-Ammar et al., 2019; Guihot et al., 2018). Another
class of agents known as second mitochondrial-derived activator of caspases (SMAC) mimetics
has potential as LRAs. AZD5582, which activates the non-canonical NF-κB pathway, showed
promise in a rhesus macaque model in increasing viremia when combined with CD8+ T cell
depletion (Mavigner et al., 2021). Another study involving CD8+ T cell depletion but with a
different LRA (a IL-15 superagonist) showed a large reactivation of infected cells (McBrien et al.,
2020), thus indicating the contribution of CD8+ T cells in maintaining latency. However, both
these studies saw no significant change in the viral reservoir. These and other studies have
demonstrated the immense difficulty in awakening all the latent cells while allowing for effective
clearance of infected cells. Combinatorial and personalized LRA may need to be used along with
additional “kill” factors to see more effect on the reservoir.

A related approach to the “shock and kill” strategy is the “block and lock” strategy where latency
promoting agents (LPA) are introduced to suppress HIV expression to a point of “deep-latency”
(Hayashi et al., 2017; Mousseau et al., 2012, 2015). In this regard, Tat is a primary target given
its critical role in HIV transcription. Didehydro-Cortistatin A (dCA) and levosimendan have been
shown to inhibit viral transcription in vitro and ex vivo (Hayashi et al., 2017; Mousseau et al.,
2012). Inhibition of cellular pathways such as the JAK/STAT pathway (Gavegnano et al., 2014;
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Yeh et al., 2020) and CDK9 pathway (Chao et al., 2000) can block HIV transcription in vitro.
However, no LPAs have reached in vivo clinical trials and remains an extensive area of research.

The search for a functional cure is ongoing as additional drug screens and development attempt
to uncover novel agents to use for the various functional cure strategies. Regardless of the
“shock and kill”, “block and lock”, or alternative functional cure strategies, there is an immense
barrier to surmount in targeting the HIV reservoir. The overall heterogeneity of the infected cells,
the multi-tissue compartmentalization, and the complex dynamics with the host immune system
are some of the many factors that have hindered the success of any functional cure strategy.
Despite this, research must continue to benefit the lives of PLWH and to end the HIV/AIDS
epidemic.

1.10 Objectives
A functional cure as an attainable and beneficial strategy to suppress or eliminate the HIV
reservoir for all PLWH is one of the major goals of HIV research. Through the course of more
than four decades of research, HIV is one of most studied diseases since its emergence in the
1980s, largely due to the significant involvement of the HIV community in advocating for better
insights about HIV and pushing for therapies in treating infection to prevent AIDS. A vast corpus
of HIV virology and the intricate host-pathogen interactions is known through this global push for
knowledge. However, the seeding and persistence of HIV in the tissue environment has made it
difficult to understand HIV in its predominant context as findings from studies of the more easily
accessible peripheral blood cannot fully be extrapolated and applied to the tissue. As such, more
insight is urgently needed in the tissue context to examine the differences, if any, when compared
to peripheral blood. This is further compounded with the increasing recognition of the
heterogeneity of infected cells in causing differential responses to different functional cure
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strategies. Along with the fact that no known signature of HIV infected cells exists, this is a
significant gap in knowledge and highlights the need to study these cells at higher resolution –
whether at an immune subset and/or single-cell level to parse apart differences that may be
obscured by the spectrum of cellular phenotypes.

Given this current state, the main goal of this dissertation is to decipher the heterogeneity of the
HIV reservoir with respect to tissue and the myriad of CD4+ T cell phenotypes through two high
resolution approaches. The primary aims of this dissertation is 1) to determine if there is
differential integration site targeting between lymphoid tissue and peripheral blood and to
determine the degree of clonal expansion between different tissue compartments and 2) to
assess the surface antigen and epigenetic signatures of HIV-infected cells directly ex vivo without
cellular stimulation. These results will add insights to our understanding of the HIV reservoir with
the goal of better informing targeted cure therapies against HIV.
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CHAPTER 2
ASSESSMENT OF HIV-1 INTEGRATION IN TISSUES AND SUBSETS ACROSS INFECTION
STAGES

This chapter is presented as an adapted re-print of the article titled “Assessment of HIV-1
integration in tissues and subsets across infection stages” by Wu VH, Nobles CL, Kuri-Cervantes
L, McCormick K, Everett JK, Nguyen S, Del Rio Estrada PM, González-Navarro M, Torres-Ruiz
F, Ávila-Ríos S, Reyes-Terán G, Bushman FD, Betts MR. Assessment of HIV-1 integration in
tissues and subsets across infection stages. JCI Insight. 2020;5(20).
doi:10.1172/jci.insight.139783

2.1 Introduction
HIV infection remains an important global health issue, despite the advent of antiretroviral therapy
(ART). An HIV cure remains elusive, mainly due to integration of viral DNA into the genome of
potentially long-lived memory CD4+ T cells. This integration of intact HIV-1 proviruses can
establish a latent reservoir that is capable of lifelong persistence based on estimated rates of viral
decay (Crooks et al., 2015; Siliciano et al., 2003). ART interruption typically leads to viral
rebound, indicating that intact proviruses lie dormant during ART treatment but can later be
reactivated (Wong et al., 1997a). Increasing our understanding of the characteristics of the HIV-1
reservoir is necessary for the development of a functional cure.

HIV-1 integrates DNA copies of the RNA genome into host cells, predominantly through a
coordinated interaction between HIV integrase and host-encoded LEDGF/p75 (Ciuffi et al., 2005;
Engelman and Singh, 2018; Van Maele et al., 2006). HIV-1 integration sites are found more
commonly in active transcription units, a finding which is largely explained by the ability of
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LEDGF/p75 to tether to these sites (Cherepanov et al., 2003; Ciuffi et al., 2005; Han et al., 2004;
Ikeda et al., 2007; Maertens et al., 2003). As HIV-1 integration is not site specific, the host-viral
junction site in the genome provides a unique marker of infected cells that allows for the tracking
of these cells through integration site analyses. Longitudinal tracking studies have shown an
increase in clonally expanded cells during ART, with a selection for cells containing integration
sites within cancer-related genes over time (Cohn et al., 2015; Wagner et al., 2014). These
clones are established early in HIV-1 infection and persist after ART treatment (Maldarelli et al.,
2014; McManus et al., 2019; Wagner et al., 2014). However, most integration site studies have
been carried out on bulk PBMCs or peripheral blood CD4+ T cells, which may not fully
recapitulate the complexity of the integrated reservoir in the body for two reasons: (a) the majority
of HIV-1–infected CD4+ T cells reside in lymphoid tissues (Deleage et al., 2016; Estes et al.,
2017; Pantaleo et al., 1993) and (b) CD4+ T cells are composed of multiple heterogeneous tissuesequestered and circulating subsets in vivo (Banga et al., 2016; Bucy et al., 1999; Buggert et al.,
2018; Chun et al., 2008; Miles et al., 2015).

CD4+ T cells display diverse memory and effector phenotypes, each with different epigenetic and
transcriptomic signatures. While many studies have compared various internal proviral
sequences across cell subsets (Cohn et al., 2015; De Scheerder et al., 2019; Einkauf et al., 2019;
Jones et al., 2020; Lee et al., 2019, 2020), few studies have compared the integration site
landscape between different cell subsets (Cohn et al., 2015). Viral sequence studies generally
observed overlapping sequences between cell subsets, but one study has suggested potential
compartmentalization based on nef sequences between memory cell subsets in 3 of 5 individuals
(Jones et al., 2020). In vivo compartmentalization of CD4+ T cells can be seen with tissueresident memory cells in different contexts, including HIV-1 infection (Beura et al., 2019; CanteroPérez et al., 2019). This raises the hypothesis that tissue residency may lead to a different
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landscape of integration sites between tissue and blood, especially for CD4+ T cells that are
either tissue resident or have limited egress capabilities. Overall, these studies highlight a gap in
our understanding of HIV-1 reservoirs, demonstrating the need to better understand the
integration site landscape in the context of tissue/blood compartments and CD4+ T cell
heterogeneity at different stages of HIV-1 infection.

To address this, we obtained PBMCs and lymph node mononuclear cells (LNMCs) from cervical
lymph nodes (CLN) and inguinal lymph nodes (ILN) from HIV-infected untreated acutely
infected/chronically infected (acute/chronic) individuals or tonsils from ART-treated individuals.
From these, we profiled integration sites within memory, follicular, and resident CD4+ T cell
subsets to assess the effect of compartmentalization and cellular residency on integration sites.
While we observed that HIV-1 integration site targeting characteristics were largely shared in the
different compartments, cell subsets, and stages of HIV-1 infection, overlap of integration sites
between subsets and compartments was rare, despite the presence of clonally expanded sites.
Together, these findings suggest that tissue compartmentalization of the HIV-1 reservoir can
occur between different anatomical sites, supporting the need to further understand the dynamics
and fate of HIV-infected cells from different cell subsets and tissues.
2.2 Results
Study design and identification of HIV-1 integration sites
To assess the effect of compartmentalization and cellular residency on integration site
distributions, we sorted LNMCs from ART-treated individuals into 4 CD4+ T cell subsets (Figure
2.1) (supplemental material also available online; https://doi.org/10.1172/jci.insight.139783DS1):
(a) CD45RA+CCR7+ (naive; for individuals T1 and T2 only), (b) HLA-DR–CXCR5hiPD-1hi (germinal
center T follicular helper [GC-Tfh]; HLA-DR– GC-Tfh), (c) non–GC-Tfh memory HLA-DR–
CD69+ (labeled as HLA-DR–CD69+), and (d) non–GC-Tfh memory HLA-DR–CD69– (labeled as
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HLA-DR–CD69–). As HLA-DR has been shown to be a marker of T cell activation (Moriya et al.,
1987), we sorted HLA-DR– cells to enrich for the latent reservoir in ART-treated individuals as
seen in previous studies (Chun et al., 1995, 1997a; Finzi et al., 1997). Because the residency
marker CD69 is also upregulated by T cells upon activation (Shiow et al., 2006; Testi et al., 1989;
Yokoyama et al., 1988), we selectively sorted HLA-DR–CD69+ cells to focus on resting resident
CD4+ T cells.

Figure 2.1: Sorting strategy for ART-treated samples. Representative flow plots showing the
sort strategy for (A) tonsil samples or (B) peripheral blood samples. Subsets are indicated in pink
numbers and detailed in the lists by their specific marker combinations and designation.
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From acutely and chronically infected lymph nodes, we sorted 4 CD4+ T cell subsets: (a)
CD45RA+CCR7+ (naive), (b) non-naive PD-1hiCXCR5hi (GC-Tfh), (c) non–GC-Tfh memory
CD69+ (labeled as CD69+), and (d) non–GC-Tfh memory CD69– (labeled as CD69–) (Figure 2.2).
Given the high viral load and ongoing inflammation in these individuals, we did not exclude HLADR+CD4+ T cells. We did include the CD69+ sorting strategy from ART-treated samples to allow
analysis of integration sites in resident memory CD4+ T cells; however, some of these cells may
have been recently activated. Regardless, CD69 expression would still limit tissue egress
potential of any recently activated CD69+ cells, resulting in potentially unequal distribution of
integration sites between tissues and blood.
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Figure 2.2: Sorting strategy for acute and chronic samples. Representative flow plots showing
the sort strategy for (A) lymph node samples or (B) peripheral blood samples. Subsets are indicated in pink
numbers and detailed in the lists by their specific marker combinations and designation.

PBMCs were sorted into memory phenotypes as described in Figure 2.1 and Figure 2.2. These
subsets consisted of (a) CD45RA+CCR7+ (naive), (b) CD45RA–CCR7+ (central memory T [Tcm]),
(c) CD45RA–CCR7– (effector memory T [Tem]), and (d) CD45RA+CCR7– (Tem cells reexpressing
CD45RA [Temra]) for acute and chronic samples only. For ART-treated individuals, the Tcm and
Tem subsets further excluded CD69+ cells to select for resting cells. Information on individuals is
provided in Table 2.1 while all sort counts are detailed in Table 2.2.
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Table 2.1: Individual information.

A

Patient

HIV infection
stage

Time on
ART (mo)

Age
(yrs)

Sex

CompartmentsA

Viral load
(cps/ml)

CD4+ T-cell
counts
(cells/ul)

A1

Acute
(Fiebig IV)

-

22

M

P, I, C

179,832

696

A2

Acute
(Fiebig IV)

-

27

M

P, I, C

5,112,511

589

A3

Acute
(Fiebig IV)

-

24

M

P, I, C

58,355

501

C1

Chronic

-

32

M

P, I, C

1,771,593

462

C2

Chronic

-

23

M

P, I, C

143,916

509

C3

Chronic

-

21

M

P, I, C

1,019,989

251

T1

ART-treated

16.9

24

M

P, T

<40

584

T2

ART-treated

93

32

M

P, T

<40

497

T3

ART-treated

38.64

32

M

P, T

<40

346

P = PBMC, T = tonsil, I = inguinal lymph node, C = cervical lymph node

Table 2.2: Sort counts for all individuals by subset.
Individual
A1
A1
A1
A1
A1
A1
A1
A1
A1
A1
A1
A1
A2
A2
A2
A2
A2
A2
A2
A2
A2
A2
A2
A2
A3
A3
A3
A3
A3
A3
A3
A3
A3
A3
A3

Compartment
CLN
CLN
CLN
CLN
ILN
ILN
ILN
ILN
PBMC
PBMC
PBMC
PBMC
CLN
CLN
CLN
CLN
ILN
ILN
ILN
ILN
PBMC
PBMC
PBMC
PBMC
CLN
CLN
CLN
CLN
ILN
ILN
ILN
ILN
PBMC
PBMC
PBMC

Subset
Naive
CD69+
CD69GC-Tfh
Naive
CD69+
CD69GC-Tfh
Naive
Tcm
Tem
Temra
Naive
CD69+
CD69GC-Tfh
Naive
CD69+
CD69GC-Tfh
Naive
Tcm
Tem
Temra
Naive
CD69+
CD69GC-Tfh
Naive
CD69+
CD69GC-Tfh
Naive
Tcm
Tem
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Cells
Sorted
572035
60933
527767
27146
223515
152367
170757
18284
357108
272419
124110
6943
600000
423512
594576
27241
600000
600000
600000
31236
368968
370430
326801
54203
298427
119084
206693
4794
600000
563028
600000
32990 (est)
301167
438878
307559

A3
C1
C1
C1
C1
C1
C1
C1
C1
C1
C1
C1
C1
C2
C2
C2
C2
C2
C2
C2
C2
C2
C2
C2
C2
C3
C3
C3
C3
C3
C3
C3
C3
C3
C3
C3
C3
T1
T1
T1
T1
T1
T1
T1
T2
T2
T2
T2
T2
T2
T2
T3
T3
T3
T3
T3
T3

PBMC
CLN
CLN
CLN
CLN
ILN
ILN
ILN
ILN
PBMC
PBMC
PBMC
PBMC
CLN
CLN
CLN
CLN
ILN
ILN
ILN
ILN
PBMC
PBMC
PBMC
PBMC
CLN
CLN
CLN
CLN
ILN
ILN
ILN
ILN
PBMC
PBMC
PBMC
PBMC
Tonsil
Tonsil
Tonsil
Tonsil
PBMC
PBMC
PBMC
Tonsil
Tonsil
Tonsil
Tonsil
PBMC
PBMC
PBMC
Tonsil
Tonsil
Tonsil
PBMC
PBMC
PBMC

Temra
Naive
CD69+
CD69GC-Tfh
Naive
CD69+
CD69GC-Tfh
Naive
Tcm
Tem
Temra
Naive
CD69+
CD69GC-Tfh
Naive
CD69+
CD69GC-Tfh
Naive
Tcm
Tem
Temra
Naive
CD69+
CD69GC-Tfh
Naive
CD69+
CD69GC-Tfh
Naive
Tcm
Tem
Temra
Naive
HLA-DR- CD69+
HLA-DR- CD69HLA-DR- GC-Tfh
Naive
CD69- Tcm
CD69- Tem
Naive
HLA-DR- CD69+
HLA-DR- CD69HLA-DR- GC-Tfh
Naive
CD69- Tcm
CD69- Tem
HLA-DR- CD69+
HLA-DR- CD69HLA-DR- GC-Tfh
Naive
CD69- Tcm
CD69- Tem
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70494
292381
427023
118286
10410
250000
352598
309110
12946
300000
328703
99323
9699
250000
57482
400000
20470
179983
233480
309093
18608
98217
98051
110528
30732
251842
239197
386289
15522
149399
76952
169360
2565
160477
86471
56693
2948
100951
280330
405538
132190
155961
79002
23208
26812
196982
229894
34275
175051
313144
109794
277341
192100
200638
132554
76688
180667

Sorted cells were assayed for integration sites using an established pipeline (Berry et al., 2017;
Sherman et al., 2017), wherein sonicated adapter-ligated genomic DNA was amplified with a
nested PCR using HIV-1 U3 and U5 long terminal repeat primers. Since random fragment lengths
are generated during sonication, fragments with different lengths that are associated with
integration sites mapping to the same genomic position can be counted as a proxy for the number
of infected cells (termed sonic abundance) (Sherman et al., 2017). Even with the limited number
of cells (ranging from ~3000 to >400,000 cells per subset), integration site analyses are sufficient
to detect clonal CD4+ T cell expansions carrying integrated virus (Patro et al., 2019). We
recovered a total of 3540 unique sites and an inferred count of 3973 cells with integration sites
across 9 individuals. The breakdown of sites by infection stage, location, and cell subset are
shown in Table 2.3, Table 2.4, and Table 2.5, while the entire data set of sites is provided in
Supplemental File 1 (available at https://insight.jci.org/articles/view/139783/sd/2).
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Table 2.3: Total integration sites and clones profiled for acute individuals.

Individual Compartment Cell Subset
CD69GC-Tfh
CLN
CD69+
Naive
Tcm
A1
PBMC
Tem
CD69GC-Tfh
ILN
CD69+
Naive
CD69+
CD69ILN
GC-Tfh
Naive
CD69+
A2
GC-Tfh
CLN
CD69Naive
Tem
PBMC
Tcm
Temra
PBMC
Tcm
CD69CLN
CD69+
A3
Naive
CD69ILN
CD69+
A

Subset
Subset
#
abundance clones*
138
2
123
0
22
0
2
0
122
4
66
2
30
0
18
1
15
0
4
0
97
0
84
2
30
0
2
0
51
0
48
0
43
0
1
0
100
1
36
0
4
0
13
0
5
0
1
0
1
0
4
0
1
0

Clones determined by >= 3 sonic abundance.
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Location
abundance
sum

Location
Individual
#
Individual
#
clonesA abundance clonesA

285

2

188

6

67

1

213

2

143

0

140

1

13

0

7

0

5

0

540

9

496

3

25

0

Table 2.4: Total integration sites and clones profiled for chronic individuals.
Cell
Subset
Individual Compartment Subset abundance
CD69335
GC-Tfh
128
CLN
CD69+
12
Naive
11
CD69101
GC-Tfh
49
C3
ILN
CD69+
7
Naive
2
Tcm
36
Tem
34
PBMC
Naive
4
Temra
2
GC-Tfh
138
CD69117
CLN
CD69+
45
Naive
1
CD69109
C2
CD69+
27.5
ILN
GC-Tfh
12
Naive
8
Tem
75
PBMC
Tcm
62
Naive
4
CD69157
CD69+
63
CLN
GC-Tfh
10
Naive
8
CD6985
GC-Tfh
76
C1
ILN
CD69+
64
Naive
6
Tem
65
Tcm
23
PBMC
Temra
8
Naive
3

Subset
# clones
44
5
1
0
6
3
0
0
2
2
1
0
9
12
4
0
6
1
2
2
4
5
0
4
2
1
2
4
2
0
0
4
1
1
1

Location
abundance sum

Location Individual Individual
# clones abundance # clones

486

50

159

9

76

5

301

25

156.5

11

141

9

238

9

231

6

99

7

721

64

598.5

45

568

22

Table 2.5: Total integration sites and clones profiled for ART-treated individuals.
Individual Compartment
Tonsil
T1
PBMC
PBMC
T2
Tonsil

T3

PBMC
Tonsil

Subset
Subset
Location
Location Individual Individual
Cell Subset abundance # clones abundance sum # clones abundance # clones
HLA-DR- CD69+
272.5
17
HLA-DR- CD69237.5
14
595
37
HLA-DR- GC-Tfh
83
6
625.5
38
Naive
2
0
CD69- Tem
27.5
1
30.5
1
Naive
3
0
CD69- Tem
188
2
207
6
CD69- Tcm
19
4
245
7
HLA-DR- CD6933
1
38
1
HLA-DR- CD69+
5
0
CD69- Tem
95
13
CD69- Tcm
35
1
131
14
154
16
Naive
1
0
HLA-DR- GC-Tfh
11
0
23
2
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HLA-DR- CD69HLA-DR- CD69+

6
6

2
0

Comparable characteristics in HIV integration sites across infection stage, compartment,
and cell subset
For our initial analysis, we conducted a deep characterization of the genomic characteristics of
the integration sites obtained from each donor. Comparable to previous studies (Cherepanov et
al., 2003; Ciuffi et al., 2005; Maertens et al., 2003), the majority of sites were enriched in
transcription units, with about 15% being in distal intergenic regions. The majority of the
integration sites (71%) were found within introns. When separated by experimental factors
(infection stage, compartment, and cell subset), the pattern of favored integration events in
transcription units was also observed at similar relative values (Figure 2.3 and Figure 2.4A). In
order to assess any positional biases in chromosomal position, we generated bins after
normalizing for chromosomal size (Figure 2.4B). Most integration sites were detected near the
end of the chromosome as previously observed (Haworth et al., 2018). While there was no
discernible pattern between infection stages, we observed a higher distribution of integration sites
at the ends of chromosomes from acute individuals compared with those from chronic or ART
individuals (Figure 2.4B). This parallels findings from Haworth et al., where their sites recovered
from in vitro cultures had increased frequency at either end of the chromosome compared with
sites from 12- to 14-week infections in humanized mice (Haworth et al., 2018).
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Figure 2.3: HIV-1 integration sites are primarily found in intronic regions across infection
stages, compartments, and cell subsets. For each cell subset, the percentage of total
integration sites combined across individuals is displayed for each feature annotation. Integration
sites are binned based on cell subset, where inferred cell numbers by sonic abundance are
shown in parentheses.
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Figure 2.4: Overall characteristics of HIV integration in the entire compiled dataset. (A)
Annotation of the sites relative to genic regions is displayed. (B) Sites were compiled based on
their sonic abundance (rounded down to the nearest integer if needed for sites with an estimated
non-integer sonic abundance). Normalized chromosomal positions were binned (bin width of
0.01) and a density plot was plotted for sites compiled by infection stage. (C) Annotations relative
to genic regions are subsetted based on infection stage and tissue compartment. (D) Annotations
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relative to genic regions are subsetted based on infection stage and residency subsets.
Integration sites were annotated using the ChIPSeeker package in R.
When grouping our recovered integration sites by infection stage and compartment, we observed
similar results with the majority of recovered sites being in intronic regions of transcription units
followed by distal intergenic regions. However, there was a trend for an increase in nonintron and
nondistal intergenic sites from tissue compartments during ART (Figure 2.4C-D). When
combining these specific annotations (labeled “Other”) into one category and depicting each
subset, we observed a significant increase from tissue samples during ART (Figure 2.5A; P <
0.05; Wilcoxon rank sum test). This increase was also observed in sites obtained from cellular
subsets with a residency phenotype during ART (Figure 2.5B; P < 0.01; Wilcoxon rank sum test),
suggesting integration sites in resident cells have different integration site profiles or that there
are different selective pressures compared with infected nonresident cells during ART.
Furthermore, integration sites in distal intergenic regions were enriched in the blood compared
with tissue during ART (Figure 2.5A; P < 0.05; Wilcoxon rank sum test).
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Figure 2.5: Characteristics of HIV integration separated by infection stage, compartment,
and residency phenotype. Integration sites were annotated using the ChIPSeeker package in
R. Each subset was plotted to assess for differences between intronic, distal intergenic, and other
(non-intronic and non-distal intergenic; a full list of these can be seen in Supplemental Figure 3A)
annotations. Subsets were grouped by infection stage and (A) tissue compartment or (B)
residency phenotype. Statistical comparisons were assessed with Wilcoxon tests. * p < 0.05; ** p
< 0.01
We next pooled the unique transcription unit sites across individuals by infection stage and
anatomical compartment and assessed the enrichment of gene ontology annotations using
Metascape (Zhou et al., 2019) (Figure 2.6-8). The significant gene ontology terms were similar
across the stages, with potentially more enrichment of chromatin modification/organizationrelated genes in sites identified from lymphoid tissue than those found in blood. Due to the
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sparsity of our samples, we used a previously published bulk RNA-Seq data set on GC-Tfh and
non-Tfh cells from lymph nodes of healthy donors (Vella et al., 2019) to generate bins of
increasing gene expression. Genic integration sites from GC-Tfh cells (independent of HLA-DR)
were in genes found in the higher expression bins for the GC-Tfh RNA-Seq data set, but other
genic integration sites also followed a similar pattern (Figure 2.9A). This was similarly observed
with the non-Tfh cell RNA-Seq data set (Figure 2.9B), suggesting that there was no bias
observed for subset-specific integration sites based on gene expression from published RNA-Seq
data sets. The overall enrichment of normal cellular pathway and lymphocyte function terms
along with the RNA-Seq comparison supports the preferential integration of HIV DNA into genes
with higher levels of transcription (Jordan et al., 2001; Mitchell et al., 2004; Schröder et al., 2002).
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Figure 2.6: Gene ontology analysis for acute samples. Unique integration sites within genic
regions were compiled without accounting for abundance. Gene ontology analysis was run on the
compiled genes using Metascape for (A) cervical lymph node, (B) inguinal lymph node, and (C)
peripheral blood samples.
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Figure 2.7: Gene ontology analysis for chronic samples. Unique integration sites within genic
regions were compiled without accounting for abundance. Gene ontology analysis was run on the
compiled genes using Metascape for (A) cervical lymph node, (B) inguinal lymph node, and (C)
peripheral blood samples.
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Figure 2.8: Gene ontology analysis for ART-treated samples. Unique integration sites within
genic regions were compiled without accounting for abundance. Gene ontology analysis was run
on the compiled genes using Metascape for (A) tonsil and (B) PBMC samples.
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Figure 2.9: Integration sites binned by transcriptional activity. RNAseq datasets on (A)
lymph node GC-Tfh and (B) lymph node non-Tfh were binned by increasing levels of
transcriptional activity. Genic integration sites grouped by subsets were placed into the
appropriate bin and displayed. NA counts genic integration sites where the gene was not
detected in the RNAseq experiments.
We then compared genomic annotations of the recovered integration sites, including features
such as DNaseI accessibility, CpG counts/density, and GC content (Berry et al., 2006; Nobles et
al., 2020). Briefly, 3 random control sites were chosen in the human genome for each integration
site in the data set to calculate a receiver operating characteristic (ROC) curve. A ROC value of 1
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indicates that all actual integration sites in the data have a given feature (or have higher values)
compared with all random controls; the opposite is true for a ROC value of 0. A ROC value of 0.5
indicates that this feature is unable to discern between actual and random control sites. For
annotations with varied genomic windows, the overall integration site characteristics were
comparable across infection stages, compartments, and cell subsets (Figure 2.10A). While there
were subtle differences (i.e., GC content within a 1000 bp window being more significantly
enriched in the acute and ART-treated samples compared with chronic samples), our findings are
consistent with the tendencies of preferential HIV integration into genic regions (Berry et al.,
2006; Ciuffi et al., 2005; Schröder et al., 2002; Wang et al., 2007).

Finally, we assessed epigenetic annotations within a 10 kb window of the integration site (±5000
bp). Due to the lack of available annotations specific for each sorted subset, we used epigenetic
annotations from bulk CD4+ T cells for all comparisons (Nobles et al., 2020). While in general we
observed comparable epigenetic annotations, we did identify differences across the different
combinations of factors (Figure 2.10B). For instance, H3K79me3 histone methylation was lower
in integration sites during ART and chronic states compared with random controls but not during
acute infection (Figure 2.10B). H3K79me3 is an important factor for transcriptional regulation that
correlates with active gene transcription (Farooq et al., 2016; Wang et al., 2008). Further studies
would be needed to determine if these sites are depleted in H3K79me3 during ART and chronic
states in the specific cell subsets.
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Figure 2.10: Genomic and epigenetic characteristics of HIV integration are comparable
across infection stage, compartment, and cell subset. Receiver operating characteristic
(ROC) curve analysis was conducted to assess a given annotation’s ability to predict actual vs
matched random control (MRC) sites. ROC analyses were done for different (A) genomic
annotations and (B) epigenetic annotations from previously published studies on bulk CD4+ T69

cells. For genomic annotations, the numeric value at the end of the annotation represents the
genome window from the integration site (i.e 10k is 5000 bp ± of integration site). Epigenetic
annotations are assessed within a 10kb window. ROC value of 1 indicates that the given
annotation was present or observed at a higher level in all actual integration sites over MRC sites.
Significance was tested between actual integration sites and MRC sites using a chi-squared test.
*p < 0.05, ** p < 0.01, ***p < 0.001
Identification of integration hotspots during multiple stages of HIV infection
We next identified genes commonly targeted for integration during different stages of HIV
infection. We filtered the integration sites for genes (or nearest genes within 50 kb) present in 3 or
more combinations of individuals/cell subsets/compartments for acute and ART-treated
individuals (Figure 2.11A and C). We raised this threshold to 4 or more combinations for chronic
individuals due to the larger number of genes (Figure 2.11B).
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Figure 2.11: Hotspots of HIV-1 integration across individuals, compartments, and subsets
during different infection stages. Integration sites in a gene or within 50 kb of a gene were
identified across combinations of individual, compartment, and cell subsets. (A) Hotspots
identified in 3 or more combinations in acute individuals. (B) Hotspots identified in 4 or more
combinations in individuals with chronic HIV-1 infection. (C) Hotspots identified in 3 or more
combinations in ART-treated individuals.
For acute and chronic infections (Figure 2.11A and B respectively), we identified numerous
hotspots. Integrations in or near PACS1 and ANKRD17 were the most common hotspot in acute
and chronic data sets, respectively. Furthermore, we detected integrations within or near STAT5B
and FOXK2 genes during acute and/or chronic states, lending support to the notion that clonally
expanded sites during ART treatment can be established early during infection (Coffin et al.,
2019; Maldarelli et al., 2014; Wagner et al., 2014).
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In ART-treated individuals, we observed a number of genes classically associated with
integration, including STAT5B, FOXK2, BACH2, and TET2/TET2-AS1 (Fraietta et al., 2018;
Maldarelli et al., 2014; Wagner et al., 2014), across different subjects, tissues, and CD4+ T cell
subsets. However, none of these integration-associated genes were found in every individual or
within all of the assessed cell subsets within an individual. In the HLA-DR–CD69– population from
tonsils of individual T1, we detected a TET2 (and TET2-AS1) integration in intron 2, which is of
clinical interest given a recent report on the in vivo expansion of a CAR T cell with an integrated
lentiviral vector in TET2 (Fraietta et al., 2018; Nobles et al., 2020). Together, our data support
previous studies documenting the enrichment of certain sites during ART treatment, but highlight
the differential complexity of the integrated reservoir within each individual. We did not find any
single specific gene preferentially associated with integration across all individuals or tissues.

Detection of clonal expansion across multiple stages of infection
Clonal expansion in peripheral blood has been documented previously during ART treatment
(Maldarelli et al., 2014; Wagner et al., 2014) as well as acute and chronic infection (Coffin et al.,
2019) but has not been compared between blood and lymphoid tissue at multiple stages of
infection. Using sonic abundance, we could identify separate fragments with the same integration
site originating from clonally expanded cells with the same integration site in all 3 stages of
infection (Supplemental File 1 and Figure 2.12-14). To identify cell clones during acute infection
(Figure 2.12), we used a sonic abundance threshold of 3 to ensure the detection of at least 2
infected cells, as cells undergoing mitosis during acute infection may die (Coffin et al., 2019). We
found limited examples of clonal expansion during acute infection, with the most dominant clone
(by absolute sonic abundance) integrated in TUBGCP6 in the PBMC Tcm subset from individual
A1 (Figure 2.12). For both the chronic and ART-treated samples, the sonic abundance threshold
was set to 2. In chronic samples, we detected higher levels of clonal expansion, with some clones
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representing 10% or more of the total relative abundance in a cell subset (Figure 2.13). The most
dominant clone detected in a chronic individual was integrated in ZNF34 within the CD69+ subset
in CLN from individual C2. During ART treatment, some clones also represented 10% or more of
the total infected cell population detected in a given cell subset, similar to our observations for
chronic individuals (Figure 2.14). The most dominant clone, by absolute sonic abundance,
contained an integrated provirus in PTPN9, within the HLA-DR–CD69– subset in the tonsil from
individual T2. Overall, these results indicate that clonal expansion can be detected in tissues
early in infection as well as during chronic infection and ART treatment.

Figure 2.12: Identification of clonal expansion from individuals during acute infection.
Relative sonic abundance for each integration site is shown for each acutely infected individual.
Sites with color indicate that the site is clonal (defined as a sonic abundance ≥3 for acute
infection). Different colors indicate different integration sites across an individual (i.e., two
different integration sites in the same gene with clonal expansion would have different colors).
Clones consisting of 10% or more of the total relative sonic abundance are labeled with the
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integrated gene or nearest gene. Genes within 50 kb of the integration site are denoted with “+,”
while genes that are more then 50 kb from the integration site are demoted with “#.” The number
of inferred total cells is indicated parenthetically on the x axis.

Figure 2.13: Identification of clonal expansion from individuals during chronic infection.
Relative sonic abundance for each integration site is shown for each individual. Sites with color
indicate that the site is clonal (defined as a sonic abundance ≥2 for chronic infection). Different
colors indicate different integration sites across an individual (i.e., two different integration sites in
the same gene with clonal expansion would have different colors). Clones consisting of 10% or
more of the total relative sonic abundance are labeled with the integrated gene or nearest gene.
Symbols appear after gene names as detailed in the legend for Figure 2.12.
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Figure 2.14: Identification of clonal expansion from ART-treated individuals. Relative sonic
abundance for each integration site is shown for each individual. Sites with color indicate that the
site is clonal (defined as a sonic abundance ≥2 for ART-treated individuals). Different colors
indicate different integration sites across an individual (i.e., two different integration sites in the
same gene with clonal expansion would have different colors). Clones consisting of 10% or more
of the total relative sonic abundance are labeled with the integrated gene or nearest gene.
Symbols appear after gene names as detailed in the legend for Figure 2.12.
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Within the subset and infection stage resolution across our cohort, we asked if any particular
subsets (pooled across tissue sites) were enriched for clones. As detailed in Table 2.6, most
subsets contained clones. In acute individuals, Tcm cells had the highest percentage, with 2.78%
of detected unique sites being clonal. The maximum values were 9.54% (CD69– from tissues)
from chronic individuals and 7.56% (HLA-DR–CD69– from PBMCs) from ART-treated individuals
when considering only subsets in which we recovered more than 100 unique sites. Furthermore,
clonal proportions significantly differed between infection stages (Figure 2.15). There was also a
trend toward higher clonality in nonresident phenotypes compared with resident phenotypes in
chronic and ART-treated individuals, but this did not reach statistical significance, likely due to
limited sample size. Together, these data suggest that the proportion of clonal sites increases
over time during the course of infection and with the installment of ART and highlights the need to
further explore tissue-resident phenotypes in the context of HIV-1 reservoirs.

Table 2.6: Clonal percentages by subset and infection stage.
Stage

Acute

Chronic

ART

Subset*
CD69CD69+
GC-Tfh
Naive
Tcm
Tem
Temra
CD69CD69+
GC-Tfh
Naive
Tcm
Tem
Temra
CD69- Tcm
CD69- Tem
HLA-DR- CD69HLA-DR- CD69+
HLA-DR- GC-Tfh
Naive

Total unique sites
282
177
213
9
144
153
4
797
190
368
38
112
156
5
48
266
225
259
88
6

Clonal sites
4
0
1
0
4
3
0
76
8
22
6
8
10
1
5
16
17
17
6
0

% clonal
1.42
0.00
0.47
0.00
2.78
1.96
0.00
9.54
4.21
5.98
15.79
7.14
6.41
20.00
10.42
6.02
7.56
6.56
6.82
0.00

* Naïve subsets were pooled between tissue and blood. Tissue subsets for acute and chronic
individuals were pooled between inguinal and cervical lymph nodes.
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Figure 2.15: Clonal expansion proportions by residency phenotype. Sites were combined
across individuals and grouped by residency phenotype. Proportions of clonal sites over total
unique sites were then calculated. Bars indicate mean clonal percentage. Significance between
different factors was assessed by Wilcoxon Rank Sum test. * p < 0.5; ** p < 0.01, *** p < 0.001.
Limited overlap detected between cell subsets and compartments
Recent reports have documented overlap of proviral sequences across compartments and across
subsets. We thus examined whether there was overlap of integration sites within individuals
between different T cell subsets. Since integration sites can serve as a unique barcode of an
infected cell, we used integration site data to examine if infected cells after cell division have
trafficked and/or differentiated.

For acute infection, we detected no overlap in any of the individuals (
Figure 2.16A), likely due to the rampant viral replication and death/turnover of infected cells.
Despite the depth of our analysis, we only detected a few overlaps of integration sites between
data from T cell subsets or anatomic sites in 2 chronically infected individuals (
Figure 2.16B). These included a clone in LINC02068 shared between ILN (naive) and CLN
(CD69–), a clone near LINC00466 in PBMCs shared between naive and Tem cells, a clone
in UBE2W shared between CLN (CD69–) and PBMCs (Tcm), and a clone in INPP4B shared
between CLN (CD69–) and PBMCs (Temra).
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We only detected overlap of integration sites between subsets or tissue in 1 of the 3 ART-treated
individuals (
Figure 2.16C). These included a BACH2 clone shared between tonsil HLA-DR–CD69+ and HLADR–CD69–CD4+ T cells, 2 separate TRABD clones between tonsil HLA-DR– GC-Tfh and HLADR–CD69+CD4+ T cells, and an expanded clone near P4HB between tonsil HLA-DR–CD69– and
HLA-DR–CD69+CD4+ T cells. No overlaps were detected between peripheral blood CD4+ T cells
and tonsil cells in any of the 3 ART-treated individuals, despite the detection of clonal expansion (
Figure 2.16C).

We assessed partitioning of clones in different anatomical sites by comparing our observations to
results of computational simulations. We assumed that clones could be shared randomly between
compartments and/or subsets. For each individual, we pooled all the sites according to their sonic
abundance and then randomly sampled the pool based on the original sample size recovered in a
given cell subset. The number of overlaps were counted across 10,000 simulations. Our
simulations indicate that considerable overlap is expected in all pairs of samples tested (Figure
2.17), in contrast to our observations of limited overlap. Thus, our integration site data set was not
dominated by expanded clones that were common to multiple compartments, though it will be
valuable to challenge this conclusion in future studies with deeper sampling over more subjects.
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Figure 2.16: Limited overlap of integration sites detected within cell subsets and
compartments. For (A) acute, (B) chronic, and (C) ART-treated states, each plot represents an
individual. Each spoke on the inner wheel represents a unique integration site. Spokes with a
darker color represent clonally expanded sites. The outer wheel represents the compartment and
subset where the integration site was detected. Connecting lines indicate that the same
integration site was detected in a different cell subset and is labeled with the gene (or nearest
gene) along with genomic location. Symbols appear after gene names as detailed in the legend
for Figure 2.12.
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Figure 2.17: Sampling simulation of integration sites by individual. Sites for each individual
were compiled while accounting for sonic abundance (abundance was rounded down to the
nearest integer if needed). These sites were then randomly sampled into subset/compartment
groups based on the original size of the group based on our original sequencing depth. The total
number of overlaps across subset/compartment groups were counted. This simulation was run
10,000 times and the number of overlaps is displayed as a cumulative distribution frequency for
each individual. The dotted line represents the actual number of overlaps detected in our original
dataset.

2.3 Discussion
Our current understanding of the integrated HIV-1 reservoir is largely derived from studies of the
peripheral blood on bulk CD4+ T cells, with the assumption that these represent infected CD4+ T
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cells in lymphoid tissues. While some infected CD4+ T cells may traffic between tissues and
blood, it is unclear to what degree this occurs. Moreover, some memory CD4+ T cells can
establish residence in tissues and thus may not be well represented in the circulation. For
example, Tfh cells, a population known to be a key HIV-1 reservoir, are mostly anatomically
restricted to lymphoid tissues. These anatomical and subset characteristics of CD4+ T cells raise
the question of whether bulk peripheral blood CD4+ T cell populations provide an accurate
representation of the HIV-1 integration landscape throughout the body at multiple stages of
infection. To address this gap, we examined integration site distributions in acute, chronic, and
ART-treated HIV-1 individuals at compartment and subset resolutions. We found comparable
characteristics of integration site distributions, where most sites were found in transcription units.
The CD4+ T cell subset, tissue of origin, or the infection stage had at most slight effects on the
initial integration site selection based on comparison to genomic and epigenetic annotations.
Previously identified genes that are commonly detected in infected cells were also found among
our data set. As expected, clonal expansion was found in most compartments and was more
prominent in chronic and ART-treated individuals. Despite these expanded clones, we detected
little overlap between subsets and compartments.

The general observation of similar characteristics of HIV-1 integration across subset and
compartment supports previous studies documenting the tendencies of HIV-1 integration. While it
is known for HIV-1 to prefer sites of active transcription, our observed lack of noticeable
transcriptional activity bias by subset could potentially be explained by similar global
transcriptomic profiles of CD4+ T cell subsets, irrespective of known differentially expressed
subset-defining genes. Despite largely similar characteristics, we were still able to detect some
differences in our comparisons. We observed a corresponding increase in frequencies of
nonintronic and nondistal-intergenic sites during ART in tissue and resident subsets, suggesting
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that infected resident cells might have subtle differences compared with nonresident infected
cells. Furthermore, the trend in increased detection of clonality in nonresident cell subsets
requires more sampling to better understand how residency phenotype may impact HIV-1
reservoirs.

Recent studies have investigated the HIV-1 integration site landscape in bulk CD4+ T cells or
LNMCs from lymphoid tissue, finding integration site overlaps between tissue compartments in
ART-treated individuals (McManus et al., 2019; Patro et al., 2019). This suggests that trafficking
of infected cells may occur between compartments over long-term ART treatment. Other groups
have observed identical internal proviral sequences between lymphoid tissue and peripheral
blood (De Scheerder et al., 2019; Kuo et al., 2020; Lee et al., 2020; McManus et al., 2019; Patro
et al., 2019; Vibholm et al., 2019). However, the existence of identical proviral sequences
between compartments does not indicate clonality, as different cells can harbor the same proviral
sequence integrated at different sites in the host genome (Patro et al., 2019).

The limited overlap between integration sites in different subset and compartments in our data set
has potential ramifications. With limited ongoing viral replication in lymphoid tissue during ART
(McManus et al., 2019) and the low likelihood of the same integration site occurring from two
separate cellular infection events, the emergence of identical sites in different compartments
would require proliferation of the infected cell followed by migration and/or differentiation. This
lack of integration site overlap suggests that migration and/or differentiation may impart a fitness
cost (whether by immune clearance from viral reactivation, disruption of required
cellular/differentiation programs due to integration, or other means). This scenario is supported by
the observation that the infection of resting memory CD4+ T cells likely stems from an infection
event during an activated state prior to the transition to a quiescent state, thus escaping
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elimination (Shan et al., 2017). Any exit from quiescence could lead to the presentation of viral
antigens and subsequent clearance, resulting in the general maintenance of segregation. The
observation of shared proviral sequences from before ART treatment (Lee et al., 2020) and our
limited observation of integration site overlap supports the notion of a genetic bottleneck (likely
from immune pressure prior to ART (Patro et al., 2019)).

Insertional mutagenesis affecting specific cellular genes may be linked to cellular proliferation.
Some of the overlapping genes that we detected have been documented for their roles in
oncogenesis. LINC00466 has been implicated as a potential factor in promoting lung
adenocarcinoma (Ma et al., 2019). BACH2 has known tumor immunosuppressive capacity
(Roychoudhuri et al., 2016), and P4HB upregulation may be involved with glioblastoma
multiforme (Sun et al., 2017) as noticed for integration sites recovered from the ART-treated
individuals, thus suggesting that oncogenic genes may play a role in the overlap. Strikingly, these
limited overlaps were all within the same compartment or involved the nonresident subsets (i.e.,
all subsets except tissue CD69+ or GC-Tfh phenotypes), suggesting that migration of infected
clones through lymphatic tissues does occur. The dilution of a given infected clone among the
vast network of lymphatics and vasculature could explain the small degree of sharing among the
nonresident subsets.

Recent studies reported overlap in bulk CD4+ T cells between tonsils and peripheral blood in
ART-treated individuals (McManus et al., 2019; Patro et al., 2019), but our data highlighted the
lack of overlap in our subjects. The statistical concern of the “unseen species problem” (where
the overlapping clones might have been undetected given the size of the pool of infected cells) is
always present for these types of studies, especially with our samples from peripheral blood
during ART. However, clonal expansion was still detectable from both compartments in our data
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set. The discrepancy between our findings and these previous studies can potentially be
explained by two hypotheses. First, the duration of ART treatment may play a role in the
emergence of sharing between blood and tissues. Our study cohort was sampled at a generally
shorter duration of ART (1.4, 7.8, and 3.2 years) compared with previous studies (5.7, 13, and
<15.8 years) (McManus et al., 2019). Time may be needed under suppressive therapy to allow
cells to differentiate after antigenic stimulation or equilibrate between the subsets and/or
compartments. Second, the overlaps between blood and tonsil may exist in the HLA-DR+activated subset, as we specifically examined resting HLA-DR– cells for tonsil samples. A recent
study showed that there was an increase in infected HLA-DR+ cells over time during ART (Lee et
al., 2019), suggesting that these two hypotheses are not mutually exclusive. Both HLA-DR+ and
HLA-DR– cells are capable of harboring intact proviruses and in some cases have identical p6-RT
sequences (Lee et al., 2019). However, integration site distributions were not assessed, thus
leaving the question of true overlap between these subsets unresolved. The presence of HLA-DR
and the likelihood of an activation state may suggest the ability for cells to traffic between
compartments.

The limited overlap of integration sites reported here in the HIV-1 reservoir has consequences for
cure strategies. Latency reversal agents to date have generally been unable to “shock” the entire
reservoir, thus limiting the effectiveness of viral elimination. A recent study has demonstrated
differential effects in activating HIV-1 RNA transcription via latency reversal agents in diverse
CD4+ T cell memory subsets from blood (Grau-Expósito et al., 2019). These previous findings,
combined with the differences we observed based on residency phenotypes, highlight the need to
better understand the HIV-1 reservoir at an increased subset resolution.
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Our study has several limitations, with the primary limitation being our sample size. Due to the
large size of the HIV-1 reservoir and the possibility of single sites being actual clones, more
studies with a variety of lymphoid tissues, including the gut-associated lymphoid tissue (GALT),
are needed from individuals in different cohorts to validate our findings. While we did profile from
2 lymph nodes that are distal to each other, this does not preclude the possibility of clonally
expanded cells being in the remaining hundreds of other structures distributed throughout the
body. However, these samples, especially the multiple paired lymph nodes are difficult to acquire
and costly to sequence at the cell subset resolution. Another limitation is the lack of dual
integration site and viral DNA sequencing at the time of our study, which was difficult with the
number of cells procured from each subset. As studies have documented the existence of
replication competent viruses in clonally expanded cells (Einkauf et al., 2019; Patro et al., 2019;
Simonetti et al., 2016), the understanding of which cells in our study have replication competent
viruses would add additional resolution. New techniques for paired integration site and proviral
profiling could be used for further studies (Einkauf et al., 2019; Patro et al., 2019). The
identification of integration sites, however, is sufficient for determining clonal expansion in
infected cells (Patro et al., 2019).

Overall, our data set provides a resource to the HIV community, as it is the first to our knowledge
to profile integration sites from acute, chronic, and ART-treated individuals with paired tissue and
blood comparisons at a subset resolution. This resource will be valuable for both the HIV-1
reservoir field as well as for clinical methods using retroviral vectors. Our data highlight the need
to better understand the reservoir — in terms of specific subreservoirs that may need to be
differentially targeted with a focus on the residency status of infected cells.
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2.4 Methods
Samples
For acute and chronic infection studies, peripheral blood and tissue samples (CLN and ILN) were
simultaneously obtained from HIV-1+ individuals prior to the introduction of ART (n = 3 for acute
and n = 3 for chronic). For ART-treated studies, peripheral blood and tonsil samples were
simultaneously obtained at the same time point from HIV-1+ individuals undergoing ART
treatment (n = 3). Donor information is summarized in Table 2.1.

PBMCs and LNMCs were prepared as previously described (Nguyen et al., 2019). All cells were
cryopreserved before being shipped on dry ice for experimental studies.

CD4+ T cell subset sorting
PBMCs and LNMCs were thawed and suspended at 2 million cells/mL in complete RPMI medium
supplemented with 10% FBS, 1% L-glutamine, and 1% penicillin/streptomycin (R10). Cells were
rested overnight in a humidified incubator with 5% CO2 at 37°C, and RNase-free DNase I (10
units for every mL media used; MilliporeSigma) was added to reduce cell clumping for sorting.
After overnight rests, cells were washed with PBS prior to extracellular staining of cellular
markers for FACS on the same day.

Cells were first stained with CCR7 APC-Cy7 (G043H7, BioLegend, 353211) for 10 minutes in a
humidified incubator with 5% CO2 at 37°C. LIVE/DEAD Fixable Aqua (Thermo Fisher Scientific)
was then added to the cells for a 10-minute incubation at room temperature. Cells were stained
with a master mix of monoclonal antibodies with fluorescent conjugates (antibodies and clones
are listed below) for 20 minutes at room temperature. Samples with greater than or equal to 15 ×
106 cells were subjected to 2× of the titration volumes for all staining steps. Cells were then
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washed with PBS before being resuspended in 350 μl phenol red–free RPMI if samples had
greater than or equal to 15 million cells. Otherwise, cells were resuspended in 250 μl phenol red–
free RPMI. Prior to FACS, the cells were subjected through a 35 μm nylon mesh strainer-top tube
(Thermo Fisher Scientific) to reduce cell clumping. All samples were sorted with a FACS Aria II
SORP (BD) situated in a biosafety cabinet for biohazardous samples using standard
methodology. The gating strategy is described in Figure 2.1 and Figure 2.2. Individual T3 had a
further CD32– gate on cells from tonsil, as this sample’s sort was done from a previous study
(Abdel-Mohsen et al., 2018). Cells were sorted into the 1.5 mL DNA LoBind tubes (Eppendorf)
prefilled with 200–300 μl of a solution containing 1 part FBS and 1 part phenol red–free RPMI or
PBS.

Sorted cells were pelleted in a centrifuge at 3000g for 5 minutes, and supernatants were
discarded. Cell pellets were resuspended in 200 μl PBS and snap frozen on dry ice before storing
at –80°C.

Antibodies
The following monoclonal antibodies were used for FACS: CCR7 APC-Cy7 (G043H7, Biolegend,
353211), CD69 PE (FN50, BD, 555531), CD3 APC R700 (UCHT1, BD, 565119), PD-1 BV421
(EH12.2H7, Biolegend, 329920), HLA-DR BV605 (G46-6, BD, 562845), CXCR5 BB515 (RF8B2,
BD, 564624), CD14 PE-Cy5 (61D3, abcam, ab25395), CD16 PE-Cy5 (3G8, Biolegend, 3012010),
CD19 PE-Cy5 (HIB19, Biolegend, 302210), CD45RA PE CF594 (HI100, BD, 562298), CD8 PECy5.5 (RPA-T8, eBioscience, 35-0088-42), and CD4 PE Cy7 (RPA-T4, Biolegend, 300512).
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Integration site profiling
Sorted cells were thawed for DNA extraction using the DNeasy Blood & Tissue Kit (Qiagen) using
standard protocols. The final eluate was reeluted through the column to improve DNA yields, as
recommended in the manufacturer’s protocol. 100 μl of the DNA eluate was supplemented with
30 μl molecular-grade water (mH2O) to proceed with library preparation as previously published
(Berry et al., 2017; Sherman et al., 2017). Briefly, genomic DNA was sonicated using a Covaris
M220 unit (peak power: 50 W, duty factor: 5%, cycles/burst: 200, treatment time: 60 seconds,
water temperature: 25°C) to generate approximately 800–900 bp fragments. A genomic
uninfected DNA control (purified from 293T cells; Bushman Lab) was added during the sonication
stage. Fragmented DNA was cleaned using AMPure XP beads (Beckman Coulter) (ratio of 0.7
beads/1 DNA volume) and resuspended in 40 μl mH2O.

DNA ends were repaired using NEBNext Ultra End Repair/dA-Tailing Module (New England
Biolabs) and incubated at 20°C for 30 minutes, 65°C for 30 minutes, and rested at 4°C
indefinitely. A no-template control of mH2O was added during the end-repair stage. End-repaired
fragmented DNA was then ligated with unique linkers using the NEBNext Ultra Ligation Module
(New England Biolabs) for 16 hours at 16°C and rested at 4°C indefinitely (Sherman et al., 2017).
The resulting product was then bead purified using AMPure XP beads (0.7 beads/1 DNA volume)
and eluted in 60 μl of mH2O.

The first round of nested PCR (PCR1) was performed in replicates of 4 per sample using the
Advantage 2 PCR kit (Takara Bio). 15 μl DNA from the previous step was used for each replicate.
U3 and U5 primers targeting the HIV-1 LTR region primers and unique linker primers were added
at a final concentration of 300 nM each. Final volume was adjusted to 25 μl per replicate with
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mH2O. Thermocycler settings were set for 1 cycle of 95°C for 1 minute; a linear amplification of 5
cycles of 95°C for 30 seconds plus 70°C for 1 minute and 30 seconds; a log amplification of 20
cycles of 95°C for 30 seconds plus 67°C for 1 minute and 30 seconds; a final extension cycle of
70°C for 4 minutes; and an indefinite hold at 4°C. 5 μl PCR1 product was run on a 1% agaroseTAE gel to check for smears.

The second round of nested PCR (PCR2) was performed on 2 μl PCR1 product for each
replicate. Samples at this stage were separated into 2 different reactions, one containing U3
primers and the other containing U5 primers. All LTR primers contained sequencing adaptors as
well as a unique barcode with the goal of all samples (including replicates) having a unique LTRassociated barcode and linker combination. PCR2 linker primers and U3 or U5 primers were
added at a final concentration of 300 nM each. No internal fragment blocking oligo was added.
Final volume was adjusted to 25 μl with mH2O. Thermocycler settings were set for 1 cycle of
95°C for 1 minute; a linear amplification of 5 cycles of 95°C for 30 seconds plus 70°C for 1 minute
and 30 seconds; a log amplification of 15 cycles of 95°C for 30 seconds plus 67°C for 1 minute
and 30 seconds; a final extension cycle of 70°C for 4 minutes; and an indefinite hold at 4°C. 5 μl
PCR2 product was run on a 1% agarose-TAE gel to check for smears.

All PCR2 replicates were pooled together (U3 and U5 products are kept separate). PCR2
replicate pools were bead purified with AMPure XP beads (0.7 beads/1 DNA volume) and eluted
in 40 μl mH2O. Libraries were then assessed for molarity of readable amplicons using quantitative
PCR with the 2X MasterMix, ROX Low kit (Roche). Average fragment size was determined with
an Agilent 2200 TapeStation using a High Sensitivity D1000 ScreenTape Assay.
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Samples were pooled using the calculated readable molarity to attempt to equalize molarities
across samples by using the Microsoft Excel Solver add-in. 1 μl each of uninfected and notemplate controls were added to this pool. Bead purification with AMPure XP beads (0.7 beads/1
DNA volume) was performed as needed to get a final molarity of approximately 2 nM or greater.
Final readable molarity concentrations were determined for the pooled library in addition to an
average fragment size determination. Samples were then prepared for paired-end sequencing
using a 300 cycle MiSeq v2 Reagent Kit (Illumina) with 30% PhiX spike-in and custom primers on
the MiSeq platform (Illumina).

Primers
All primers are displayed in a 5′–3′ direction and were manufactured by Integrated DNA
Technologies. Linker-associated primers and barcodes are from a previous study (Sherman et
al., 2017). The following primers were used: HIV-1 PCR1 (U3):
CCCTGGCCCTGGTGTGTAGTTCTG; HIV-1 PCR1 (U5),
GAACCCACTGCTTAAGCCTCAATAAAG; HIV-1 PCR2 (U3),
CAAGCAGAAGACGGCATACGAGATBARCODEAGTCAGTCAGCCCAGGGAAGTAGCCTTGTG
TGTGGT; HIV-1 PCR2 (U5),
CAAGCAGAAGACGGCATACGAGATBARCODEAGTCAGTCAGCCCAAGTAGTGTGTGCCCGT
CTGTTG; sequencing R1, ATCTACACCAGGACTGACGCTATGGTAATTGT; sequencing index
(U3), CAAGGCTACTTCCCTGGGCTGACTGACT; sequencing index (U5),
AGTCAGTCAGCCCAGGGAAGTAGCCTTG; sequencing R2 (U3),
GGGCACACACTACTTGGGCTGACTGACT; and sequencing R2 (U5),
AGTCAGTCAGCCCAAGTAGTGTGTGCCC.
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Read to site mapping and abundance scoring
The processing of raw reads to final integration site counts was done using the cHIVa pipeline
(https://github.com/cnobles/chiva; branch, master; commit ID,
d43d01ebc577bb626dbdcda2eddefc9dc7387469), which is a streamlined and updated version of
the original INSPIIRED pipeline (https://github.com/BushmanLab/INSPIIRED; branch, master;
commit ID, 35e4b0b06182e3dcdb15f2abb6dbaab45b0ac225) (Berry et al., 2017). Briefly, raw bcl
files from sequencing were converted into fastq files using bcl2fastq2 (Illumina). The fastq files
are demultiplexed, trimmed, filtered, consolidated, aligned, and further processed with crossover
filtering to get human (hg38) and viral integration site junctions by sample. Sonic abundance was
then calculated as previously described by counting the unique fragment lengths for a given
integration site to infer the number of infected cells containing the site of interest (Berry et al.,
2017; Sherman et al., 2017). Since U3 and U5 were multiplexed together, the average of U3 and
U5 sonic abundances for each original PCR replicate was used if there were both U3 and U5
reads detected with the same integration site. Additional R code
(https://github.com/wuv21/intsite_analysis; branch, master; commit ID,
2d770df836b556cb841caef0d1124c1aeed5c058) was used to process and combine data from
different runs for graphs and summary information. The ChIPSeeker package in R was used to
annotate sites based on genomic location (Yu et al., 2015). Demultiplexed sequencing files are
deposited in the Sequence Read Archive database (accession PRJNA655671).

RNA-Seq analysis
Bins of genes with increasing transcriptional activity were derived from published RNA-Seq data
sets from GEO series GSE130793 (Vella et al., 2019). GC-Tfh samples
(GSM3753986, GSM3753990, and GSM3753994) and non-Tfh (GSM3753987, GSM3753991,
and GSM3753995) from lymph nodes were used. The raw counts were read using the R
91

statistical language with the DESeq2 package (Love et al., 2014). After normalization and scaling
with default parameters, the transcriptional levels for each gene were then placed into 10 equal
bins. The levels were determined by the samples within each subset (GC-Tfh or non-Tfh).
Integration sites were then filtered from our data set to select for those residing in a gene. Sites
were pooled together based on subset (as indicated in Figure 2.9). Since genes may overlap, we
included all of the overlapping genes in the comparison. The proportion of our recovered genic
integration sites within each transcriptional bin was counted and plotted.

Genomic and epigenetic annotation heatmaps
Integration sites were grouped based on criteria of interest. Groups of sites were only included if
there were 30 or more sites in preparation for site annotations as previously detailed (Berry et al.,
2006; Nobles et al., 2020; Wang et al., 2007). Briefly, 3 matched random control (MRC) sites
were chosen for each integration site in the filtered data set. The actual and MRC sites were then
marked for different genomic and CD4+ T cell epigenetic annotations in order to compute a ROC
curve. Significance for the proportions between actual integration sites and MRC sites was found
using a χ2 test.

Pooled overlap sampling
For each individual, all integration sites were pooled based on their sonic abundance. The sites
were then randomly sampled by the original sonic abundance of a given cell subset to preserve
our original sequencing depth and breadth. If a site was found in 2 or more of these simulated cell
subsets, the site would be recorded as being a simulated overlap. This simulation was repeated
10,000 times, and the number of simulated overlaps detected was plotted as a cumulative
distribution frequency plot.
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Statistics
Statistical analyses are detailed in the Methods and figures legends and are consolidated here.
Differences between genic annotations were assessed using a Wilcoxon rank sum test. For the
genomic/epigenetic heatmaps, significance between actual integration sites and MRCs was
assessed using a χ2 test. Clonal proportions by residency phenotype and by stage were
assessed using a Wilcoxon rank sum test. P values below 0.05 were deemed significant.

Study approval
All donors were recruited by the Department of Infectious Diseases at the National Institute for
Respiratory Diseases (INER-CIENI) in Mexico City, Mexico. All donors provided written informed
consent in compliance with protocols set forth by the INER-CIENI Ethics Committee and the
Institutional Review Board at the University of Pennsylvania. Protocols were approved by the
Institutional Review Boards at the University of Pennsylvania (no. 809316) and Comité de Ciencia
y Bioética en Investigación (Committee for Science and Bioethics in Research) from INER
(Mexico City, Mexico; study no. B03-16).
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CHAPTER 3
PROFOUND PHENOTYPIC AND EPIGENETIC HETEROGENEITY OF THE HIV-1 INFECTED
CD4+ T CELL RESERVOIR

This chapter is presented as a modified version of the following preprint: Wu VH, Nguyen S,
Nordin JML, Joy J, Mampe F, Tebas P, Montaner LJ, Bar KJ, Vella LA, Betts MR. Profound
phenotypic and epigenetic heterogeneity of the HIV-1 infected CD4+ T cell reservoir. bioRxiv.
Published online July 5, 2022:2022.04.02.486753. doi:10.1101/2022.04.02.486753.

3.1 Introduction
The establishment and persistence of the HIV reservoir remains one of the greatest barriers
preventing a functional cure in people living with HIV (PLWH). This reservoir, primarily composed
of infected long-lived memory CD4+ T cells (Chun et al., 1995, 1997a; Finzi et al., 1997), resides
in blood and tissue compartments throughout the body and almost invariably reactivates upon
antiretroviral therapy (ART) interruption (Deleage et al., 2016; Estes et al., 2017; Pantaleo et al.,
1993; Wong et al., 1997a). Reservoir persistence results from the stable integration of viral DNA
into the genome of a host cell, enabling infection for the lifetime of the cell and its progeny.
Substantial strides have been made towards understanding the virological aspects of the HIV
reservoir, including intactness, reactivation potential, and integration site landscapes (De
Scheerder et al., 2019; Ho et al., 2013). However, beyond population level characterization and
quantification, the cellular identity of the HIV reservoir in vivo remains an enigma. Defining a
surface marker and or epigenetic signature of the cellular HIV reservoir for targeting is of central
importance to the HIV cure agenda.
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The major impediment towards our understanding of the cellular reservoir is the challenge of
identifying infected cells. On average during ART, fewer than 1/1000 CD4+ T cells are infected
with HIV in the blood (Eriksson et al., 2013), the majority of which have little to no viral RNA
production (Einkauf et al., 2022; McManus et al., 2019). To overcome this, the field to date has
used in vitro models (Bradley et al., 2018; Golumbeanu et al., 2018), exogenous stimulation
strategies (Cohn et al., 2018; Liu et al., 2020b), and marker-targeted analysis (many studies
including (Fromentin et al., 2016; Neidleman et al., 2020; Pardons et al., 2019)) to identify surface
protein and/or transcriptomic properties of the HIV reservoir. These studies have collectively
made inroads into the identity of infected cells but have been inherently limited by the
experimental systems employed. These limitations, including 1) the heterogeneity of infected
CD4+ T cells within bulk populations, 2) incomplete representation of the reservoir by sorting for
viral RNA+ and/or protein-expressing cells, and 3) activation-induced malleability of both the cell
surface proteome and underlying transcriptome, have obfuscated the precise characterization of
infected cells and highlight the need to develop novel strategies to characterize the cellular HIV
reservoir at steady state and ultimately following cure-directed strategies.

Here, we used the presence of integrated provirus as a molecular tag to directly identify individual
infected cells using single-cell Assay for Transposase Accessible Chromatin (scATACseq)
(Buenrostro et al., 2013) and employing a human-viral alignment strategy first developed in a
chimeric antigen receptor (CAR) T-cell model (Wang et al., 2020). Further, scATACseq provides
unbiased, single-cell epigenetic profiles and can therefore assign cellular identity to cells with and
without detectable provirus. An additional goal of reservoir research is to identify cell surface
proteins that identify or substantially enrich for infected cells. We therefore combined scATACseq
with cell surface protein identity using the recently described ATAC with Select Antigen Profiling
by sequencing (ASAPseq) (Mimitou et al., 2021; Swanson et al., 2021). We employed ASAPseq
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to study both in vitro and direct ex vivo HIV infection, including the most clinically relevant setting
with peripheral blood memory CD4+ T cells from ART-treated PLWH. Our findings provide the
first direct and unbiased identification of experimentally and in vivo infected memory CD4+ T cells
at single-cell resolution with cellular identity. With our multidimensional dataset, we highlight the
heterogeneity of HIV+ cells and the variation of surface and epigenetic markers between and
across infection contexts. Together, our extensive characterization of HIV infection using
ASAPseq results in a multimodal single-cell dataset of cell surface protein composition,
epigenetic landscape, and potential regulatory mechanisms to accelerate our understanding of
the HIV reservoir for targeted therapy.

3.2 Results
ASAPseq identification of HIV-infected cells in vitro
To determine the potential for ASAPseq to detect HIV-infected cells, we first tested an in vitro
primary CD4+ T-cell infection model (Table 3.1). CD4+ T cells from an HIV-uninfected individual
were activated with anti-CD3, anti CD28/CD49d, and IL-2 for two days, infected with HIV-1
(molecular clone; SUMA), and rested for four subsequent days. We next performed ASAPseq,
obtaining 7095 cells that passed quality checks for both ATAC and the antibody-derived tag
(ADT) components (Table 3.2 and Figure 3.1A). Following alignment of sequencing data to both
human and viral genomes, 1323 cells (18.6%) contained an integrated HIV genome in open
chromatin (HIV+, Figure 3.2A-B). As expected, a smaller proportion of the in vitro infected cells
expressed p24 protein by flow cytometry (5.1%, Figure 3.1B), consistent with known per-cell
discrepancies between HIV integration and p24 production (Shan et al., 2017). To confirm the
specificity of provirus detection, we aligned an unrelated ASAPseq dataset of uninfected
peripheral blood mononuclear cells (Mimitou et al., 2021) using our chimeric human-virus
genomes (human (hg38) + SUMA HIV and hg38 + HXB2 HIV). No cells contained reads aligning
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to either HIV genome, demonstrating the high specificity for ASAPseq-based detection of HIV+
cells (Figure 3.1C). Within the HIV+ CD4+ T cells, proviral reads spanned the viral genome but
were most prevalent in the long-terminal repeats (LTR) as well as gag and env genes (Figure
3.1D). Fewer reads spanned the pol gene consistent with previous findings (Jefferys et al., 2021).
Twenty-eight percent of HIV fragments were in LTR regions, 0.01% spanned both LTR and
internal (i.e. not LTR), and the remaining fragments (71%) were internal.

Table 3.1: Donor Information.
Stage

Donor

Sex

Age
(y)

Plasma viral
load

In vitro infection
ART-treated
infection

ND492
A01
A08
A09
B45

M
M
M
M
M

37
*
*
*
43

<1.7
<1.7
<1.7
<1.7

* Age was not reported at the participant level for the original study. However, the age range was
reported as between 34 to 52 years.
Table 3.2: Catalog of TotalSeqA (BioLegend) antibodies used for study.
DNA_ID

Description

Clone

Barcode

A0006
A0007
A0020
A0023
A0024
A0026
A0029
A0031
A0032
A0033
A0034
A0046
A0047
A0050
A0052
A0053
A0058
A0063
A0064
A0066
A0070
A0071
A0072
A0073
A0081

CD86
CD274 (B7-H1, PD-L1)
CD270 (HVEM, TR2)
CD155 (PVR)
CD112 (Nectin-2)
CD47
CD48
CD40
CD154
CD52
CD3
CD8
CD56 (NCAM)
CD19
CD33
CD11c
HLA-A,B,C
CD45RA
CD123
CD7
CD49f
CD194 (CCR4)
CD4
CD44
CD14

IT2.2
29E.2A3
122
SKII.4
TX31
CC2C6
BJ40
5C3
24-31
HI186
UCHT1
SK1
5.1H11
HIB19
P67.6
S-HCL-3
W6/32
HI100
6H6
CD7-6B7
GoH3
L291H4
RPA-T4
IM7
M5E2

GTCTTTGTCAGTGCA
GTTGTCCGACAATAC
TGATAGAAACAGACC
ATCACATCGTTGCCA
AACCTTCCGTCTAAG
GCATTCTGTCACCTA
CTACGACGTAGAAGA
CTCAGATGGAGTATG
GCTAGATAGATGCAA
CTTTGTACGAGCAAA
CTCATTGTAACTCCT
GCGCAACTTGATGAT
TCCTTTCCTGATAGG
CTGGGCAATTACTCG
TAACTCAGGGCCTAT
TACGCCTATAACTTG
TATGCGAGGCTTATC
TCAATCCTTCCGCTT
CTTCACTCTGTCAGG
TGGATTCCCGGACTT
TTCCGAGGATGATCT
AGCTTACCTGCACGA
TGTTCCCGCTCAACT
TGGCTTCAGGTCCTA
TCTCAGACCTCCGTA
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A0083
A0085
A0087
A0088
A0089
A0090
A0091
A0092
A0095
A0100
A0101
A0124
A0127
A0134
A0136
A0138
A0140
A0141
A0142
A0143
A0144
A0145
A0146
A0147
A0149
A0151
A0152
A0153
A0154
A0155
A0156
A0158
A0159
A0160
A0161
A0162
A0163
A0165
A0167
A0168
A0170
A0171
A0172
A0174
A0176
A0179
A0180
A0181
A0185
A0187
A0189
A0206
A0214
A0215
A0216
A0217
A0218
A0219
A0224
A0236
A0237
A0238

CD16
CD25
CD45RO
CD279 (PD-1)
TIGIT (VSTM3)
Mouse IgG1, κ isotype Ctrl
Mouse IgG2a, κ isotype Ctrl
Mouse IgG2b, κ isotype Ctrl
Rat IgG2b, κ Isotype Ctrl
CD20
CD335 (NKp46)
CD31
Podoplanin
CD146
IgM
CD5
CD183 (CXCR3)
CD195 (CCR5)
CD32
CD196 (CCR6)
CD185 (CXCR5)
CD103 (Integrin αE)
CD69
CD62L
CD161
CD152 (CTLA-4)
CD223 (LAG-3)
KLRG1 (MAFA)
CD27
CD107a (LAMP-1)
CD95 (Fas)
CD134 (OX40)
HLA-DR
CD1c
CD11b
CD64
CD141 (Thrombomodulin)
CD314 (NKG2D)
CD35
CD57
CD272 (BTLA)
CD278 (ICOS)
CD275 (B7-H2, B7-RP1, ICOSL)
CD58 (LFA-3)
CD39
CX3CR1
CD24
CD21
CD11a
CD79b (Igβ)
CD244 (2B4)
CD169 (Sialoadhesin, Siglec-1)
integrin β7
CD268 (BAFF-R)
CD42b
CD54
CD62P (P-Selectin)
CD119 (IFN-γ R α chain)
TCR α/β
Rat IgG1, κ isotype Ctrl
Rat IgG1, λ Isotype Ctrl
Rat IgG2a, κ Isotype Ctrl
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3G8
AAGTTCACTCTTTGC
BC96
TTTGTCCTGTACGCC
UCHL1
CTCCGAATCATGTTG
EH12.2H7
ACAGCGCCGTATTTA
A15153G
TTGCTTACCGCCAGA
MOPC-21
GCCGGACGACATTAA
MOPC-173
CTCCTACCTAAACTG
MPC-11
ATATGTATCACGCGA
RTK4530
GATTCTTGACGACCT
2H7
TTCTGGGTCCCTAGA
9E2
ACAATTTGAACAGCG
WM59
ACCTTTATGCCACGG
NC-08
GGTTACTCGTTGTGT
P1H12
CCTTGGATAACATCA
MHM-88
TAGCGAGCCCGTATA
UCHT2
CATTAACGGGATGCC
G025H7
GCGATGGTAGATTAT
J418F1
CCAAAGTAAGAGCCA
FUN-2
GCTTCCGAATTACCG
G034E3
GATCCCTTTGTCACT
J252D4
AATTCAACCGTCGCC
Ber-ACT8
GACCTCATTGTGAAT
FN50
GTCTCTTGGCTTAAA
DREG-56
GTCCCTGCAACTTGA
HP-3G10
GTACGCAGTCCTTCT
BNI3
ATGGTTCACGTAATC
11C3C65
CATTTGTCTGCCGGT
SA231A2
CTTATTTCCTGCCCT
O323
GCACTCCTGCATGTA
H4A3
CAGCCCACTGCAATA
DX2
CCAGCTCATTAGAGC
Ber-ACT35 (ACT35)AACCCACCGTTGTTA
L243
AATAGCGAGCAAGTA
L161
GAGCTACTTCACTCG
ICRF44
GACAAGTGATCTGCA
10.1
AAGTATGCCCTACGA
M80
GGATAACCGCGCTTT
1D11
CGTGTTTGTTCCTCA
E11
ACTTCCGTCGATCTT
QA17A04
AACTCCCTATGGAGG
MIH26
GTTATTGGACTAAGG
C398.4A
CGCGCACCCATTAAA
9F.8A4
GTTAGTGTTAGCTTG
TS2/9
GTTCCTATGGACGAC
A1
TTACCTGGTATCCGT
K0124E1
AGTATCGTCTCTGGG
ML5
AGATTCCTTCGTGTT
Bu32
AACCTAGTAGTTCGG
TS2/4
TATATCCTTGTGAGC
CB3-1
ATTCTTCAACCGAAG
C1.7
TCGCTTGGATGGTAG
7-239
TACTCAGCGTGTTTG
FIB504
TCCTTGGATGTACCG
11C1
CGAAGTCGATCCGTA
HIP1
TCCTAGTACCGAAGT
HA58
CTGATAGACTTGAGT
AK4
CCTTCCGTATCCCTT
GIR-208
TGTGTATTCCCTTGT
IP26
CGTAACGTAGAGCGA
RTK2071
ATCAGATGCCCTCAT
G0114F7
GGGAGCGATTCAACT
RTK2758
AAGTCAGGTTCGTTT

A0240
A0241
A0242
A0246
A0247
A0352
A0353
A0355
A0357
A0358
A0359
A0364
A0367
A0368
A0369
A0370
A0371
A0372
A0373
A0383
A0384
A0385
A0386
A0389
A0390
A0391
A0393
A0394
A0396
A0398
A0404
A0406
A0407
A0408
A0419
A0420
A0446
A0447
A0575
A0576
A0577
A0579
A0581
A0582
A0586
A0590
A0591
A0599
A0817
A0822
A0830
A0845
A0853
A0861
A0864
A0866
A0867
A0868
A0870
A0871
A0872
A0894

Rat IgG2c, κ Isotype Ctrl
RTK4174
Armenian Hamster IgG Isotype CtrlHTK888
CD192 (CCR2)
K036C2
CD122 (IL-2Rβ)
TU27
CD267 (TACI)
1A1
FcεRIα
AER-37 (CRA-1)
CD41
HIP8
CD137 (4-1BB)
4B4-1
CD43
CD43-10G7
CD163
GHI/61
CD83
HB15e
CD13
WM15
CD2
TS1/8
CD226 (DNAM-1)
11A8
CD29
TS2/16
CD303 (BDCA-2)
201A
CD49b
P1E6-C5
CD61
VI-PL2
CD81 (TAPA-1)
5A6
CD55
JS11
IgD
IA6-2
CD18
TS1/18
CD28
CD28.2
CD38
HIT2
CD127 (IL-7Rα)
A019D5
CD45
HI30
CD22
S-HCL-1
CD71
CY1G4
CD26
BA5b
CD115 (CSF-1R)
9-4D2-1E4
CD63
H5C6
CD304 (Neuropilin-1)
12C2
CD36
5-271
CD172a (SIRPα)
15-414
CD72
3F3
CD158 (KIR2DL1/S1/S3/S5)
HP-MA4
CD93
VIMD2
CD200 (OX2)
OX-104
CD49a
TS2/7
CD49d
9F10
CD73 (Ecto-5’-nucleotidase)
AD2
CD9
HI9a
TCR Vα7.2
3C10
TCR Vδ2
B6
CD354 (TREM-1)
TREM-26
CD305 (LAIR1)
NKTA255
LOX-1
15C4
CD158e1 (KIR3DL1, NKB1)
DX9
CD109
W7C5
CD142
NY2
CD319 (CRACC)
162.1
CD99
3B2/TA8
CLEC12A
50C1
CD151 (PETA-3)
50-6
CD352 (NTB-A)
NT-7
CLEC1B (CLEC2)
AYP1
CD94
DX22
IgE
MHE-18
CD150 (SLAM)
A12 (7D4)
CD162
KPL-1
CD84
CD84.1.21
Ig light chain κ
MHK-49
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TCCAGGCTAGTCATT
CCTGTCATTAAGACT
GAGTTCCCTTACCTG
TCATTTCCTCCGATT
AGTGATGGAGCGAAC
CTCGTTTCCGTATCG
ACGTTGTGGCCTTGT
CAGTAAGTTCGGGAC
GATTAACCAGCTCAT
GCTTCTCCTTCCTTA
CCACTCATTTCCGGT
TTTCAACGCCCTTTC
TACGATTTGTCAGGG
TCTCAGTGTTTGTGG
GTATTCCCTCAGTCA
GAGATGTCCGAATTT
GCTTTCTTCAGTATG
AGGTTGGAGTAGACT
GTATCCTTCCTTGGC
GCTCATTACCCATTA
CAGTCTCCGTAGAGT
TATTGGGACACTTCT
TGAGAACGACCCTAA
TGTACCCGCTTGTGA
GTGTGTTGTCCTATG
TGCAATTACCCGGAT
GGGTTGTTGTCTTTG
CCGTGTTCCTCATTA
GGTGGCTAGATAATG
AATCACGGTCCTTGT
GAGATGTCTGCAACT
GGACTAAGTTTCGTT
TTCTTTGCCTTGCCA
CGTGTTTAACTTGAG
CAGTCGTGGTAGATA
TATCAACCAACGCTT
GCGCTACTTCCTTGA
CACGTAGACCTTTGC
ACTGATGGACTCAGA
CCATTCAACTTCCGG
CAGTTCCTCAGTTCG
GAGTCACCAATCTGC
TACGAGCAGTATTCA
TCAGTCAGATGGTAT
TAGCCGTTTCCTTTG
ATTTCCATTCCCTGT
ACCCTTTACCGAATA
GGACGCTTTCCTTGA
CACTTAACTCTGGGT
CACTGCCGTCGATTA
AGTATGCCATGTCTT
ACCCGTCCCTAAGAA
CATTAGAGTCTGCCA
CTTACCTAGTCATTC
AGTTTCCACTCAGGC
TGCCAGTATCACGTA
CTTTCCGGTCCTACA
GGATGTACCGCGTAT
GTCATTGTATGTCTG
ATATGTCAGAGCACC
CTCCCTAGTTCCTTT
AGCTCAGCCAGTATG

A0896
A0897
A0898
A0902
A0912
A0920
A0923
A0931
A0935
A0940
A0941
A0944
A1018
A1046

CD85j (ILT2)
CD23
Ig light chain λ
CD328 (Siglec-7)
GPR56
CD82
NKp80
CD131
CD74
CD116
CD37
CD101 (BB27)
HLA-DR, DP, DQ
CD88 (C5aR)

GHI/75
EBVCS-5
MHL-38
6-434
CG4
ASL-24
5D12
1C1
LN2
4H1
M-B371
BB27
Tü39
S5/1

CCTTGTGAGGCTATG
TCTGTATAACCGTCT
CAGCCAGTAAGTCAC
CTTAGCATTTCACTG
GCCTAGTTTCCGTTT
TCCCACTTCCGCTTT
TATAGTTCCTCTGTG
CTGCATGAGACCAAA
CTGTAGCATTTCCCT
ATGGACAGTTCGTGT
ACAGTCACTGGGCAA
CTACTTCCCTGTCAA
AGCTACGAGCAGTAG
GCCGCATGAGAAACA

We next examined the phenotypic identity of HIV+ versus HIV- cells. We clustered the cells using
the epigenetic data component and annotated based on imputed gene scores from chromatin
accessibility and the ADT component (Figure 3.2A, Figure 3.1E, Figure 3.3, and Figure 3.4).
Given that PBMCs were enriched for CD4+ T cells prior to infection, most clusters consisted of
CD4+ T cells with some contaminating B and antigen presenting (APC) cells. Clusters were
separated by activated versus naive/early memory phenotypes, with the greatest number of HIV+
cells (78.6% of all HIV+ cells, Figure 3.2B-D) found within activated and/or effector memory
CD4+ T cell clusters. We also observed some HIV+ cells in other CD4+ T-cell phenotypes
(18.3%) and a small proportion in monocytes (1.8%). These findings reflect the known
phenomenon of preferential in vitro HIV infection of activated CD4+ T cells and demonstrate that
this feature can be resolved on a single-cell level by ASAPseq.

In a comparison between all HIV+ and uninfected T cells, we observed significantly higher
expression of many surface markers including those associated with T-cell activation on HIV+
cells (Figure 3.5A and Table 3.3). The top 5 upregulated markers by π-score (Xiao et al., 2014)
on HIV+ cells included CCR5, SLAM, PD-1, CD49a, and CD161 while the top 5 upregulated
markers on HIV- cells were CD31, CD62L, CD55, CD27, and CD7 (Figure 3.5A). The significant
upregulation of CCR5 in HIV+ cells is consistent with the usage of CCR5 as the co-receptor for
HIV-1 infection (Alkhatib et al., 1996). The other differentially expressed surface markers in HIV+
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cells reflect the known preferential infection of activated CD4+ T cells (Zack et al., 1990; Zhang et
al., 1999). We therefore asked whether any surface protein distinguished between infected and
uninfected cells in the activated clusters (Figure 3.2E, Figure 3.6, and Table 3.3). In activated
HIV+ cells, we found that CCR5, SLAM, CD2, GPR56, PD-1 were the top upregulated markers,
while CD62L, CD127, CD49f, CXCR5, and CCR4 were increased in activated HIV- CD4+ cells.
This finding suggests that even within the activated/effector cells, the HIV+ cells have higher
expression of CCR5 and other activation markers. In the early differentiated HIV+ T cells, we
found several significantly increased expression of ICOS, CXCR3, CD25, CD11a, and CD49b
while the early differentiated HIV- cells were enriched in CD62L, CD55, CD127, CD162, and
CD45RA (Figure 3.5B and Table 3.3). These surface antigen marker findings highlight the
heterogeneity of infected cells even in the activated cell population.
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Figure 3.1: Properties of ASAPseq library for in vitro model. (A) UpSet plot of unique cell
barcodes that were collected from each modality (ATAC versus ADT) and whether or not the
barcode was associated with proviral reads (HIV). Barcodes that passed ATAC and ADT quality
checks (see Methods) were used for downstream analyses. (B) Flow cytometry plot of cell culture
before conducting ASAPseq analysis. X-axis is p24 while Y-axis is CD8. Value in the highlighted
box is the percent of total live singlets that are p24+. (C) Reported mapped and unmapped readsegments by chromosome (as determined by samtools idxstats) from alignment of ASAPseq
dataset of uninfected PBMC (Mimitou et al., 2021) to chimeric reference genomes with HXB2
(left) or SUMA (right). HIV genomes were added as a separate chromosome during creation of
the chimeric reference genome. (D) (top) Sequenced regions that are aligned by bwa mem to the
proviral genome (SUMA) and recovered by hiv-haystack. Each row is a cell and each column is a
base pair spanning the proviral genome. Regions in orange indicate actual reported coverage
while regions in blue indicate inferred coverage if provirus was intact as paired-end sequencing
can only obtain at most 50bp from either end of the genomic/transposed fragment if the genomic
fragment is > 50bp. Many LTR alignments can be ambiguous and it is unclear whether the actual
read is in the 3’ LTR or 5’ LTR. The primary alignment from bwa-mem is recorded here. (middle)
Proportion of coverage is reported across all cells spanning the entire proviral genome. (bottom)
Genome map of SUMA. (E) UMAP representation of the ATAC component with numeric labeling
prior to manual annotation.
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Figure 3.2: ASAPseq identification of HIV-infected cells in vitro. (A) UMAP representation of
ATAC component colored by manually annotated cell phenotypes. (B) UMAP representation of
ATAC component colored by detection of HIV reads. (C) Absolute count of cell numbers based
on annotated clusters. Red color denotes HIV+ cells while gray color denotes HIV- cells. (D)
Percentage of HIV+ cells found in each annotated cluster. (E) Surface enrichment profile in
activated HIV+ cells (red) versus activated HIV- cells (gray). Activated cells are defined as the
combination of CD4 Activated/effector, CD4 Activated #1, and CD4 Activated #2 clusters. π-score
is defined as (-log10(FDR) * log2(FC)).
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Figure 3.3: ADT base panel for in vitro model. Each subplot shows the ADT signal for a
specific surface antigen for each cluster as seen in Supplemental Figure 1E. X-axis values are
normalized count values as processed via Seurat.
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Figure 3.4: ATAC base panel for in vitro model. Each subplot shows the imputed gene activity
score overlaid on the UMAP coordinate space as seen in Supplementary Figure 1E. Gene activity
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score was calculated by ArchR and imputed using MAGIC to aid in visual interpretation as
recommended by ArchR.

Figure 3.5: Differential expression of select antigens for in vitro model. Significant surface
markers (adjusted p value < 0.05) enriched in HIV- or HIV+ cells are shown for (A) all CD4+ T107

cells and (B) early differentiated CD4+ T-cells. Gray indicates markers for HIV- cells while gray
indicates markers for HIV+ cells. π-score was calculated as log10(adjusted p value) * log2(fold
change).

Figure 3.6: Differential expression of select antigens in activated T cells for in vitro model.
Violin-scatter plots are shown for the top 10 surface markers from Figure 1E that are enriched in
(A) activated HIV- cells and (B) activated HIV+ cells. Grey color (FALSE) indicates HIV- cells
while red color (TRUE) indicates HIV+ cells. Markers are ordered from left to right; top to bottom
by order of decreasing |π-score| as seen in Figure 3.2E.
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Table 3.3: Significant surface markers enriched in HIV+ versus HIV- cells for in vitro model.
Subset

Cluster Marker

log2(fold change)

Adjusted p value π-score

CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+
CD4+

HIVHIVHIVHIVHIVHIVHIVHIVHIVHIVHIVHIVHIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+

-1.06
-0.52
-0.52
-0.37
-0.38
-0.52
-0.22
-0.27
-0.06
-0.06
-0.09
-0.11
2.08
1.64
1.36
1.68
1.94
0.87
0.97
1.61
0.79
1.03
1.39
1.34
1.12
1.04
0.84
0.89
1.21
1.37
0.94
0.60
0.99
0.77
0.66
0.65
0.85
0.91
0.53
0.61
0.70
0.80
0.69
0.84
0.54
0.60
0.60
0.52
0.52
0.43
0.63
0.34
0.38
0.43
0.47
0.35
0.39
0.12

1.0e-158
9.1e-265
1.0e-178
1.8e-241
5.9e-123
8.2e-45
1.9e-89
1.4e-44
7.5e-83
8.6e-72
4.5e-41
1.3e-25
2.2e-308
2.2e-308
1.3e-228
1.7e-172
7.5e-145
2.2e-308
5.6e-260
1.6e-154
1.4e-235
1.1e-173
4.4e-115
1.4e-113
2.3e-134
1.3e-141
3.9e-151
1.4e-121
4.7e-89
1.1e-74
2.2e-100
3.4e-132
2.2e-66
4.1e-83
1.2e-95
1.1e-85
1.2e-53
4.4e-49
1.9e-75
2.0e-65
1.9e-53
3.7e-44
3.4e-49
8.1e-40
5.5e-54
9.0e-45
1.7e-35
9.3e-24
4.6e-22
3.0e-20
1.3e-13
4.2e-22
4.9e-19
2.2e-16
3.9e-08
2.0e-10
3.6e-07
5.3e-19

CD31
CD62L
CD55
CD27
CD7
CD9
CD45RA
CD38
CD3
TCR α/β
CD127 (IL-7Rα)
CD272 (BTLA)
CD195 (CCR5)
CD150 (SLAM)
CD279 (PD-1)
CD49a
CD161
CD2
CD95 (Fas)
CD49b
CD99
CD29
KLRG1 (MAFA)
GPR56
HLA-DR, DP, DQ
CD151 (PETA-3)
CD226 (DNAM-1)
CD58 (LFA-3)
CD244 (2B4)
CD69
HLA-DR
CD11a
CD196 (CCR6)
CD49d
CD278 (ICOS)
CD45RO
CD25
CD192 (CCR2)
CD18
CD54
CD26
CD194 (CCR4)
CD84
CD146
CD82
CD39
CD119 (IFN-γ R α chain)
CD81 (TAPA-1)
CD305 (LAIR1)
CD352 (NTB-A)
CD73 (Ecto-5’-nucleotidase)
CD45
CD48
HLA-A,B,C
integrin β7
CD44
CD183 (CXCR3)
CD52
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-167.94
-136.14
-91.74
-89.81
-46.54
-23.03
-19.14
-12.02
-4.54
-4.20
-3.54
-2.69
640.57
504.37
309.43
288.33
279.09
267.60
251.16
247.25
185.04
177.44
158.63
151.04
149.85
146.42
126.37
107.82
107.21
101.26
93.74
79.11
65.06
63.34
62.58
55.12
45.13
43.98
39.68
39.15
36.72
34.62
33.30
32.93
28.76
26.33
20.78
11.99
11.02
8.36
8.05
7.27
7.05
6.79
3.50
3.36
2.50
2.25

CD4+
CD4+
CD4+
CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
activated/late diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+

HIV+
HIV+
HIV+
HIV+
HIVHIVHIVHIVHIVHIVHIVHIVHIVHIVHIVHIVHIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIVHIVHIVHIVHIVHIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+

CD43
CD47
CD101 (BB27)
CD19
CD62L
CD127 (IL-7Rα)
CD49f
CD185 (CXCR5)
CD194 (CCR4)
CD27
TIGIT (VSTM3)
CD31
CD55
CD7
CD5
CD162
CD195 (CCR5)
CD150 (SLAM)
CD2
GPR56
CD279 (PD-1)
CD95 (Fas)
CD119 (IFN-γ R α chain)
CD26
HLA-DR, DP, DQ
CD244 (2B4)
CD11a
CD305 (LAIR1)
CD146
CD161
CD73 (Ecto-5’-nucleotidase)
HLA-DR
CD54
CD151 (PETA-3)
CD196 (CCR6)
CD192 (CCR2)
CD48
CD25
CD49b
KLRG1 (MAFA)
CD49a
CD101 (BB27)
CD99
CD47
CD52
CD82
CD62L
CD55
CD127 (IL-7Rα)
CD162
CD45RA
CD278 (ICOS)
CD25
CD183 (CXCR3)
CD11a
CD49b
CD2
CD38
CD151 (PETA-3)
CD305 (LAIR1)
CD71
CD18
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0.30
0.01
0.37
0.12
-0.38
-0.28
-0.31
-0.26
-0.18
-0.06
-0.14
-0.10
-0.02
-0.02
-0.01
0.00
0.90
0.79
0.41
0.86
0.66
0.33
0.46
0.41
0.46
0.57
0.27
0.42
0.55
0.59
0.56
0.43
0.29
0.38
0.48
0.52
0.23
0.30
0.38
0.50
0.43
0.39
0.22
0.05
0.07
0.07
-0.27
-0.24
-0.09
-0.10
-0.08
0.57
0.79
0.77
0.55
0.67
0.50
0.60
0.60
0.57
0.52
0.45

3.3e-07
1.8e-102
6.0e-03
2.6e-07
1.0e-54
1.7e-20
4.4e-14
8.6e-13
3.1e-08
3.7e-14
7.2e-06
2.6e-04
3.1e-05
8.7e-03
1.0e-03
1.1e-03
2.1e-32
1.9e-35
4.4e-36
7.3e-15
1.1e-18
3.8e-16
2.5e-10
2.5e-06
2.3e-05
2.8e-04
5.9e-08
2.3e-05
4.1e-04
2.1e-03
1.9e-03
3.4e-04
9.6e-06
1.6e-03
6.5e-03
1.7e-02
2.5e-04
2.1e-03
9.3e-03
3.4e-02
4.5e-02
4.1e-02
5.1e-03
5.9e-07
3.0e-03
1.7e-02
7.0e-31
1.3e-19
4.5e-14
1.7e-10
1.2e-10
3.0e-17
2.5e-12
8.0e-10
1.1e-12
1.7e-09
3.4e-09
5.4e-07
1.4e-06
8.3e-06
2.5e-04
1.1e-04

1.94
1.17
0.81
0.81
-20.54
-5.57
-4.15
-3.09
-1.33
-0.77
-0.70
-0.37
-0.07
-0.04
-0.02
-0.01
28.34
27.31
14.40
12.12
11.79
5.13
4.46
2.32
2.13
2.04
1.97
1.94
1.88
1.57
1.53
1.49
1.43
1.07
1.06
0.92
0.82
0.81
0.77
0.74
0.58
0.53
0.50
0.30
0.17
0.13
-8.17
-4.57
-1.21
-0.96
-0.77
9.46
9.21
7.00
6.53
5.87
4.24
3.74
3.54
2.89
1.87
1.80

early diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+
early diff CD4+

HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+

CD47
CD101 (BB27)
HLA-A,B,C
CD95 (Fas)
CD4
CD19
CD49f

0.10
0.57
0.18
0.42
0.42
0.12
0.04

4.5e-17
1.6e-03
5.3e-07
5.6e-03
1.1e-02
3.9e-02
3.0e-03

1.69
1.61
1.10
0.95
0.82
0.16
0.10

Differential chromatin accessibility in HIV-infected cells and surface marker based
supervised machine learning in vitro
We next examined whether there was any differential genomic accessibility between activated
HIV+ and activated HIV- cells. We observed heightened accessibility in several genomic regions
in activated HIV+ cells (Figure 3.7A-B and Table 3.4). Several nearest genes to these peaks
have been previously implicated for HIV infection and replication. We also observed a greater
accessibility at a peak ~1kb upstream of the CCR5 transcription start site (Figure 3.7C), thus
showing a potential concordance between CCR5 surface expression and gene accessibility.
From these differentially accessible genomic regions, we assessed transcription factor motif
enrichment. In the activated HIV- cells (Figure 3.7D), the top enriched motifs include several
members of the TCF family including TCF7 (TCF-1) and LEF1, both regulators of CD4+ T-cell
development and differentiation (reviewed in (Ma et al., 2012)). In the activated HIV+ cells
(Figure 3.7D), the top motifs included proliferation and activation motifs in the AP-1 related family
such as the JUN and FOS families (reviewed in (Foletta et al., 1998)). These findings, in
combination with the surface marker profiles, are concordant with the known immunobiology of
HIV-1 infection, thus showing that ASAPseq is a viable technique for ascertaining phenotypes of
HIV+ cells.

Finally, as an initial step towards selectively recognizing and targeting HIV+ cells, we employed
several supervised machine learning methods to determine whether any cell surface proteins
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could, in combination, predict infected cells. We assessed logistic regression, naive Bayes, and
random forest methods using a 70/30 (training/test) split of our dataset. Using all CD4+ T cells,
we found similar results between the models with area under the receiver operating curve (ROC)
(AUC) values of 0.89, 0.88, and 0.9 respectively (Figure 3.7E) suggesting a reasonable
classification of HIV+ cells in vitro with this current ADT panel. In the logistic regression, markers
with the greatest odds ratio and significance included CD2, CD49b, CD95, SLAM, and TCR α/β
for classifying HIV+ cells while CD4, NKG2D, CD62L, and CD162 were the top markers for
classifying HIV- cells (Figure 3.7F). For the random forest model, the top markers by importance
(measured as mean decrease in accuracy when permuted) were CCR5, SLAM, CD49b, CD2,
and CD95. When applied to only activated CD4+ T cells, the random forest model and logistic
regression both performed the best with an AUC of 0.78, compared to 0.74 with naive Bayes.
Compared to the total CD4+ T cell models, there were higher false positive rates suggesting that
additional markers tailored to activated T cells might benefit classification efforts (Figure 3.7G).
The activated CD4+ T cell random forest was driven primarily by CCR5, SLAM, CD69, CD2, and
NKG2D in decreasing order of importance. Overall, these supervised machine learning models
are in concordance with our differential expression testing and highlight the prominent roles of
CCR5, SLAM, and CD2 as markers of HIV-1 in vitro infection (Figure 3.7H).

112

Figure 3.7: Differential chromatin accessibility in HIV-infected cells and surface marker
based supervised machine learning in vitro. (A) Volcano plot showing differentially accessible
peaks between activated HIV+ versus activated HIV- cells. (B) Top 15 significant peaks in
activated HIV- versus activated HIV+ cells. Peaks are ranked by π-score (-log10(FDR) *
log2(FC)). Y-axis labels denote nearest TSS and/or if the peak is in a gene (marked by asterisk *)
and numbers in parentheses indicate distance to the nearest TSS. Negative numbers indicate
that the nearest TSS is upstream of the peak. (C) (top) Aggregated and normalized ATAC signal
between activated HIV- (gray) and activated HIV+ cells (red) at the CCR5 locus. (middle)
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Binarized ATAC signal at a single-cell resolution (showing random 750 cells for each group).
(bottom) Gene map for the genomic region shown: chr3:46360853-46380854 (centered on
CCR5). Orange genes are in positive orientation while blue genes are in negative orientation. (D)
Significant motif enrichments found in the differential peaks (ordered by significance) are shown
in activated HIV- cells or activated HIV+ cells. (E) Area under the receiver operating curve (ROC)
(AUC) plots for multiple supervised machine learning models for all CD4+ T cells. RF = random
forest. Ratios for different RF models indicate the number of HIV- cells used for each HIV+ cell
(i.e. 5:1 ratio meant that the HIV- cells in the training dataset were randomly downsampled to get
only 5 times the number of HIV+ cells in the training dataset). (F) Significant coefficients for the
logistic regression model shown in (E). Positive odds ratio (red) indicates a marker has more
weight for HIV+ cells while negative odds ratio (gray) indicates a marker has more weight for HIVcells. (G) AUC plots for multiple supervised machine learning models for activated CD4+ T cells.
(H) Proportion of HIV- (gray) and HIV+ (red) activated CD4+ T cells with different surface marker
combinations. In the bottom dot plot, a black dot indicates that the combination is positive for that
marker, which was determined by the thresholds indicated with the dotted line on the ridge plots.
These ridge plots display the expression distribution of activated HIV+ CD4+ T cells (red),
activated HIV- CD4+ T cells (gray), and total cells in the in vitro dataset (blue) to help with gating.
Table 3.4: Differential peak list for activated CD4+ T cells between HIV+ and HIV- for in
vitro model.
FDR

πscore

In Gene

133763071
128840083
120344302
29013010

Log2
Fold
change
-5.76
-2.32
-1.62
-1.51

2.00E-02
3.40E-04
4.30E-04
4.30E-04

-9.73
-8.04
-5.47
-5.08

GPC3
KCNJ1
LRRC58
MIR3680-1

chr5

75078009

-2.44

9.50E-03

-4.94

ANKRD31

chr17
chr13
chr7
chr6

62164986
73984895
127322273
149366167

-3.33
-1.91
-1.49
-1.44

4.40E-02
7.80E-03
2.10E-03
1.80E-03

-4.51
-4.03
-4
-3.93

chr1

87045694

-2.48

2.70E-02

-3.89

KLF12
TAB2
HS2ST1,
LINC01140

HIV-

chr5

109921610

-1.41

2.00E-03

-3.82

-

HIVHIVHIVHIVHIVHIVHIVHIVHIV-

chr5
chr10
chr1
chr3
chr8
chr7
chrX
chr12
chr15

39186867
3800532
39653445
10263496
120472266
1925895
136674455
64494944
44560876

-1.84
-2.74
-1.9
-2.19
-2.41
-1.53
-1.51
-1.89
-1.87

8.40E-03
4.70E-02
1.70E-02
3.00E-02
4.50E-02
7.80E-03
7.80E-03
2.10E-02
2.10E-02

-3.82
-3.65
-3.35
-3.34
-3.25
-3.23
-3.18
-3.17
-3.15

HIV-

chr8

120775213

-2.19

3.80E-02

-3.13

HIV-

chr11

14463556

-2.33

4.70E-02

-3.1

FYB1
TATDN2
MTBP
MAD1L1
ARHGEF6
TBK1
EIF3J
SNTB1,
LOC101927543
COPB1

HIV-

chr6

37289865

-2.29

4.60E-02

-3.06

TBC1D22B

HIVHIV-

chr15
chr3

88904581
153643435

-1.01
-1.59

2.00E-03
2.10E-02

-2.72
-2.68

HIV-

chr16

29827058

-1.85

4.40E-02

-2.52

MFGE8
BOLA2, SLX1A,
SLX1A-SULT1A3,

Subset

Chr

Start*

HIVHIVHIVHIV-

chrX
chr11
chr3
chr16

HIVHIVHIVHIVHIVHIV-
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Nearest
TSS

Nearest
TSS Dist

GPC3
KCNJ1
LRRC58
LAT
LINC013
36
MED13
KLF12
GRM8
SUMO4
LINC011
40
LINC018
48
FYB1
KLF6
HEYL
TATDN2
MRPL13
MIR4655
CD40LG
TBK1
EIF3J
LOC101
927543
COPB1
TMEM21
7
MFGE8
C3orf79

222324
26790
4537
28184

MVP

6664

-25166
-99704
148510
-68979
-33560
52685
38428
87161
-15251
-13500
15473
-26864
-81642
26262
43064
23819
13960
35971
-31710
8330
158940

chr2

203987082

-1.65

4.40E-02

-2.24

SULT1A4,
LOC388242,
PAGR1, MVP
-

HIV-

chr3

187027350

-1.03

7.80E-03

-2.18

ST6GAL1

HIV-

chr10

118732697

-1.59

4.80E-02

-2.09

CACUL1

HIV-

chr3

118955786

-1.29

4.10E-02

-1.78

IGSF11

HIV-

chr13

49371836

-1.12

3.10E-02

-1.7

CAB39L

HIV-

chr14

32102444

-1.21

4.50E-02

-1.63

ARHGAP5

HIV-

chr10

43332102

-1.16

4.00E-02

-1.62

-

HIV-

chr1

100927241

-0.91

3.00E-02

-1.38

SLC30A7

HIVHIV-

chr17
chr14

66331088
89903512

-0.94
-1.01

3.40E-02
4.70E-02

-1.38
-1.34

PRKCA
FOXN3, EFCAB11

HIV-

chr13

51825061

-0.85

2.70E-02

-1.33

HIV-

TMEM272

HIV-

chr16

27235313

-0.99

4.60E-02

-1.32

HIV-

chr10

110225646

-0.83

2.60E-02

-1.32

MIR3680-1,
NSMCE1
MXI1

HIV-

chr13

40485590

-0.61

1.50E-02

-1.1

LINC00598

HIV+

chr1

221829595

1.39

3.90E-05

6.15

LINC01655

HIV+

chr9

73869213

2.09

1.40E-03

5.99

-

HIV+

chr6

117465645

2.53

6.70E-03

5.5

GOPC, DCBLD1

HIV+

chr14

68719698

1.16

3.50E-05

5.17

-

HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+
HIV+

chr8
chr14
chr15
chr9
chr15
chr6
chr2
chr2
chr3
chr9

72000175
59275611
101199696
75148484
90412628
13747556
101223824
136362680
71447689
86348418

1.52
1.76
1.15
2.03
2.94
1.1
1.52
1.86
2.51
1.66

1.40E-03
5.10E-03
3.30E-04
1.10E-02
4.40E-02
4.30E-04
5.40E-03
1.50E-02
4.60E-02
9.70E-03

4.34
4.05
4
3.99
3.98
3.7
3.44
3.38
3.36
3.35

MSC-AS1
DAAM1
CHSY1
IQGAP1
TBC1D8
FOXP1
TUT7

HIV+

chr7

23595009

2.5

4.70E-02

3.32

-

HIV+

chr11

14288180

1.57

9.10E-03

3.22

RRAS2

HIV+

chr3

71392986

1.9

2.00E-02

3.22

FOXP1

HIV+
HIV+
HIV+

chr17
chr1
chr11

3795234
25099439
43316418

1.8
2.11
2.09

2.00E-02
3.80E-02
3.80E-02

3.04
3
2.97

ITGAE
API5

HIV+

chr13

27131122

0.85

3.80E-04

2.89

USP12

HIV+
HIV+
HIV+

chr5
chr4
chr16

72194799
26076133
82660155

2.07
1.52
2.05

4.00E-02
1.50E-02
4.80E-02

2.88
2.75
2.7

MAP1B
CDH13

HIV+

chr15

38610792

1.3

9.10E-03

2.66

-

HIV+
HIV+
HIV+
HIV+
HIV+
HIV+

chr8
chr8
chr10
chr11
chr4
chr16

133152859
28365700
22505996
34235166
121256332
23504680

1.2
1.93
1.85
1.43
1.18
1.09

7.00E-03
4.80E-02
4.50E-02
2.00E-02
9.50E-03
6.70E-03

2.58
2.53
2.48
2.41
2.39
2.37

ZNF395
ABTB2
MIR3680-1, GGA2
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ICOS
ST6GAL
1
CACUL1
IGSF11AS1
CAB39L
ARHGA
P5-AS1
FXYD4
SLC30A
7
PRKCA
FOXN3
TMEM27
2

50334

-25651

KDM8

31818

MXI1
LINC005
98
LINC016
55
LOC101
927358
DCBLD1
ZFP36L
1
TRPA1
DAAM1
CHSY1
OSTF1
IQGAP1
RANBP9
CNOT11
CXCR4
MIR1284
TUT7
CCDC12
6
RRAS2
FOXP1AS1
ITGAE
MIR4425
API5
USP12AS1
MIR4803
RBPJ
MIR8058
RASGR
P1
WISP1
PNOC
SPAG6
ABTB2
TNIP3
GGA2

18041

96865
22052
12713
71790
-39040
31165
28452
50647
19614

49717
10571
-501818
11828
76055
74942
86965
51736
59941
24410
-35992
-28478
-244515
93900
5536
-1870
75826
103217
5509
75936
4455
-31233
25332
-86822
-28276
-45217
-37680
48714
160551
122342
-28866
16815

HIV+

chr5

127785555

1.07

8.40E-03

2.22

CCDC192

HIV+

chr8

97980061

1.27

2.00E-02

2.14

MATN2

HIV+
HIV+

chr10
chr2

22597125
65232542

1.6
1.24

4.70E-02
2.00E-02

2.13
2.1

PIP4K2A
ACTR2

HIV+

chr11

128551675

1.22

2.20E-02

2.03

ETS1

HIV+
HIV+
HIV+

chr13
chr3
chr10

50245013
46369194
88270827

1.42
1.43
1.03

3.90E-02
4.10E-02
1.20E-02

2.01
1.97
1.96

DLEU1
LOC102724297
-

HIV+

chr6

108921393

1.19

2.40E-02

1.94

ARMC2

HIV+

chr1

32263726

1.42

4.50E-02

1.91

LCK

HIV+

chr8

100493218

1.33

4.70E-02

1.76

-

HIV+

chr4

101039328

1.24

4.10E-02

1.73

PPP3CA

HIV+

chr2

178514591

0.78

6.40E-03

1.71

PLEKHA3

HIV+
HIV+
HIV+
HIV+
HIV+

chr3
chr14
chr22
chr13
chr8

155862523
74573941
39961397
76991309
66467771

1.29
1.08
0.87
0.65
0.76

4.80E-02
4.30E-02
2.00E-02
1.30E-02
4.10E-02

1.7
1.48
1.47
1.21
1.06

LTBP2
GRAP2
CLN5
ADHFE1, VXN

CCDC19
2
SNORA
72
PIP4K2A
ACTR2
ETS1AS1
DLEU2
CCR5
RNLS
ARMC2AS1
LCK
ANKRD4
6
EMCN
TTNAS1
GMPS
LTBP2
FAM83F
CLN5
VXN

82165
61656
116930
4789
25533
-119293
-1160
313203
2210
12487
66066
-159202
-6092
-7513
37937
-33052
649
7768

* Peak region is represented by the Start position to the Start position + 500bp.

ASAPseq identification of heterogeneous HIV-infected cells from peripheral blood of ART
suppressed PLWH
We next applied ASAPseq to blood CD4+ T cells in the setting of ART to assess the reservoir in
the most accessible compartment and in a clinically relevant context. To define the characteristics
of the HIV CD4+ T cell reservoir in the blood of ART-treated PLWH (ART-PLWH), we purified
memory CD4+ T cells from the PBMC of 4 ART-PLWH and performed ASAPseq. Given the rarity
of infected cells during ART treatment (Chun et al., 1997a) and the relative paucity of infected
cells in peripheral blood compared to tissues, we substantially increased the number of memory
CD4+ T cells assessed compared to our in vitro infection studies. Altogether, the combined ARTtreated dataset contained 127761 cells of which 149 (0.12%) cells were HIV+ (Figure 3.8A and
Table 3.5). For all donors, we aligned the ATAC reads to autologous HIV sequences (near full
length or HIV env) and HXB2 to increase the odds of detecting infected cells due to the
prevalence of proviral mutations in long-term PLWH (Ho et al., 2013). With the autologous
alignments, most aligned regions were primarily detected in the LTR and/or nef region (Figure
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3.9). Cells from donor A09 during both timepoints also had internal fragments that mapped to
gag, pol, and env genes (Figure 3.9).

Figure 3.8: Properties of ASAPseq library during treated infection. (A) UpSet plot of unique
cell barcodes that were collected from each modality (ATAC versus ADT) and detection of
proviral reads (HIV) separated by individual. (B) UMAP representation of the ATAC component
with numeric labeling prior to manual annotation.
Table 3.5: Cell counts stratified by individual for ART-PLWH.

Individual
A01
A08

Total cells
23962
16398

HIV+ cells
(% of total cells)
5 (0.02%)
31 (0.19%)

A09

77242

105 (0.14%)

B45

10159

8 (0.08%)
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Total HIV DNA copies per
million CD4+ T cells
(percentage) (Salantes et
al., 2018)
293.8 (0.029%)
1564.5 (0.16%)
1297.3 (0.12% pre-ATI)
1221.8 (0.12% post-ATI)
-
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Figure 3.9: HIV alignment for ART-PLWH samples. (left) Sequenced regions that are aligned
by bwa mem to the proviral genome (autologous + HXB2) and recovered by hiv-haystack. Each
row is a cell and each column is a base pair spanning different autologous sequences. Tracks are
separated by autologous sequence (sequence name is shown on the left in gray box). (right) For
each row, the coverage is labeled by its annotation (as determined from Gene Cutter).
After clustering based on the ATAC component and annotating with both ADT and ATAC
components (Figure 3.8B, Figure 3.10, and Figure 3.11), we identified multiple memory CD4+ T
cell subsets with only small numbers of contaminating cells (Figure 3.12A-B). The T cell clusters
separated based on epigenetic profiles associated with T-cell differentiation states. For example,
central memory T cells (Tcm) had distinct epigenetic and surface antigen profiles compared to
those seen in effector/effector memory (Tem) cells (Figure 3.10 and Figure 3.11). Across the
ART-PWLH, we observed no consistent cell type that was predominantly infected. Some donors
(A01 and B45) showed more dominant populations of HIV+ cells within a single cell type while
other donors (A08 and A09) had more detections across different cell types (Figure 3.12C). In
sharp contrast with the heterogeneity across donors, we noticed a remarkable maintenance of
cell types amongst the HIV+ cells between the pre- and post-ATI timepoints from donor A09
(Figure 3.12D), indicating relative compositional stability of the cellular phenotypes of the HIV
reservoir in this donor after ATI. After aggregating all HIV+ cells across donors, we detected HIV+
cells within multiple subsets including CD4+ Tcm, Th2, circulating Tfh (cTfh), mucosal associated
invariant T (MAIT) cells and Tem/effector cells (Figure 3.12B,E). We also detected a small
proportion of HIV+ cells within the contaminating APC clusters, but it is unclear whether these
were in actual APCs, CD4+ T cells included in doublets with APCs, or miscalled as APCs.
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Figure 3.10: ADT base panel during treated infection. Each subplot shows the ADT signal for
a specific surface antigen for each cluster as seen in Figure 3.12B. X-axis values are normalized
count values as processed via Seurat.
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Figure 3.11: ATAC base panel during treated infection. Each subplot shows the imputed gene
activity score overlaid on the UMAP coordinate space as seen in Figure 3.12B. Gene activity
121

score was calculated by ArchR and imputed using MAGIC to aid in visual interpretation as
recommended by ArchR.

Figure 3.12: ASAPseq identification of heterogeneous HIV-infected cells from peripheral
blood of ART suppressed PLWH. (A) UMAP representation of ATAC component colored by
manually annotated cell phenotypes. (B) UMAP representation of ATAC component colored by
detection of HIV reads. (C) Absolute count of cell numbers based on annotated clusters. Red
color denotes HIV+ cells while gray color denotes HIV- cells. (D) Percentage of HIV+ cells found
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in each annotated cluster separated by donors A01, A08, and B45. Y-axis represents percent of
the individual’s HIV+ cells found in each annotated cluster. (E) Percentage of HIV+ cells found
before and after treatment interruption in donor A09. (F) Percentage of HIV+ cells found in each
annotated cluster, aggregated across all ART-treated donors.

High degree of heterogeneity in HIV-infected cells from peripheral blood of ART
suppressed PLWH
We next assessed whether differential surface markers were present between the HIV+ CD4+ T
cells versus the HIV- CD4+ T cells. Using the statistical test employed by Seurat and DESeq2,
we found significant enrichment of CD99 and CD2 in the HIV+ cells, markers associated with T
cell adhesion and co-stimulation, respectively. We found enrichment of several markers in the
HIV- T cells including CD200, CD74, CD41, and NKG2D (Figure 3.13A and Table 3.6). With
another statistical test (Wilcoxon), we found enrichment of different markers including activation
markers such as SLAM, CCR2, CD49d, CD26, HLA-DR, and PD-1 that were more highly
expressed on HIV+ CD4+ T cells (Figure 3.13B, Figure 3.14, and Table 3.6). Similar to the
results from the DESeq2 method, we found that CD200 and CD74 were also more expressed on
HIV- CD4+ T cells. It is important to note that the enrichment of some of these markers (from
either test) can vary across donors as seen with PD-1 primarily being driven by individual A08
(Figure 3.14).

To reduce the variance caused by differential expression of markers based on memory and
functional differentiation (i.e. central/transitional memory, effector memory, and MAIT), we
conducted differential expression testing between HIV+ and HIV- cells in the following aggregated
CD4+ T cell groups: Tcm/Ttm cells (Figure 3.13C), Tem cells (Figure 3.13D), and MAIT cells.
Other cell types were excluded for this analysis due to low HIV+ cell counts. In the Tcm/Ttm cells,
we found enrichment of CD71, CD2, and CD11a on HIV+ cells while there was an enrichment of
CD62L on the HIV- cells indicating that the Tcm/Ttm cells were contributing to the CD2 from the
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bulk CD4+ T cell analyses (Figure 3.13C). In the Tem cells, the integrin CD49a and receptor
CCR5 were significantly enriched on HIV+ cells, while multiple markers including CD74, CD41,
and CD3 were enriched on HIV- Tem cells (Figure 3.13D). No significant markers were
differentially expressed for either HIV+ or HIV- MAIT cells (data not shown). These results
highlight the surface marker and phenotypic heterogeneity present in specific memory
phenotypes as well as the inability of any marker amongst the 154 antibodies tested to uniquely
identify HIV+ cells.

Figure 3.13: High degree of heterogeneity in HIV-infected cells from peripheral blood of
ART suppressed PLWH. (A) Surface enrichment profile in all HIV+ CD4+ T cells (red) versus
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HIV- CD4+ T cells (gray). Test performed using the DESeq2 pseudobulk method in Seurat. (B)
Surface enrichment profile of the same cells as in (A) but using the Wilcoxon statistical test in
Seurat. (C) Surface enrichment profile of Tcm/Ttm HIV+ (red) versus Tcm/Ttm HIV- cells (gray)
using the DESeq2 method. Tcm/Ttm cells are defined by the combination of all clusters
containing the terms “Tcm” or “Ttm” (but not MAIT) in Figure 3.12A. (D) Surface enrichment
profile of Tem HIV+ (red) versus Tem HIV- (gray) cells using the DESeq2 method. Tem cells are
defined by the combination of all clusters containing the term “Tem” in Figure 3.12A. X-axis units
for (A-D) are in π-score (see Figure 3.2E legend). Heatmap of mean chromVAR deviations (zscore) of transcription factor motifs from CISBP database (displayed by row) that define each
aggregate group (MAIT, Tcm/Ttm, and Tem) separated by HIV- versus HIV+ (displayed by
column). Motifs were selected by FDR < 0.05 and a mean difference > 0.5, indicating a significant
accessibility of regions containing a given transcription factor motif for cells in the cluster
(indicated by asterisks) as compared to all other cells (getMarkerFeatures function in ArchR).
Each cell is colored by the mean deviation (z-score) where values > 0 indicate positive
enrichment of a motif. Motifs were clustered using k-means clustering and the motifs are labeled
to the right of the heatmap in order from top to bottom for each cluster. Asterisks indicate that the
motif was significantly enriched in the specific group (column). * < 0.05; ** < 0.01 (F) chromVAR
deviations were compared between HIV+ Tcm/Ttm cells and HIV- Tcm/Ttm cells and the top 15
most significant motifs are shown. The dotted line indicates a -log10 transformed FDR value of
0.05. Color indicates the mean difference in chromVAR deviations (value > 0 indicates
enrichment in HIV+ cells).
Table 3.6: Significant surface markers enriched in HIV+ versus HIV- cells during treated
infection.
Subset

Cluster

Marker

log2(fold change)

Adjusted p value

π-score

CD4+ (DESeq2)

HIV-

CD200 (OX2)

-0.84

1.4e-09

-7.42

CD4+ (DESeq2)

HIV-

CD74

-0.75

2.0e-09

-6.49

CD4+ (DESeq2)

HIV-

CD41

-0.80

6.2e-07

-4.98

CD4+ (DESeq2)
CD4+ (DESeq2)

HIVHIV-

CD314 (NKG2D)
GPR56

-0.64
-0.87

5.5e-07
4.0e-04

-4.02
-2.96

CD4+ (DESeq2)

HIV-

CD158e1 (KIR3DL1, NKB1)

-0.69

5.4e-05

-2.94

CD4+ (DESeq2)

HIV-

CD103 (Integrin αE)

-0.71

1.9e-04

-2.65

CD4+ (DESeq2)

HIV-

CD3

-0.18

6.5e-13

-2.19

CD4+ (DESeq2)
CD4+ (DESeq2)

HIVHIV-

CD8
CD62L

-0.55
-0.29

1.7e-03
1.7e-05

-1.54
-1.40

CD4+ (DESeq2)

HIV-

CD79b (Igβ)

-0.55

3.2e-03

-1.38

CD4+ (DESeq2)

HIV-

CD122 (IL-2Rβ)

-0.34

9.9e-04

-1.01

CD4+ (DESeq2)

HIV-

CD49b

-0.45

1.3e-02

-0.84

CD4+ (DESeq2)
CD4+ (DESeq2)

HIVHIV-

CD305 (LAIR1)
CD38

-0.32
-0.51

2.5e-03
2.3e-02

-0.83
-0.83

CD4+ (DESeq2)

HIV-

IgE

-0.40

1.1e-02

-0.79

CD4+ (DESeq2)

HIV-

CD94

-0.43

2.1e-02

-0.72

CD4+ (DESeq2)
CD4+ (DESeq2)

HIVHIV-

LOX-1
CD134 (OX40)

-0.33
-0.31

1.6e-02
1.9e-02

-0.59
-0.53

CD4+ (DESeq2)

HIV-

CD56 (NCAM)

-0.37

4.3e-02

-0.51

CD4+ (DESeq2)

HIV-

TCR α/β

-0.03

1.1e-02

-0.07
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CD4+ (DESeq2)

HIV+

CD99

0.36

7.6e-05

1.49

CD4+ (DESeq2)
CD4+ (Wilcoxon)

HIV+
HIV-

CD2
CD200 (OX2)

0.34
-0.18

8.4e-03
2.0e-03

0.70
-0.49

CD4+ (Wilcoxon)

HIV-

CD74

-0.18

3.7e-02

-0.26

CD4+ (Wilcoxon)

HIV+

CD150 (SLAM)

0.18

6.1e-07

1.10

CD4+ (Wilcoxon)
CD4+ (Wilcoxon)

HIV+
HIV+

CD192 (CCR2)
CD49d

0.18
0.13

1.7e-04
4.4e-04

0.70
0.44

CD4+ (Wilcoxon)

HIV+

CD26

0.14

5.6e-03

0.32

CD4+ (Wilcoxon)

HIV+

HLA-DR, DP, DQ

0.16

2.2e-02

0.27

CD4+ (Wilcoxon)

HIV+

CD279 (PD-1)

0.14

1.9e-02

0.24

CD4+ (Wilcoxon)
Tcm/Ttm (DESeq2)

HIV+
HIV-

HLA-DR
CD62L

0.13
-0.53

3.3e-02
9.9e-03

0.20
-1.06

Tcm/Ttm (DESeq2)

HIV+

CD71

1.10

6.7e-04

3.48

Tcm/Ttm (DESeq2)

HIV+

CD2

0.46

2.4e-02

0.75

Tcm/Ttm (DESeq2)

HIV+

CD11a

0.47

3.8e-02

0.68
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Figure 3.14: Differential expression of select antigens during treated infection. Violin-scatter
plots are shown for all significantly expressed (adjusted p value < 0.05; Wilcoxon) surface
markers from Figure 3.13B that are enriched in (A) all CD4+ HIV+ T-cells and (B) all CD4+ HIV127

T-cells. Grey color indicates HIV- cells while red color indicates HIV+ cells. Markers are ordered
from left to right; top to bottom by order of decreasing |π-score| as seen in Figure 3.13B. Cells
are separated by individual and the aggregate data (across individuals) is also shown.
To address this heterogeneity in a more unbiased way, we next assessed if there were unique
epigenetic signatures between the HIV+ and HIV- CD4+ T cells. We used chromVAR, specifically
designed for differential motif analysis from sparse scATACseq data (Schep et al., 2017), on all
HIV+ versus HIV- cells grouped by the same three aggregate memory/functional phenotypes
(Tcm/Ttm, Tem, and MAIT) in the surface marker analyses. We identified several highly enriched
motifs in the different groups over all other cells that are not in the analyzed group (collectively
referred to as background cells). Motifs were clustered into different modules via hierarchical
clustering (Figure 3.13E). In support of our manual annotation, Tcm/Ttm cells showed greater
enrichment of Tcf7 and Lef1 motifs (module 1) compared to Tem cells, while the Tem cells
showed greater enrichment of Tbx21 (T-bet), Eomes, and interferon related motifs (modules 5
and 9). MAIT cells, which can be heterogeneous in terms of different memory phenotypes,
showed enrichment in motifs from the nuclear factor-kappaB (NF-κB) transcription factor family
including NFKB1, REL, RELA, and RELB (modules 3 and 4).

While HIV+ and HIV- cells shared similar motifs within the aggregate clusters, we observed
patterns of greater enrichment of certain motifs in the HIV+ cells. Module 10 - consisting of
BACH2 and AP-1 related family transcription factors such as Jun and Fos - was highly enriched
for HIV+ Tcm/Ttm and Tem cells, but was not significant when compared to the background of all
other cells. When comparing Tcm/Ttm HIV+ versus Tcm/Ttm HIV- cells, we found significant
enrichment of motifs associated with module 10 (Figure 3.13F). HIV+ MAIT cells curiously did not
show an enrichment in this module but did show significant enrichment in HOXA9, HOXD11,
IKZF4, IZKF1, and MYBL1 motifs over background cells (Figure 3.13E). Altogether, these motif
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signatures across our dataset indicate that Tcm/Ttm and Tem HIV+ cells share an epigenetic
signature consistent with a heightened immune activated state.

3.3 Discussion
The targeted elimination of the HIV reservoir requires a deep understanding of both the virologic
and cellular characteristics. Prior work has yielded extensive knowledge of viral diversity,
integration, clonal expansion, intactness, and latency dynamics of the viral reservoir, allowing a
deeper understanding of the target for clearance. However, precise definition of cellular reservoir
has proven more difficult due to the rarity of infected cells and the challenge of identifying infected
cells while preserving their native state. To address this, we applied a novel single-cell genomic
and bioinformatic strategy using ASAPseq to identify infected cells by the presence of integrated
proviral DNA in the multiomic context of single cell epigenetic and surface antigen profiling. Using
this strategy, we found that cells with proviral DNA can indeed be directly detected and
individually characterized directly from the peripheral blood of PLWH on ART. We anticipate that
this strategy will have broad application for in depth analysis of the HIV reservoir within different
cell populations, therapeutic interventions, and HIV cure and eradication studies (Abdel-Mohsen
et al., 2020).

Numerous studies have attempted to identify cell surface markers and memory phenotypes that
enrich or specifically identify CD4+ T cells harboring integrated proviral DNA. Recent studies
have shown that Tem cells contain high levels of transcriptionally active proviruses (Collora et al.,
2022; Grau-Expósito et al., 2019). As such, we expected Tem cells to be enriched in our dataset
due to the assumed accessible chromatin. However, we find no Tem bias in the cells harboring
integrated virus as HIV+ cells in ART-PLWH from our study were distributed amongst a wide
spectrum of memory phenotypes. Importantly, this distribution also differed between individuals
129

but not within individual A09 where we observed similar phenotypes of infected cells that were
conserved before and after ATI. This indicates that ATI does not drastically shift the reservoir and
is observed along with the reported stability of the reservoir with ATI (Salantes et al., 2018). The
lack of memory bias in our dataset might be attributed to the differences in when ART was
initiated during infection and the duration of ART, which are factors that can impact reservoir
dynamics (Chéret et al., 2015; Chun et al., 2007; Massanella et al., 2021). Until now, this degree
of heterogeneity across individuals and longitudinal conservation of phenotypes across ATI has
not been demonstrated and indicates the necessity of single-cell based approaches.

Our surface antigen profiling assessed many individual markers previously associated with HIV
infection, including PD-1 (Perreau et al., 2013), CXCR5 (Perreau et al., 2013), CCR6 (Gosselin et
al., 2017), CTLA-4 (McGary et al., 2017), CD69 (Cantero-Pérez et al., 2019), OX40 (Kuo et al.,
2018), CD2 (Iglesias-Ussel et al., 2013), Lag-3 (Pardons et al., 2019), TIGIT (Fromentin et al.,
2016; Pardons et al., 2019), CD20 (Serra-Peinado et al., 2019), and CD161 (Li et al., 2019), but
did not include CD30 (Hogan et al., 2018), α4β1 (Pardons et al., 2019), CD32a (Abdel-Mohsen et
al., 2018; Descours et al., 2017), or Sialyl-LewisX (Colomb et al., 2020). Importantly, between the
different modalities we tested, no single previously identified cell surface marker was solely
associated or predictive of the presence of integrated provirus. We do, however, find that specific
combinations of markers, both by presence and relative level, may more reliably enrich for HIVinfected cells on in vitro infected samples. For example, CCR5 and PD-1 were significantly
expressed on HIV+ over HIV- cells for bulk and activated T cells in vitro and Tem cells ex vivo
from ART-treated peripheral blood, which represent known associations with the HIV reservoir
(Fromentin et al., 2016; Perreau et al., 2013). However, CCR5 was not heightened on HIV+ cells
in Tcm/Ttm cells from ART-PLWH. We instead observed higher expression of CD71 expression,
which correlates with cell cycling (Younes et al., 2018) and is a unique surface marker for
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ferroptosis (Feng et al., 2020). This could suggest that these infected cells are dividing frequently
and are potentially predisposed to cell death. We also observed an enrichment of CD2 which has
been highlighted by prior work in enriching for HIV DNA in ART-PLWH (Iglesias-Ussel et al.,
2013). The integrin CD11a was also enriched in Tcm/Ttm and is known to be increased upon
HIV-1 infection (Rossen et al., 1989).

Identification of cell surface markers found preferentially on HIV uninfected cells is also useful.
We found higher levels of the inhibitory receptor CD200 (OX2) that appeared to be driven by Tem
cells in ART-PLWH. These may be indicative of HIV-specific cTfh cells which are known to
express CD200 and PD-1 more frequently than non-HIV-specific cTfh. For these HIV-specific
cTfh cells, their frequency and expression of inhibitory receptors are not modulated during ART
treatment (Niessl et al., 2020). We also curiously noticed an increase in CD74, which is the
invariant chain for major histocompatibility complex class II (MHC-II) which also appears to be
driven in Tem cells. However, the functional significance of decreased expression of CD74 on
HIV+ cells is less clear. Our findings, as a whole, indicate that HIV+ cells are highly
heterogeneous at interpersonal and intrapersonal levels, and that each cell subset and
compartment needs to be evaluated individually. Each of these individual subsets has its unique
biology, function, and differentiation potential that will contribute in currently unknown ways to the
establishment and maintenance of the reservoir. Along with the variable impact of latency
reversal agents on different memory subsets (Pardons et al., 2019), our results highlight the
difficulty in finding a strong candidate for a “shock and kill” therapy as the cells harboring
proviruses have different epigenetic phenotypes.

The epigenetic modality afforded by our single-cell multimodal strategy also yielded insights into
both known and potential differential regulatory factors that impact HIV infection in vitro and ex
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vivo. Infection of in vitro activated CD4+ T cells was highly associated with increased accessibility
upstream of the CCR5 transcription start site, which appears to be associated with increased
CCR5 protein expression. In this same system, we further identified accessible peaks near genes
previously implicated in HIV infection and replication, including DCBLD1, GGA2, and PLEKHA3.
DCBLD1 enhanced HIV replication during a RNA interference screen (Zhou et al., 2008), while
GGA2 is important during downregulation of CD4 by Nef (Landi et al., 2014). Knockdown of
PLEKHA3 was shown to inhibit HIV-1 replication (Brass et al., 2008).

In the case of ART-PLWH, the Tcm/Ttm/Tem HIV+ cells had a high enrichment (though not
significant when compared to background cells) of a motif module that consisted of AP-1 related
transcription factor motifs and Bach1/Bach2 motifs. The presence of AP-1 motifs suggests that
these cells are poised for or have a history of activation/proliferation which may indicate an
increased likelihood for viral RNA transcription and reactivation upon ART interruption or
treatment with latency reversal agents. Recent reports have suggested that Tem/effector cells are
the prominent memory pool with active transcription at the provirus locus during ART (Collora et
al., 2022; Einkauf et al., 2022). Given our proclivity for finding accessible proviruses, our data
indicates that the epigenetic environment in these cells may be primed for such activity or are
actively transcribing the provirus. Furthermore, many motifs in this module were significant in
comparing HIV+ versus HIV- Tcm/Ttm cells - thus indicating that even the Tcm/Ttm HIV+ pool
may also contain this poised state. We also curiously noticed high (but not significant) enrichment
of NFKB1 motifs in MAIT HIV+ cells and Tcm HIV+ cells but not Tem HIV+ cells. NFKB1 encodes
for NF-kB, which is an important pioneering factor that can lead to the chromatin accessibility and
a major transcription factor needed for HIV transcription - thus reinforcing the notion of priming for
reactivation. These findings along with the impact of other modules will need to be validated with
future studies that can incorporate ASAPseq modalities along with transcriptomic analyses to
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assess HIV viral RNA production. Taken together, our epigenetic analysis provides a framework
and new opportunities for understanding the complex regulation of HIV infection and ongoing
processes regulating uncontrolled infection.

One major limitation of ASAPseq to identify infected cells is the requirement for the provirus to be
in accessible chromatin. This may bias our surface and epigenetic profiling of virally infected cells
towards an activated phenotype or selectively profile only the “active” reservoir (Einkauf et al.,
2022). Proviruses become less accessible over time in vitro (Lindqvist et al., 2020) and after
extended ART (du Chéné et al., 2007) which is a target for the cure field through epigenetic
modification with latency reversal agents (Darcis et al., 2015; Grau-Expósito et al., 2019; Leth et
al., 2016; Reuse et al., 2009). This limitation is inherent in other reservoir measurement
techniques (including QVOA and IPDA) which are restrained by incomplete proviral awakening
via cellular stimulation or by primers being incompatible with sequence diversity, respectively
(Kinloch et al., 2021). Despite this limitation, the detection of only accessible provirus by
ASAPseq still offers unparalleled insight into those infected cells capable of reactivation or
transcription at the proviral locus. Another limitation is the difficulty in assessing proviral
intactness due to short-read sequencing and our transposase-based methodology. Alignments
towards multiple proviral genes in a single cell can be used as a proxy for intactness given that
most defective proviruses have large deletions in treated PLWH (Ho et al., 2013). In the in vitro
infected cells, we found broad coverage of reads to the HIV genome and a large detection of
infected cells, including those not actively expressing p24 protein. The ex vivo infected cells
predictably yielded much sparser proviral sequence coverage. We also observed a dropoff in
sequence recovery from pol regions, possibly explained by nucleosomal occupancy (Rafati et al.,
2011) or more persistent transcription factor binding (Van Lint et al., 1994). The inclusion of
scRNAseq as a third modality (Mimitou et al., 2021; Swanson et al., 2021) can assist in
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addressing intactness but is also limited towards accessible proviruses. Our focus on HIV DNA+
cells, regardless of intactness or transcription, is still relevant given that these cells survived
clearance by the immune system and/or the short half-life associated with HIV infection kinetics
(Perelson et al., 1996). Cells with defective proviruses from treated PWLH are still relevant as
viral proteins can still be produced (Duette et al., 2022; Imamichi et al., 2020), which may
interface with the immune system.

Overall, we have highlighted the complex heterogeneity of the HIV reservoir by using a novel
unbiased genomic strategy to identify HIV infected cells at single-cell resolution with simultaneous
surface antigen and epigenetic data. With this unparalleled resolution via ASAPseq compared to
currently published strategies for studying the HIV reservoir, we uncovered both known and novel
surface markers of HIV infection as well as accessible transcription factor motifs that may
regulate or be indicative of HIV infection. Our study paves the way for future unmanipulated
studies of the HIV reservoir. Furthermore, this approach can also be applied for lentiviral-based
immunotherapy and other latent infections that involve nuclear, viral DNA. Our strategy and data
are the start of a multiomic atlas of HIV infected cells with phenotypic and epigenetic
characteristics - thus contributing towards the united goal of identifying the HIV reservoir for a
targeted, functional cure of HIV.

3.4 Methods
Study approval
ART-treated samples, A01, A08, and A09, were provided from the ACTG clinical trial A5340,
which was conducted with protocols set forth by the Institutional Review Boards at the University
of Pennsylvania and the University of Alabama at Birmingham and was previously published (Bar
et al., 2016). All donors for this study provided informed consent in compliance with protocols set
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forth by the respective institutional review boards. Another ART-treated PLWH, B45, was
recruited from the BEAT-HIV program cohort where an apheresis sample was collected under
ART.

Samples
For the in vitro infection model, peripheral blood mononuclear cells (PBMCs) were obtained from
an HIV-negative donor apheresis from the Human Immunology Core (HIC) at the University of
Pennsylvania. PBMC were cryopreserved at the time of receipt. For ART-treated studies,
peripheral blood (PB) samples were acquired via apheresis and cryopreserved. Samples A01,
A08, and A09 had previously experienced therapy interruption through the ACTG A5340 trial, but
were under at least 6 months (for the post-ATI timepoint) of ART suppression at the time of
analysis. Peripheral blood mononuclear cells were prepared as previously described (Nguyen et
al., 2019).

In vitro infection model
Uninfected PBMC were thawed and rested overnight in a humidified incubator at 37 °C. CD4+ T
cells were negatively enriched (STEMCELL Technologies, #19052), pelleted, and resuspended in
complete RPMI media at a concentration of 2e6 cells/ml in a 6-well tissue culture plate. An
activation cocktail consisting of anti-CD3 (1 μg/mL; Bio-Rad #MCA463EL), recombinant IL-2 (100
U/mL; Sigma Millipore #11011456001), and anti-CD28 + anti-CD49d (1.5ug/ml; BD #347690)
were added to the cells. The cells were activated for 2 days in a humidified incubator at 37 °C.
Cells were then pelleted in a 15ml tube and resuspended in 1ml of complete RPMI. HIV-1 virus
stock (strain SUMA; provided by the University of Pennsylvania CFAR Virus and Reservoirs
Core) was thawed briefly in a 37 °C water bath. 50ng (p24) of viral stock was added to the
suspension and mixed by pipetting. Cells were then infected by spinoculation for 45 minutes at
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400 x g. Cells were rested in a humidified incubator at 37 °C for 1 hour (cap loosened to promote
gas exchange) before washing with complete RPMI and pelletting. Cells were resuspended at a
concentration of 2e6 cells/ml and left to rest for 2 days in a 6-well tissue culture plate. Complete
RPMI was added to the cells after two days. The cells were collected after an additional two days
and pelleted for dead cell removal based on Annexin V using the Dead Cell Removal (Annexin V)
Kit (STEMCELL Technologies, #17899).

Flow cytometric verification of HIV-1 infection
Staining and flow cytometry were based on a previously published protocol (Kuri-Cervantes et al.,
2020). Approximately 1.5 million cells from the in vitro infection culture were spun down at 400 x g
for 5 min and resuspended in 45ul of PBS. Live/dead staining was performed using 5μl of a 1:60
dilution stock of prepared Live/Dead Fixable Aqua Dead Cell Stain (Invitrogen). Cells were
stained for 5 minutes in the dark at room temperature. A staining cocktail with FACS buffer and
CD8 BV570 (BioLegend #301038, clone RPA-T8) was added for a 10 minute stain in the dark at
room temperature. 1ml FACS buffer was added and the cells were spun down at 400 x g for 5
min. Cells were permeabilized with 250μl of BD Cytofix/Cytoperm solution (BD #554714) for 18
minutes in the dark at room temperature. 1ml of BD Perm/Wash Buffer (BD #554714) was added
and cells were spun down at 600 x g for 5 min. After supernatant was discarded, cells were
resuspended in staining solution containing anti-p24 FITC (Beckman Coulter #6604665; clone
KC57) and BD Perm/Wash Buffer for a final staining volume of 50μl. Cells were stained in the
dark for 1 hour at room temperature. Cells were washed with 1ml of BD Perm/Wash Buffer and
fixed with 350ul of 1% paraformaldehyde. Data were acquired on a BD FACS Symphony A5
cytometer and analyzed using FlowJo (Version 10, BD).
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Memory CD4+ T-cell enrichment
Memory CD4+ T cells were enriched by negative selection using the EasySep Human Memory
CD4+ T Cell Enrichment Kit (STEMCELL Technologies #19157) following the recommended
protocol. After collecting enriched memory CD4+ T cells, the cells were spun down at 400 x g for
5 min and resuspended in 500μl PBS. Cells were counted with trypan blue staining using a
Countess II (Invitrogen) prior to beginning the ASAPseq protocol.

ASAPseq - cell preparation and staining
Buffer and cell preparation were performed as previously published (Mimitou et al., 2021) and as
summarized below. 5e5 to 1e6 cells were resuspended in 22.5μl of Staining Buffer and incubated
with 2.5μl of TruStain FcX (BioLegend #422302) for 10 minutes on ice. One test of the TotalSeqA Human Universal Cocktail, V1.0 (BioLegend #399907) was prepared according to the
manufacturer's protocol with ASAPseq Staining Buffer. 25μl of the antibody cocktail was added to
the cells for 30 minutes on ice. Cells were washed with 1ml Staining Buffer and pelleted (all spins
at 400g for 5 minutes with centrifuge set at 10C) for 3 total washes. Cells were then resuspended
in 450μl of PBS. 30ul of 16% paraformaldehyde was added to fix the cells for 10 minutes at RT
with occasional swirling and inversion. The fixation reaction was quenched with 25.26μl of 2.5M
glycine solution. Cells were then washed and pelleted with 1ml of ice-cold PBS for a total of two
washes. Fixed cells were lysed using 100μl of OMNI lysis buffer for 3 minutes on ice. Cells were
then washed and pelleted with 1ml Wash Buffer (spin at 500g for 5 min with centrifuge set at
10C). After supernatant was removed, cells were resuspended in at least 150μl (depending on
original cell input) of 1X Nuclei Buffer (10X Genomics) and strained to remove aggregates using a
40μm FlowMi strainer (Sigma #BAH136800040-50EA). Cells were counted using trypan blue
staining to verify successful permeabilization (>95% trypan blue positive staining). Cells were
diluted as needed according to the scATACseq Chip H protocol (10X Genomics).
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ASAPseq - library preparation
Single-cell droplets were generated using the Chromium platform and a scATACseq Chip H kit
(10X Genomics). Modifications mentioned in the original ASAPseq protocol were performed to
allow for capture of antibody-derived tags (ADT). Library preparation for the ATAC libraries were
performed as recommended by 10X Genomics. ADT libraries were prepared as recommended by
the ASAPseq protocol with 3μl of the silane bead elution used as additional input to the ADT
indexing PCR.

ASAPseq - library sequencing
Sequencing runs were performed on NextSeq 550 or NovaSeq 6000 platforms (Illumina) with a
target of at least 10,000 reads/cell for ADT libraries and 25,000 reads/cell for ATAC libraries.

Initial ATAC data processing
Libraries sequenced via the NovaSeq were filtered for potential index hopping by using indexhopping-filter (10X Genomics; v1.1) in ATAC mode. Filtered reads were then processed the same
as other libraries sequenced with the NextSeq. A chimeric genome was built using cellrangeratac mkref (10X Genomics; v2.0.0) with the default hg38 genome (10X Genomics; refdatacellranger-arc-GRCh38-2020-A-2.0.0) along with either SUMA_TF1 (for in vitro) or autologous
sequences + HXB2 (for ART). The motifs.pfm file from the default hg38 genome reference was
copied over to the new chimeric genome to assist with quality control during downstream
processing by cellranger. The reads were aligned and counted to their respective chimeric
genome using cellranger-atac count. Raw fastq files and processed cellranger-atac files are
deposited in the NCBI Gene Expression Omnibus (GEO) under accession number GSE199727.
After alignment, barcodes pertaining to multiplets were selected using AMULET (Thibodeau et al.,
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2021) for downstream filtering. Fragment files from cellranger-atac were loaded into ArchR
(v.1.0.2) (Granja et al., 2021) for downstream analysis. Arrow files were created for each sample.
Cells were filtered for TSS Enrichment ≧ 8. Barcodes that were selected by AMULET as being
multiplets were then filtered out of the Arrow file. Samples, by level, continued in the ArchR
pipeline. Briefly, iterative latent semantic indexing, Harmony (for batch effect correction as
needed), cluster generation (via Seurat) and UMAP generation were performed. All specific
parameters and settings are documented in our code (https://github.com/betts-lab/asapseq-hivart).

Initial ADT data processing
Sequencing reads were converted to fastq files and demultiplexed using bcl2fastq (Illumina).
Reads were then inputted into kallisto bustools (Melsted et al., 2021) to generate cell barcode by
feature matrices. These matrices were loaded into R and checked for empty droplets (i.e.
background noise) using the emptyDrops function from the DropletUtils (Lun et al., 2019)
package with a lower bound of 500 UMIs. Barcodes with false discovery rates < 0.01 were kept
as genuine cells. This filtered matrix was then loaded into Seurat (v4.1) (Hao et al., 2021) for
centered log ratio transformation with a scale factor of 10000. Harmony (Korsunsky et al., 2019)
was used for batch correction if multiple 10X GEM wells were used for the same individual. A
wilcoxon test (right-tailed) was used to select for features with a count distribution that was
significantly different than background signal detected from isotype control antibodies, as
analyzed similarly in a prior report (Swanson et al., 2021). A feature was not included in
downstream analyses if p > 0.05 in at least 4 isotype controls.
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Identification of HIV+ cells
We built a custom Python pipeline (hiv-haystack; https://github.com/betts-lab/hiv-haystack) built
and derived from epiVIA (Wang et al., 2020) to identify proviral reads from the BAM output file of
cellranger-atac count. BAM records are parsed and selected into three groups: 1) both mates
aligning to provirus, 2) both mates in host with a soft align clip, and 3) one mate in provirus and
one mate in host. In scenario 1, the original alignments were kept as bona fide proviral
alignments. If there was a soft clip present, we aligned it to the host genome using bwa mem as
done in epiVIA to assess if an integration site is present. In scenario 2, any host soft clips were
checked for exact matching to LTR sequences to allow for integration site detection. This was
only allowed if a LTR alignment was reported (checked with BLAST against HXB2 5’ LTR). In
scenario 3, the proviral mate was saved as a proviral fragment. If either mate had a soft clip,
integration site checking is performed similar to scenarios 1 and 2. In all scenarios, only exact
integration sites with exact nucleotide position are kept for downstream analyses. Our program
also differs from epiVIA in that hiv-haystack allows for alignments to multiple sequences (from
near full-length genomes and single genome sequencing of HIV env) which enhances the
detection of donor-derived sequences.

Downstream data processing
After initial ATAC and ADT processing, barcodes that passed quality control metrics in both
modalities were selected for downstream analyses. Clusters were annotated from a base panel of
ADT expression patterns, imputed gene scores from ATAC, and differentially expressed markers
present in any given cluster over all other cells. UMAP embeddings in lower dimension were
generated using ArchR’s latent semantic indexing implementation. Manual annotations were then
used to subset cells for downstream ADT differential expression analysis between HIV+ and HIVcells using Seurat FindMarkers (using “DESeq2” for the findMarkerMethod parameter) to limit
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false discoveries (Squair et al., 2021) and the subset of features that were significantly different
from background expression. For downstream ATAC differential expression analysis, manual
clusters were grouped based on CD4+/- and HIV+/- (and by memory phenotype for the in vitro
experiment) and pseudo-bulk replicates were generated. Clusters with less than 0.5% of the
population were filtered out due to annotation difficulty. Peaks were called using the default 501bp fixed-width method with ArchR and MACS2 (Zhang et al., 2008). Differential peaks were
assessed using a wilcoxon test as implemented by ArchR’s getMarkerFeatures with bias
parameters set to “c(TSSEnrichment”, “log10(nFrags”))” as recommended by ArchR. Motif
annotations of differential peaks were added using addMotifAnnotations from the CISBP dataset.
For experiments with lower numbers of HIV+ cells, we used ArchR’s implementation of
chromVAR to determine differential motifs. getMarkerFeatures was called to determine
differentially expressed motifs using the chromVAR deviation scores (i.e. z-score).

Supervised machine learning
Samples were split into a 70% training and 30% testing dataset using the sample.split function
from the caTools package in R with a random seed set at 21. Logistic regression models were
developed using the glm function with parameters “family = binomial(link = ‘logit’)”. Naive
Bayesian models were constructed using the niave_bayes function from the naivebayes package
in R with parameters “useKernel = TRUE”. Random forest models were constructed using the
randomForest package in R with ntree = 4000 along with the sampsize parameter being set to
different downsampling sizes. Classifier performances (true positive rate and false positive rate)
were calculated using the ROCR package in R and plotted using ggplot2. All code for classifiers
is available on the study GitHub repository (https://github.com/betts-lab/asapseq-hiv-art).
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NFL SGS of proviral DNA from resting CD4+ T cells
DNA was extracted from multiples of 4 million resting CD4+ T cells according to the
manufacturer’s instructions (QIAamp DNA Mini and Blood Mini Kit, QIAGEN). Amplification of
NFL genomes was performed by limiting dilution, nested PCR using Platinum Taq High Fidelity
Polymerase (Life Technologies, Thermo Fisher Scientific) as previously described (Bar et al.,
2016), adapted for NFL genomes with primary forward and reverse primers, respectively 5′AAATCTCTAGCAGTGGCGCCCGAACAG-3′ and 5′-TGAGGGATCTCTAGTTACCAGAGTC-3′
followed by nested forward and reverse primers, respectively 5′GCGGAGGCTAGAAGGAGAGAGATGG-3′ and 5′-GCACTCAAGGCAAGCTTTATTGAGGCTTA3′. Amplicons of appropriate size were directly sequenced on the Illumina MiSeq platform,
inspected for evidence of priming from multiple templates, stop codons, large deletions, or
introduction of PCR error in early cycles; a threshold of 85% identity at each nucleotide position
was used.

HIV custom sequence annotation
HIV custom sequences from untreated and treated PLWH were loaded into the Gene Cutter tool
(HIV LANL Database) for alignment to HIV genes/regions. The output was then loaded into our
custom tool, called geneCutterParser (https://github.com/wuv21/geneCutterParser), to extract the
coordinate locations for any alignments. The coordinate locations were then used for alignment
graphs in the supplemental figures.

Graphics
All figures were made in R with the following packages: gridExtra, ggplot2 (Wickham, 2016),
ArchR, and patchwork. Graphical abstract cell icons were made with Biorender.com. All code to
produce graphs can be found in the study GitHub repository.
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CHAPTER 4
CONCLUSIONS AND FUTURE DIRECTIONS

4.1 Summary and implications
The search for a functional cure of HIV has been elusive as it requires a comprehensive
understanding of the virologic and cellular characteristics of the HIV reservoir. The field’s
understanding of the reservoir has been heavily focused on aspects of the proviral and plasma
viral sequences in understanding viral diversity, especially in the context of transmission, ART,
and drug resistance. Meanwhile, our understanding of the cellular characteristics is more limited
as most studies have been conducted from peripheral blood due to ease of access. However,
conclusions from peripheral blood cannot be simply generalized and applied to the lymphoid
tissue. The tissue predominant nature of HIV infection and persistence requires a more holistic
view – that takes into consideration tissue resident cells as well as circulating cells that interface
between peripheral blood and lymphoid tissue. Moreover, even in the context of peripheral blood,
the HIV reservoir is composed of a broad diversity of CD4+ T cells (and other cell types), which
require stronger resolution in deciphering the phenotypic heterogeneity. Given this complexity,
this dissertation aims to add to our understanding of the cellular characteristics by assessing the
reservoir in the context of residency and circulating phenotypes and to determine if there is an
underlying epigenetic and/or surface antigen signature of the HIV reservoir at single-cell
resolution.

In Chapter 2, we addressed the gap in our understanding about the potential differences between
the integration site landscape between tissue and blood by assessing the role of tissue residency
on this landscape in PLWH during the different stages of HIV infection. As explained in Chapter 1,
HIV-1 preferentially integrates into genes with active transcription due to the tethering ability of
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the host cellular factor LEDGF/p75 (Cherepanov et al., 2003; Ciuffi et al., 2005; Han et al., 2004;
Maertens et al., 2003; Wang et al., 2007). Since there are known transcriptomic differences
between cells residing in lymphoid tissue versus those in circulation (Kumar et al., 2017; Vella et
al., 2019), we hypothesized that there would be differential integration sites based on the
differential transcriptomics. By sorting different CD4+ T cell subsets by different memory,
residency, and functional phenotypes, we profiled the integration sites from one or more tissue
sites to compare with cell subsets from peripheral blood. This approach provided the immune and
cellular context that previous integration site studies did not capture. As such, the key findings
from this study were: 1) similar characteristics in HIV-1 integration targeting across subset and
compartments; 2) a trend towards increased clonal expansion in non-resident phenotypes during
chronic and ART-treated infection; and 3) a lack of clonal overlap between tissue resident
subsets and blood.

These findings have important ramifications for HIV cure research in how we, as a field, need to
adjust our perception of the reservoir and consequently evolve cure research to consider more
strongly the biological impact of tissues. Our detection of a trend towards increased clonal
expansion in non-resident phenotypes was identified during both chronic and ART-treated
infections. This can potentially be attributed to non-resident cells (excluding naïve) being skewed
towards a more later differentiated phenotype, especially in the peripheral blood (Sathaliyawala et
al., 2013). These clonal expansions are likely a result of antigenic stimulation from other chronic
infections, with CMV being the likely antigen given its high prevalence in the general human
population and amongst PLWH (Berry et al., 1988). CMV-specific CD4+ T cells are known to be
more terminally differentiated with targeting towards vascular endothelium (Pachnio et al., 2016),
can contribute to chronic immune activation (Hunt et al., 2011), and are known to harbor infected
cells (Douek et al., 2002). A recent study has also found clonal expansion of infected cells in
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peripheral blood with similar phenotype as the CMV-specific cells (Collora et al., 2022).
Furthermore, study of proviral sequences have indicated that terminally differentiated cells
contain identical sequences (suggesting clonal expansion) while earlier differentiated cells harbor
more genetically diverse sequences (Hiener et al., 2017; von Stockenstrom et al., 2015). Our
findings highlight the disparity between blood and tissue as tissue resident cells may be more
diverse (i.e. less clonal) in their integration site landscape. Importantly, different integration site
landscapes may indicate differential permissibility to “shock and kill” or “block and lock”
approaches as the epigenetic environment is likely different by integration site and by cellular
phenotype as was seen in Chapter 3. Monotherapy LRA regimens are thus unlikely to reawaken
the entire reservoir. As such, combinatorial LRA regimens will be needed to induce a broader
degree of reactivation from a wider panel of different epigenetic backgrounds, as will be
discussed later in this chapter.

Another profound ramification is concerning the limited overlap of clones between tissue and
peripheral blood. The few detected overlaps were between subsets in the same compartment or
between the nonresident subsets capable of circulation. This suggests that the migration of
infected clones through lymphatic tissues can occur, but that it may be restricted to circulating
cells. As there is limited HIV replication during ART (McManus et al., 2019), identical integration
sites that are found in different compartments result from proliferation of the infected cell followed
by migration and/or differentiation. Our observed lack of overlap suggests that there may be a
fitness barrier to migration and/or differentiation. This could include immune clearance from viral
reactivation, interference in host cellular programs from integration, or a combination of these
factors. An exit from a cellular quiescence program (that is induced after initial infection and
results in evasion of immune clearance) could lead to presentation of viral antigens via MHC-I
and a subsequent clearance by the immune system (Boucau et al., 2020). Similarly, an activation
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event could permit a cell to access a different compartment (Bankovich et al., 2010; Shiow et al.,
2006) but may also trigger transcription at the host gene site that is disrupted by the integration
event (Liu et al., 2020b). This aberrant transcription could lead to cell death, thus maintaining the
degree of sequestration of clones that we observe.

It is important to note that our findings are from one to two lymph nodes per each donor. As a
result, additional tissue sites and donors are needed to see if our findings are more generalizable
in different tissue sites and different cohorts. The notion of compartmentalization between cellular
subsets has been seen before where proviral sequencing of nef showed potential
compartmentalization between memory subsets in a portion of their cohort (Jones et al., 2020).
Given the difference in memory phenotypes between tissue CD4+ T cells and blood CD4+ T cells
(Sathaliyawala et al., 2013), this may indicate support for our findings of compartmentalization.

These overall findings from Chapter 2 show that any profiling of the reservoir needs to be able to
discern the impact of cellular homing and tissue localization. Differences in the distribution of
clonal expansions and the lack of clonal overlap will inevitably impact our quest for a functional
cure. Our findings indicate that there may be sub-reservoirs that will need to be uniquely defined
and targeted for a functional cure to be effective throughout the body. The notion of subreservoirs between resident and non-resident phenotypes is still an initial step, as additional
resolution is likely needed to truly resolve the identity of these sub-reservoirs given that many
phenotypes are encapsulated within the more general resident and non-resident classification.

In Chapter 3, we built upon this impetus from Chapter 2 with the need to study the reservoir at
deeper resolution to parse through the heterogeneity of sub-reservoirs and the spectrum of
memory and functional phenotypes. Given the degree of heterogeneity, a single-cell approach
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was the only approach that would enable an unbiased assessment of each cell. Our desire to do
a direct ex vivo analysis would only be achievable by determining if a cell is infected based on the
presence of a provirus as opposed to depending on presence of viral RNA and/or viral protein. As
such, this was enabled through a scATACseq approach paired with surface antigen profiling to
gain additional information per cell. Our approach, called viral ASAPseq, was designed to answer
our main experimental aim to determine if there was a unique epigenetic and/or surface antigen
signature of the HIV reservoir during ART. Our focus was on the peripheral blood for this chapter
due to ease of access and to test the limits of the method given that there are fewer infected cells
in blood compared to the tissue (Deleage et al., 2016; Eriksson et al., 2013; Estes et al., 2017).
However, this is still a clinically relevant context of samples from ART-treated PLWH and has
direct parallels with most LRA studies that analyze or use peripheral blood samples. The main
findings from this section were: 1) HIV-infected cells from peripheral blood of PLWH are highly
heterogeneous within and between donors with no single phenotype consistent across donors; 2)
phenotypes of HIV-infected cells were maintained before and after analytical treatment
interruption; and 3) HIV-infected cells within Tcm and Tem memory phenotypes show increased
accessibility in regions associated with AP-1 transcription factor motifs.

Through both an in vitro infection model and through direct ex vivo analysis of peripheral blood
from ART-treated PLWH, alignment of sequencing reads to a chimeric human and virus genome
allowed us to identify viral sequences at a single-cell level. The findings from this study provide
the highest resolution dataset to date of the HIV reservoir. Even though viral ASAPseq is geared
towards accessible chromatin (and therefore proviruses within these regions), we found no
consistent phenotype of infected cells between individuals. This is in sharp contrast with recent
studies indicating that Tem cells have high proportions of both viral RNA positive cells and intact
proviruses when compared to other memory subsets (Duette et al., 2022; Einkauf et al., 2022).
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While we did detect Tem cells with high proportions of infected cells, this was not a predominant
phenotype amongst the different individuals in our study.

This discrepancy can potentially be attributed to two factors: 1) the field’s understanding of
proviral epigenetics is insufficient and 2) different durations of ART may impact the relative
proportion of different subsets in the reservoir. In the former factor, the epigenetics of the entire
sub-10kb region for an intact provirus has not been studied ex vivo as the integration site and
corresponding epigenetic background likely obfuscates any signal when studied in bulk. For
instance, repressive histone marks are not consistent across the provirus in a transcriptionally
silent (i.e. fully latent) infected cell at least from in vitro studies (Jefferys et al., 2021; Lindqvist et
al., 2020). However, this has yet to be shown ex vivo and future studies will thus need to conduct
single-cell studies to test that assumption. The DNA fragments that we are using to signify an
infected could be result of tagmentation in euchromatin or linker (DNA between nucleosomes)
regions. In vitro studies have found abnormally large linker DNA regions between nuc-0 and nuc1 (252bp) as well as between nuc-1 and nuc-2 (144bp) whereas typical linker DNA in the human
genome is around 20-90bp (Verdin, 1991; Verdin et al., 1993). The linker DNA sizes for the rest
of the provirus is less clear. As such, tagmentation within the open linker DNA regions could be
included in our infected cells. In the latter factor, the duration of ART may shape the reservoir as
contractions and expansions from homeostatic proliferation and antigenic stimulation could
change the relative composition of the reservoir (Liu et al., 2020a; Wang et al., 2018).

Regardless of factor, the lack of a consistent phenotypic signature indicates that each individual
has a unique reservoir. This was observed from general cellular phenotypes as well as the lack of
a major identifying surface antigen signature. However, there was a curious finding where we
observed similar compositions of the reservoir before and after analytical treatment interruption.
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This finding, although from a sample of one, has direct implications in cure research as it shows
that a robust viral rebound and activation of the immune system followed by 6 months of ART is
not sufficient to alter the general phenotypes of the reservoir. Although this individual was part of
a clinical trial that studied the impact of a broadly neutralizing antibody (bNAb) called VRC01 on
delaying viral rebound during ATI, this particular individual had VRC01 resistant strains even
before ATI (Bar et al., 2016), which indicate that the VRC01 infusion likely did not have much
impact on the reservoir. This observed stability in phenotypes highlights the relative resistance of
the reservoir to external perturbation in terms of ATIs and could be a prime explanation of why
current LRAs are unsuccessful in reducing the reservoir despite reactivation. In combination with
the module of motifs that we noticed to be enriched in HIV+ Tcm and Tem cells, the cells that do
respond are likely already poised and more conducive to be awakened by an LRA. Since this
signature also includes AP-1 related motifs, these cells may be highly proliferative and could drive
additional expansion/maintenance of the reservoir. The rest of the infected cells, including MAIT
cells from our study, do not display enrichment in this module and could be more resistant to
perturbation by LRAs while presumably being maintained through homeostatic proliferation.

Together, the datasets from chapters 2 and 3 establish a high-resolution atlas of the HIV
reservoir. The profound heterogeneity documented through this dissertation emphasizes the
importance of an open atlas to encompass as much heterogeneity as possible across individuals
to allow for the discovery and fine-tuning of signatures that may be unique to the reservoir. In
particular, viral ASAPseq is a new frontier for reservoir research as this resolution of information
gathered per infected cell is currently unmatched. Furthermore, these high dimensional datasets
have increased value over time as additional development of computational methods combined
with our expanding knowledge of human epigenetics will allow for a more thorough
comprehension of this complex data. The accrual of additional data from more individuals and,
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importantly, from tissue sites in respect to potential sub-reservoirs will increase the value of this
HIV reservoir atlas.

The findings from both chapters 2 and 3 highlight why single-cell profiling of the HIV reservoir is
critical in reservoir research as the heterogeneity would be otherwise masked in studies with bulk
populations. The combination of potential sub-reservoirs based on resident versus circulating
cells as well as the detailed characterization of the inter- and intrapersonal heterogeneity of
infected cells present a significant barrier towards the goal of a functional cure. As such, this
barrier will need to be considered in not only the design of new LRAs for “shock and kill” but also
the evaluation of the cellular and epigenetic impact by the LRAs on both infected and bystander
cells. This evaluation is a critical aspect of cure research that is now made possible with the
development of viral ASAPseq. The findings from this dissertation can also be translated into a
framework for LRA development and testing as this heterogeneity must be addressed in any
feasible functional cure.

4.2 Open questions and future directions
From the findings detailed in this dissertation, many follow-up questions have been unlocked to
further our understanding of the HIV reservoir and investigate the impact on a future functional
cure of HIV. As mentioned above, the findings from this dissertation can be applied and
translated to a framework for LRA discovery and testing. Here, I present a series of open
questions that build off the work presented in this dissertation - starting with the main existing gap
in knowledge of the provirus and how that will inform my vision for a framework to design, find,
and evaluate LRAs for the purpose of a functional cure.
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What is the main impediment in reactivating the provirus and how can this provide a nextgeneration framework for designing and evaluating novel latency reversal agents?
Understanding the provirus in greater detail. The main impediment to any LRA strategy is the
unknown epigenetic nature of both the provirus and its surrounding genomic regions. The
diversity of infected cells is striking and challenging - as some cells are transcriptionally silent,
some are poised for reactivation, and some are continuously expressing viral RNA. This
combined with 1) the myriad of cellular phenotypes with their own unique cellular epigenetics and
2) the random integration of HIV presents a daunting and limitless combination of factors that
essentially makes each infected cell unique within a reservoir. This impediment must be
addressed in a multi-lab and multi-institutional manner to continue to decipher the heterogeneity
of the HIV reservoir. As such, this dissertation serves as both a foundation and a call to action in
pushing forward single-cell profiling to address this issue.

Uncovering the proviral epigenetics requires a more targeted approach that is currently not
available as a single hyperactive transposase with scASAPseq is still primarily suited for
accessible proviruses. There are at least three conceptual ways to identify all infected cells by the
presence of a provirus regardless of chromosomal compaction (Figure 4.1).
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Figure 4.1: Potential single-cell approaches to uncover novel insights on proviral
epigenetics.

The first way is derived from a recent publication where a chimeric transposase (termed TnH)
with the targeting domain of HP-1α allows for targeted transposition in heterochromatin (Tedesco
et al., 2021). By using barcoded adapters for the canonical hyperactive Tn5 used for scATACseq
and for the custom TnH, this allows for a near full genomic profiling of the infected cell with the
ability to discern both euchromatin and heterochromatin. Proviruses located in heterochromatin
would thus be detectable and this approach would allow for some context of the epigenetics at
the provirus. However, this is still dependent on recovery as recovery efficiency for single-cell
methods are actively being improved upon to increase capture and sensitivity.

A second approach is built upon the assay known as single cell CUT&Tag (Kaya-Okur et al.,
2019) in which primary antibodies first bind to an antigen of interest that is associated with DNA
(i.e. a specific histone mark or RNA polymerase II). A chimeric Protein A fused with Tn5 allows for
specific tagmentation as Protein A binds the Fc region of the primary antibody. Recovery and
sequencing of the tagmented DNA generates a specific profile of chromatin associated with a
specific protein or histone mark. Several adaptations of scCUT&TAG including multiCUT&TAG
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(Gopalan et al., 2021) and NTTseq (Stuart et al., 2022) allow for multiple primary antibodies to be
multiplexed in the same reaction with downstream in silico demultiplexing. The benefit of this
approach is that it allows for analysis of specific markers and can be adapted to include primary
antibodies against certain factors of interest – such as NF-κB, Sp1, and even viral Tat which
could assist in increasing detection at the provirus.

The final approach is a more targeted but hypothetical approach that selectively targets the
provirus using the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system
with the Cas9 endonuclease (Jinek et al., 2012). By using guide RNAs that are specific to more
conserved regions of the HIV genome (Chung et al., 2021), a catalytically inactive Cas9 (termed
dead Cas9; dCas9) can associate in specific HIV regions. This in situ method with permeabilized
cells could then be followed by an anti-Cas9 antibody fused with Tn5 that would enable
tagmentation at the provirus to better identify infected cells, and with the potential of integration
site recovery depending on the location of guide RNAs. If integration site is consistently
recoverable, this method combined with simultaneous single cell CUT&TAG (Kaya-Okur et al.,
2019) could lead to a better understanding of the epigenetics in regions proximal to the provirus.
The epigenetics of the provirus itself would be likely unfeasible for this approach given the initial
targeted tagmentation.

All three of these techniques are theoretically compatible with surface antigen labeling as seen
with our viral scASAPseq and with recent studies (Stuart et al., 2022). This would enable the
identification of cellular phenotype to help parse through the phenotypic heterogeneity of the
reservoir. It is also possible that there are distal enhancer and regulatory elements that could
interact with the provirus (Stadhouders et al., 2012; Vansant et al., 2020). Understanding these
interactions would require a chromosome conformation capture analysis (Göndör et al., 2008),
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ideally at the single-cell level due to the potential impact of integration site coordinates (Vansant
et al., 2020). However, these methods are still in active development and have added layers of
complexity in terms of bioinformatic analyses. Additional techniques that are being developed
include a single cell mass spectrophotometry approach (Budnik et al., 2018; Specht et al., 2021)
that could enable an unbiased proteomic profiling of infected cells. Identification of infected cells
would need to reply on a targeted protein-based association that is unique to infected cells (i.e.
Cas9, TALENs, and/or zinc finger nuclease association (Gaj et al., 2013) with the provirus) that
could mark a cell as infected during downstream analysis.

Regardless of the approach, this initial step of the framework will add to the current atlas that this
dissertation establishes. This future form of this atlas on the proviral and cellular epigenetics will
help identify potential targets that might be unique to the provirus such as histone mark(s) or a
regulatory transcription factor that is more consistently associated with the provirus. Identification
of a unique regulatory element or marker would enable for a more specific impact on
reawakening the provirus with fewer off-target effects.

Proposal for screening and evaluating novel LRAs. The existing methods in screening for new
LRAs are still applicable for use, whether by detecting the degree of HIV RNA reactivation or
production of viral antigen (Liu et al., 2021; Lu et al., 2021). These size of screening methods with
single-cell based approaches are most likely untenable due to the current costs of single-cell
based approaches, hence the proposed continuation of existing methods. However, upon the
identification of promising agents, our viral ASAPseq as well as the above single-cell approaches
(Figure 4.1) will allow for a more systematic characterization of the impact of any LRA. These
candiate agents will need to be tested on ex vivo samples from both blood and tissue cells of
ART-treated PLWH to address the concerns of sub-reservoirs based on residency.
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In particular, the scGETseq approach will enable researchers to tell the proportion of
heterochromatin-associated provirus relative to euchromatin-associated provirus (Tedesco et al.,
2021). Pairing scGETseq with simultaneous scRNAseq analysis (Mimitou et al., 2021; Swanson
et al., 2021; Tedesco et al., 2021) could allow for actual measurement of viral RNA to definitively
indicate active transcription and reawakening. Furthermore, the impact of the LRA on the cell
itself can also be assessed for potential detrimental effects, especially in terms of impacting its
ability to be cleared by the immune system. Similarly, the effect on bystander (not infected) cells
needs to be assessed as the LRA cannot negatively impact bystander cells. Some existing LRAs
have been shown to negatively regulate CD8+ T cell effector function, which would hinder the
“kill” process of “shock and kill” (Jones et al., 2014; Walker-Sperling et al., 2016). As such, the
single-cell approach in evaluating LRAs will provide a thorough and detailed dataset in selecting
the most promising agents to move forward in the next step.

In vivo evaluation of candidate LRAs. Potential LRAs that show promise in activating a large set
of heterochromatin-associated proviruses can be evaluated in nonhuman primate models. While
there are likely differences in proviral epigenetics between SIV and HIV, the initial screening
efforts can also include SIV-infected cells to mitigate potential discrepancies at this stage. Rhesus
macaques infected with SIV and durably controlled with ART can undergo dosing with the
candidate LRA. At this point, longitudinal biopsies of peripheral blood and tissue (lymph nodes
and gut biopsies) will ned to be profiled with scGETseq paired with scRNAseq to examine the
effect of the LRA on both the reservoir and bystander cells (uninfected CD4+ and effector cells).
This will allow for a direct comparison to see how well the candidate LRA performs in vivo relative
to the prior in vitro and ex vivo experiments. Candidate LRAs that are deemed to be effective
could then be moved into human clinical trials where the same evaluation method is
155

recommended for single-cell analysis of tissue and blood samples. This comprehensive
evaluation and assessment will not only provide additional insight to the HIV reservoir (thus
adding to the atlas), but also will better describe and explain the efficacy of the LRA for any
additional improvements to a given LRA strategy.

This proposed framework will establish a rigorous and high-resolution evaluation platform that
takes into consideration the highly heterogeneous nature of the HIV reservoir in terms of the
cellular phenotypes that are involved with tissue-specific reservoirs. Datasets at each step are
useful for more than just the LRA itself as they will contribute to the single-cell atlas of the
reservoir. Increasing the number of datasets will help refine any signatures that are unique to the
reservoir. This framework will hopefully provide a systemic approach in finding a novel LRA as a
core part of a functional cure of HIV infection.

What will a functional cure look like?
A “shock and kill” approach is a two-body problem as proviral transcription of infected cells is
activated to produce viral antigens, followed by the elimination of cells with viral antigens. As all
published studies of LRAs have shown, no single LRA is able to reawaken every provirus
although not all proviruses may need to be reawakened for the purposes of a cure as some
proviruses could theoretically be present in constitutive heterochromatin (Saksouk et al., 2015)
with a low chance of reactivation (Gallastegui et al., 2011; Han et al., 2004; Jiang et al., 2020;
Jordan et al., 2003). Even a mitogen-based stimulation in vitro is unable to completely awaken all
the infected cells (Ho et al., 2013), which indicates that this problem is unlikely to be solved by a
single LRA. Additional studies have posited the need for combinatorial LRA regimens to increase
the breadth of reactivation (Burnett et al., 2010; Darcis et al., 2015; Grau-Expósito et al., 2019;
Laird et al., 2015; Reuse et al., 2009), which is analogous to the rationale for combinatorial ART
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to increase the barrier to genetic resistance. Furthermore, combinatorial LRA regimens may have
synergistic effects and enable lower doses of each individual component which may limit side
effects (Laird et al., 2015).

Given the importance of NF-κB and Sp1 in disrupting nuc-1 as a prerequisite for efficient
transcriptional elongation (Lusic et al., 2003; Van Lint et al., 1996; Verdin et al., 1993), one or
more of the combinatorial LRAs will need to induce NF-κB signaling. The small molecule agonist,
AZD5582, which activates the non-canonical NF-κB pathway has shown some promise (when
paired with CD8+ T cell depletion) in reactivating cells (Mavigner et al., 2021; Moon et al., 2015).
However, AZD5582 by itself had limited activation of the reservoir (Mavigner et al., 2021). As
such, additional LRAs are needed to synergize with AZD5582 to promote transcription at the
proviral locus. Potential options, from those currently being studied, include Pam3CSK4 which is
a TLR1/2 agonist that can induce AP-1, NF-κB, and Sp1 activity (Novis et al., 2013) – all of which
have binding sites in the proviral promoter or in the intergenic pol enhancer element. However,
some HIV+ cells in our study, which were not as poised for reactivation (i.e. lacking the module of
transcription factors enriched in AP-1 transcription factor motifs), may have greater inertia against
reactivation as the chromatin may still be closed near the provirus. As such, LRAs will need to be
tested on these subsets to investigate how LRAs may perform differently based on the cell’s preexisting chromatin accessibility. Importantly, the combinatorial LRAs will also need to be
evaluated with the previously mentioned framework in evaluating its effect on bystander CD4+ T
cells and effector cells responsible for clearance.

On the topic of clearance, awakening the provirus is only one part of the problem as these cells
will need to be eliminated or suppressed for an effective functional cure. Some infected cells will
be cleared from cytopathic effects associated with virion production. Assuming that ART is
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maintained the “shock and kill”, ART will prevent newfound infections. The immune system may
be sufficient in clearing some infected cells (Søgaard et al., 2015), but usually the virus has some
level of escape against the antibody mediated and CD8+ T cell mediated responses (Allen et al.,
2005a; Wei et al., 2003). It is thought that the immune system is a step behind the virus in this
host-viral arms race. Duration of combinatorial LRAs may allow for enough reactivation while
letting the immune system reactivate and catch up to the viral escape. However, it is not
guaranteed and the strength of responses may differ by individual (Allen et al., 2005b). As a
result, it is likely that a kill strategy, or more likely combinatorial kill strategies, are needed to
efficiently and selectively eliminate infected cells that have reactivated. Potential kill strategies
include a possible combination of engineered CAR-T cells (Maldini et al., 2020), bNAbs (Hsu et
al., 2021), or vaccination to augment or shape the immune system (Allen et al., 2005b; Hansen et
al., 2011). These and other strategies are by themselves material for a separate and extensive
discussion and is only briefly mentioned in this current discussion to highlight the complexity of
the second half of a “shock and kill” functional cure.

As such, the ideal functional cure would comprise of a combinatorial shock that uses agents to
trigger the NF-κB and SP1 transcription factors as well as additional factors that will need to be
identified during a deeper profile of the proviral epigenetics. This combinatorial shock will
reawaken a large proportion of infected cells to be cleared by a combinatorial kill strategy that
involves the host immune response and an infusion of engineered products to eliminate this
reservoir. It will likely be necessary for multiple rounds of this combinatorial “shock and kill”
strategy, with the possibility that each iteration has a different combination. This will hopefully
result in the suppression and elimination of cells that would otherwise cause viral rebound during
treatment interruption.
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Are findings and possible implications also applicable to other HIV-1 subtypes and HIV-2?
It is important to recognize that majority of reservoir research is focused and derived from HIV-1
group M, subtype B infections. Within group M, the different subtypes have remarkable diversity
in their promoter region with different numbers of NF-κB binding sites ranking from one (subtype
AE) to three or four (subtype C) (Bachu et al., 2012; Jeeninga et al., 2000; Sarabia and Bosque,
2019; van der Sluis et al., 2011). These different subtypes can vary in rates of viral replication as
seen with chimeric viruses that swap the LTR with another LTR from a different subtype (Burnett
et al., 2010; Dahabieh et al., 2013; Jeeninga et al., 2000; van der Sluis et al., 2011). The number
of NF-κB binding sites appear to positively correlate with the degree of reactivation as seen with
tumor necrosis factor α (TNF-α) treatment (Bachu et al., 2012; Dahabieh et al., 2013; Jeeninga et
al., 2000), TCR stimulation through PMA/ionomycin (Dahabieh et al., 2013) – both of which
triggers ΝF-κB signaling. Subtype AE consistently had the lowest reactivation potential with its
single NF-κB binding site while subtype C showed the strongest reactivation during TNF-α
treatment (Bachu et al., 2012; Dahabieh et al., 2013; Jeeninga et al., 2000). This would suggest
that LRA strategies that focus on NF-κB signaling would not be as effective for subtype AE, thus
requiring additional profiling with the proposed framework to assess what may be best for
reactivating this subtype. Additionally, variations in the AP-1 promoter binding site could explain
different degrees of latency across the subtypes with subtypes A and C having increased latent
infections due to an extended AP-1 binding site which is absent in subtype AE (Duverger et al.,
2013).

Studies that have applied single or combinatorial LRAs to different group M subtypes have seen
variable reactivation potentials (Burnett et al., 2010; Duverger et al., 2013). While vorinostat (also
known as SAHA) (Kroon et al., 2020) and valproic acid (Routy et al., 2012) each have been
tested in clinical trials, it is important to consider that the primary subtype in these cohorts were
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likely subtype B which is dominant in North America and Europe (Bbosa et al., 2019). On the
other hand, subtype C has the highest prevalence worldwide and is dominant in Africa (Bbosa et
al., 2019). Combinatorial application of SAHA with prostratin (a PKC agonist that can induce NKκB signaling) saw large variability across different subtypes and a contradictory observation of
subtype C having the lowest reactivation despite the increased number of NF-κB binding sites
(Burnett et al., 2010). These studies and others demonstrate that subtype differences need to be
taken into consideration for an effective functional cure strategy that is applicable worldwide.

There is an even greater gap in understanding latency and sensitivity to LRAs for different HIV-1
groups and HIV-2. The latter virus is of potential interest as a model of latency given its less
pathogenic nature and greater latent state (Berry et al., 2002; MacNeil et al., 2006), likely
because of different T and B cell responses compared to the response against HIV-1 (Zheng et
al., 2004) and its preference for the provirus to be oriented in opposite orientation relative to the
host gene thus increasing the odds of transcriptional inference as a means of repressing viral
transcription (MacNeil et al., 2006). Furthermore, HIV-2 LTR has fewer NF-κB binding sites
compared to the HIV-1 LTR and is likely the reason behind being less sensitive to T cell activation
signaling (Tong-Starksen et al., 1990). This difference, based on observations with the group M
subtypes, would imply that certain LRAs that may work for HIV-1 group M, subtype B are not
suitable for HIV-2.

Altogether, these results for group M subtypes and HIV-2 demonstrate that more work needs to
be done to address non group M, subtype B strains as the variation in promoters and the
subsequent impact of latency are a few of the many reasons that a group M, subtype B focus will
not be sufficient for a global HIV functional cure. These differences suggest that “shock and kill”
therapies may need to be designed for each specific strain. Findings from other strains such as
160

with subtype AE may lead to the discovery of novel latency reversal agents that are both potent
and NF-κB independent – thus stressing the importance of including other HIV strains in reservoir
research.

Next steps
With the start of a multiomic atlas of the HIV reservoir with Chapter 3, there remains an impetus
to make this atlas more easily accessible and interpretable by all individuals for non-bioinformatic
research scientists and the HIV community. The richness of this dataset has multiple
opportunities for follow-up in investigating different epigenetic enrichments at the in vitro and ex
vivo levels. A vision for an open-source and accessible atlas will require an interactive and
feature-rich web portal that allows for cells to be gated and selected to analyze their surface
antigen and epigenetic patterns. As a preliminary step towards this effort, a web portal to analyze
the surface antigen component is in active development (https://github.com/wuv21/g-cyto-viewer;
Figure 4.2). Increasing accessibility to a HIV reservoir atlas will accelerate curative research
strategies by enabling more people to examine and find potential targets as more samples are
continuously added to this HIV reservoir atlas.
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Figure 4.2: Preliminary web portal for interactive access to the HIV reservoir atlas.
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Longitudinal studies from the same individuals over time on ART using ASAPseq is urgently
needed to better describe the impact of ART over time. As discussed in Chapter 2, the lack of
overlap contrasts with another report that reported overlaps in their integration site dataset
between lymph node and peripheral blood (McManus et al., 2019). One of the discussed
explanations is due to the longer time on ART in their cohort versus our cohort by a mean
difference of ~7 years. An increasing amount of time with ART mediated suppression could allow
for more opportunities for equilibration between the subsets and/or compartments as cells
expand, contract, and differentiate during typical immune responses. If this explanation holds
true, then ART duration will need to be factored in assessing and evaluating latency reactivation
potential. In reference to the proposed framework, ex vivo studies and clinical studies will need to
properly sample across different ART durations.

A major future direction for ASAPseq and future derivatives of ASAPseq (such as scGETseq) is
the paired profiling of peripheral blood and one or more tissue reservoirs from each individual.
These tissue reservoirs, from lymph node and GALT, will enable further study of the extent and
implications of sub-reservoirs. The surface antigen profiling is a significant advantage as presorting into resident and circulating subtypes based on surface markers is not needed given that
CD69 and other resident/circulating markers are included in the cocktail of oligo-tagged
antibodies used in Chapter 3. This assessment along with the additional modality of epigenetic
(and possible transcriptomic) allows for a more unbiased approach in understanding the extent of
sub-reservoirs. Along with this effort, profiling of untreated infection at both acute and chronic
stages with blood and tissue comparisons will enable a more granular understanding of the
progression of cellular and reservoir phenotypes in the context of HIV infection and treatment.
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4.3 Concluding remarks
Since the start of the AIDS epidemic in the 1980s, the HIV and AIDS epidemic has touched the
lives of more than an estimated 79 million people with more than 37 million deaths. Despite the
advent and successes of combinatorial antiretroviral therapy, HIV is still a significant burden to
many individuals worldwide with an estimated prevalence of more than 37 million PLWH and 1.5
million newly acquired infections in 2020. Both a vaccine and functional cure of HIV are urgently
needed to combat this continuing epidemic in preventing new and existing infections,
respectively.

The development of a functional cure is reliant on a comprehensive understanding of a complex
HIV reservoir that seeds and persists in the tissue. Even though HIV preferentially infects CD4+ T
cells, there is a wide spectrum of different CD4+ T cells that comprise the reservoir. To increase
our understanding of the reservoir with consideration of these factors, this dissertation deciphered
this reservoir in two ways: 1) an assessment of the integration site landscape between lymphoid
tissue and blood at a subset resolution to discern potential sub-reservoirs based on resident
versus circulating phenotypes and 2) the establishment of a multiomic atlas of epigenetic and
surface antigen profiling to identify potential signatures of infected cells during ART. The findings
indicate that infected cells are highly diverse within an individual – with potential
compartmentalization based on tissue residency as well as with extensive epigenetic and surface
antigen heterogeneity across the different flavors of CD4+ T cells. This diversity of the infected
cells between and within individuals highlights the need to find additional ways to broadly
reactivate transcription at the provirus to reverse latency for eventual clearance.

This dissertation provides a foundation for new research directions as the insights with
residency/circulating phenotypes and the different poised states for reactivation will help inform
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the selection and evaluation of novel latency reversal agents. These findings also advocate for
the increased use of single-cell methodologies to address the heterogeneous nature of the HIV
reservoir and an increased study of all strains of HIV to ensure a global application for a future
functional cure. Through the findings and implications from this dissertation, the ongoing work of
many research groups, and the synergistic relationship between researchers and the global HIV
community – a future with a functional cure of HIV is within reach.
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